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Background: The prevalence of visual impairment (VI) and dementia increases with age and these
conditions may coexist, but few UK data exist on VI among people with dementia.
Objectives: To measure the prevalence of eye conditions causing VI in people with dementia and to
identify/describe reasons for underdetection or inappropriate management.
Design: Stage 1 – cross-sectional prevalence study. Stage 2 – qualitative research exploring participant,
carer and professional perspectives of eye care.
Setting: Stage 1 – 20 NHS sites in six English regions. Stage 2 – six English regions.
Participants: Stage 1 – 708 participants with dementia (aged 60–89 years): 389 lived in the community
(group 1) and 319 lived in care homes (group 2). Stage 2 – 119 participants.
Interventions: Stage 1 gathered eye examination data following domiciliary sight tests complying with
General Ophthalmic Services requirements and professional guidelines. Cognitive impairment was assessed
using the Standardised Mini-Mental State Examination (sMMSE) test, and functional ability and behaviour
were assessed using the Bristol Activities of Daily Living Scale and Cambridge Behavioural Inventory –
Revised. Stage 2 involved individual interviews (36 people with dementia and 11 care workers); and
separate focus groups (34 optometrists; 38 family and professional carers).
Main outcome measures.: VI defined by visual acuity (VA) worse than 6/12 or worse than 6/18 measured
before and after refraction.
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Results: Stage 1 – when participants wore their current spectacles, VI prevalence was 32.5%
[95% confidence interval (CI) 28.7% to 36.5%] and 16.3% (95% CI 13.5% to 19.6%) for commonly used
criteria for VI of VA worse than 6/12 and 6/18, respectively. Of those with VI, 44% (VA < 6/12) and 47%
(VA < 6/18) were correctable with new spectacles. Almost 50% of remaining uncorrectable VI
(VA < 6/12) was associated with cataract, and was, therefore, potentially remediable, and one-third was
associated with macular degeneration. Uncorrected/undercorrected VI prevalence (VA < 6/12) was
significantly higher in participants in care homes (odds ratio 2.19, 95% CI 1.30 to 3.73; p< 0.01) when
adjusted for age, sex and sMMSE score. VA could not be measured in 2.6% of group 1 and 34.2% of
group 2 participants (p< 0.01). The main eye examination elements (excluding visual fields) could be
performed in > 80% of participants. There was no evidence that the management of VI in people with
dementia differed from that in older people in general. Exploratory analysis suggested significant deficits in
some vision-related aspects of function and behaviour in participants with VI. Stage 2 key messages – carers
and care workers underestimated how much can be achieved in an eye examination. People with dementia
and carers were unaware of domiciliary sight test availability. Improved communication is needed between
optometrists and carers; optometrists should be informed of the person’s dementia. Tailoring eye
examinations to individual needs includes allowing extra time. Optometrists wanted training and guidance
about dementia. Correcting VI may improve the quality of life of people with dementia but should be
weighed against the risks and burdens of undergoing examinations and cataract surgery on an
individual basis.
Limitations: Sampling bias is possible owing to quota-sampling and response bias.
Conclusions: The prevalence of VI is disproportionately higher in people with dementia living in care
homes. Almost 50% of presenting VI is correctable with spectacles, and more with cataract surgery. Areas
for future research are the development of an eye-care pathway for people with dementia; assessment
of the benefits of early cataract surgery; and research into the feasibility of specialist optometrists for
older people.
Funding: The National Institute for Health Research Health Services and Delivery Research programme.
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Glossary
Acute angle-closure glaucoma A condition in which the pressure inside the eye increases rapidly,
and which can be provoked by dilatation of the pupil in a predisposed eye.
Aphakia An ocular condition in which the crystalline lens is absent. It is usually the result of surgical
removal of cataract.
Aphakic An eye without the crystalline lens.
Binocular vision Vision that incorporates images from both eyes simultaneously. In normal binocular
vision these images are fused into a single impression.
Crystalline lens The lens inside the eye, situated behind the iris, which contributes to the formation of
images on the retina.
Domiciliary eye examination An eye examination undertaken at the place where the person being
examined normally lives.
Fundus The back portion of the interior of the eye visible with an ophthalmoscope.
Glasgow acuity cards A visual acuity test which consists of a set of cards contained in a flip-card format.
Intraocular lens implant A lens inserted into the eye to replace the crystalline lens after surgical removal
of cataract.
Logarithm of minimum angle of resolution chart A chart for testing visual acuity in which the size of
the rows of letters varies in a logarithmic progression.
Monocular Relating to one eye.
Opacities Non-transparent structures (often cataract) in the eye.
Ophthalmologist A medical specialist in the field of medical and surgical care of the eyes.
Ophthalmoscope A piece of equipment for viewing the inside of the eye.
Ophthalmoscopy Examination of the interior of the eye with an ophthalmoscope.
Optometrist A person who practises the profession of optometry.
Orthoptist A person who practises the profession of orthoptics, which is primarily the diagnosis and
treatment of anomalies of binocular vision.
Posterior subcapsular cataract A cataract, which is usually age-related, and which is situated towards
the back of the crystalline lens.
Refractive correction The prescription of spectacles (or contact lenses) to correct errors of focusing of
the eye.
Retinopathy A disease of the retina.
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Snellen charts A visual acuity test using a graduated series of Snellen letters.
Tonometry The measurement of intraocular pressure with a tonometer.
Visual acuity The ability to see distinctly the details of an object.
Visual field The extent of the surrounding area which is visible to an eye looking steadily in a
given position.
Visual impairment Reduced visual performance, which can be defined in various ways.
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Plain English summary
The key research questions of this study were (1) what is the prevalence of (how common are) visionproblems in people with dementia aged 60–89 years?; and (2) how often are these problems
undetected or inappropriately managed?
In stage 1, 708 people with dementia had an eye examination. Nearly one-third of participants in whom
vision could be measured were visually impaired (had significant sight loss) according to an established
definition. Almost half of the visually impaired were no longer visually impaired with up-to-date spectacle
prescriptions. Among the remainder, nearly half were visually impaired as a result of cataracts, which could
be removed. Important parts of the eye examination were possible in > 80% of participants.
In stage 2, interviews were conducted with people with dementia and care workers. Focus groups
(small groups of people brought together to give their opinions) were held with family carers, care workers
and optometrists.
The focus groups with family and professional carers revealed that:
l eye examinations were considered important
l there was uncertainty regarding whether or not eye examinations for people with dementia
were possible
l there was insufficient information about the availability of domiciliary (provided to people in their own
homes) eye-care services
l there was room for possible improvements to eye care for people with dementia.
The focus groups with optometrists revealed:
l the desire to gain knowledge about, and skills needed to provide better services to, people
with dementia
l advance information, given when making the appointment, that a patient had dementia would help
the optometrist to accommodate individual needs.
Research is needed to see if early cataract removal, by improving vision, slows the progression of
cognitive impairment.
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Scientific summary
Background
Various conditions cause visual impairment (VI) in older people, yet many cases can be prevented or
treated with early detection and correct management. Risks of dementia and VI increase with age, so a
large proportion of people with dementia may also have VI; UK demographic changes suggest that
increasing numbers will be affected by both dementia and VI.
A body of evidence exists on the impact of VI on quality of life, the increased risk of falls and higher rates
of admission to residential care, but a literature review exposed a dearth of good-quality evidence on the
prevalence of VI among people with dementia. Data from the Royal National Institute of Blind People
suggest that many older people do not have regular eye examinations, and uptake among people with
dementia is thought to be considerably lower, suggesting that an undefined proportion of older people
have VI that could be helped by cataract surgery or by wearing the correct spectacles.
Objectives
The main research questions of the Prevalence of Visual Impairment in Dementia (PrOVIDe) study were
(1) what is the prevalence of a range of vision problems in people with dementia aged 60–89 years; and
(2) to what extent are these conditions undetected or inappropriately managed?
The primary objectives were to:
1. measure the prevalence of a range of vision problems in people with dementia
2. compare the prevalences found in objective 1 with published data on the general population in a
comparable age range
3. identify and describe reasons for any underdetection or inappropriate management of VI in people
with dementia
4. recommend interventions to improve eye care for people with dementia and further research in
this area.
The secondary objectives were to:
1. identify any differences in the level of undetected or inappropriately managed VI between those living
in their own homes and those living in care homes
2. determine estimates for the percentages of people with dementia likely to be able to perform elements
of the eye examination successfully
3. relate vision problems in people with dementia to data from functional and behavioural assessments.
Methods
The study had two stages: a cross-sectional prevalence study followed by qualitative research.
In stage 1, 708 people with dementia (389 living at home and 319 living in care homes) had a domiciliary
eye examination. Inclusion criteria were people with dementia (any type), aged 60–89 years; individuals
lacking mental capacity to provide informed consent to participate required a consultee who could consent
on their behalf.
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Exclusion criteria were individuals who:
l had been in hospital in the preceding 2 weeks following acute illness, delirium or major infection
l were participating in a clinical drugs trial: the eye examination involved instilling tropicamide eye drops,
and potential drug interactions could not be determined
l were unable to understand English, as consent procedures and the eye examination were in English
l were unable to co-operate with the simplest eye examination procedures.
Participants were recruited from 20 sites in six English regions, with assistance from the National Institute
for Health (NIHR) Research Dementias and Neurodegenerative Diseases Research Network.
In stage 2, qualitative data were collected from 119 participants. Interviews were conducted with
36 people with dementia from stage 1 and 11 care workers. Focus groups were conducted with
optometrists (five groups), family carers (five groups) and professional carers (one group). Framework
analysis was used to identify, explore and describe issues around the detection and management of vision
problems among people with dementia from the perspectives of affected individuals, family carers,
professional care workers and optometrists.
Results
Key findings: stage 1
l Optometrists usually recommend that people have annual sight tests from the age of 70 years
onwards, and every 2 years before that unless there are clinical reasons for more frequent testing.
In the PrOVIDe study, 22% of participants reported not having had a test in the past 2 years, including
19 who had not been tested in the past 10 years.
l The prevalence of presenting VI was 32.5% [95% confidence interval (CI) 28.7% to 36.5%] and
16.3% (95% CI 13.5% to 19.6%) for visual acuity (VA) < 6/12 and < 6/18, respectively, in people
aged 60–89 years, generally higher than in comparable data from prevalence studies on the general
population after adjustment for age and sex.
l Notably, 51.4% (95% CI 44.5% to 58.3%) and 26.4% (95% CI 20.7% to 33.0%) of participants
living in care homes had VI using the VA < 6/12 and VA < 6/18 cut-offs, respectively.
l Visual impairment was correctable with an up-to-date spectacle prescription (uncorrected/undercorrected
VI) for 14.3% (95% CI 11.7% to 17.5%) of participants for VA < 6/12 and 7.7% (95% CI 5.7% to
10.2%) for VA < 6/18.
l With the best spectacle correction, VI remained for 18.1% (95% CI 15.2% to 21.5%) and 8.6%
(95% CI 6.6% to 11.3%) of participants for VA < 6/12 and < 6/18, respectively.
l Cataract was the primary cause in 48.0% of post-refraction VI (for the VA < 6/12 criterion). This VI is
potentially remediable. Age-related macular degeneration (AMD) was the primary cause in 36.3% of
participants. For VA < 6/18, AMD was the cause in 48.9% of cases and cataract was the cause in
36.1% of cases.
l Distance VA improved by two or more lines (Logarithm of Minimum Angle of Resolution chart) post
refraction in 17.8% of participants.
l A total of 16.2% of participants could not read standard newspaper-size print with current spectacles;
however, almost two-thirds of these participants could read this print with up-to-date spectacles.
l While research studies rarely include substantial numbers of people with dementia living in care homes,
PrOVIDe had 319 care home residents (44%). The unadjusted rate ratios of all types of VI were two to
two-and-a-half times greater for care home residents than for participants living in their own homes;
these higher rates persisted even after age and sex adjustments.
l After adjustment for age, sex and group, cognitive impairment assessed by Standardised
Mini-Mental State Examination (sMMSE) had a significant independent effect for uncorrected/
undercorrected VI (VA < 6/18) (p= 0.03) but there was no evidence for an independent sMMSE effect
for VI defined as VA < 6/12.
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l Exploratory analysis found evidence for deficits in some vision-related aspects of function and
behaviour in participants with VI versus those without VI.
l There was no evidence that management of VI in people with dementia differed from that of VI in the
general population of older people. The percentage of participants advised of a change in spectacle
prescription post refraction was consistent with the national figure. PrOVIDe’s referral rate (6.7%) was
higher than the national figure of (5%) for the population as a whole, possibly owing to the older
age-profile of PrOVIDe participants.
l When extrapolated to the UK wider population with dementia, following post-stratification calibration
and imputation, VI prevalences are generally higher, with wider CIs, than PrOVIDe sample rates.
¢ For VA < 6/12, extrapolated prevalences for presenting, post-refraction and uncorrected/
undercorrected VI were 34.6% (95% CI 29.3% to 40.3%), 22.4% (95% CI 16.4% to 29.9%),
and 13.6% (95% CI 10.5% to 17.4%), respectively.
¢ For VA < 6/18, extrapolated prevalences for presenting, post-refraction and uncorrected/
undercorrected VI were 20.3% (95% CI 16.7% to 24.6%), 12.2% (95% CI 8.8% to 16.6%) and
8.3% (95% CI 5.9% to 11.6%), respectively.
Key findings: stage 2
l Data from all parties revealed gaps in communication. Optometrists are not always informed that an
individual they are examining has dementia; optometrists explained the importance of knowing this so
that the examination could be tailored to individual need.
l Stage 1 demonstrated that it was possible for optometrists to conduct most key components of the eye
examination on > 80% of people with dementia, but carers and care workers were unsure if people
with dementia could have a full eye examination if they had difficulty answering questions.
l Optometrists are not adequately prepared during training to examine people with dementia; many
thought that there was a need for additional training and support. They suggested exploring the role
of a specialist optometric practitioner or specialist services for older people.
l The need to allow more time when examining people with dementia was identified by all participant
groups, but the current examination fee structure militates against this.
l Promoting spectacle wearing among people with dementia can be difficult owing to refusal to wear
spectacles or to missing/broken spectacles, particularly in care homes.
l Carers and care workers had concerns about risks of cataract surgery under either local or general
anaesthetic and described the need to balance the risks against the benefits and impact on quality of
life. However, most people with dementia interviewed said that they would want surgery if required.
Carers and some optometrists thought that current thresholds for cataract surgery should be lower for
people with dementia, allowing surgery while the individual was able to consent and better able
to cope.
l Almost all people with dementia who were interviewed, and family carers, had been unaware of the
availability of domiciliary eye examinations prior to their participation in PrOVIDe.
Limitations
l Sampling bias is possible owing to quota-sampling and response bias, with some participants and/or
their carers more health-orientated than the general population. PrOVIDe’s regional sample may not be
fully representative of the general UK population.
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Conclusions
Prevalence estimates of presenting VI in those with dementia from PrOVIDe are generally higher, after
adjusting for age and sex differences, than estimates from previous population studies of older people
which used comparable methods and which either excluded or had low proportions of participants with
dementia. The high prevalence of participants with uncorrected/undercorrected VI, the disproportionately
high prevalence of VI in care home residents and the high proportion of those with VI due to potentially
remediable cataracts, suggest that eye care for people with dementia could be enhanced by attention to
the following.
More eye care information for people with dementia and carers
It was possible for optometrists to conduct key components of the eye examination on > 80% of people
with dementia, visual fields being the exception. The important health checks of tonometry and direct
ophthalmoscopy were possible in > 90% of participants. The qualitative finding that some carers and care
workers were unsure that people with dementia could have a full eye examination if they had difficulty
answering questions indicates a need to increase awareness about the purpose, scope and limitations of
eye examinations to encourage uptake of eye examinations in line with health-care recommendations.
Better communication between carers, optometrists and other
health-care professionals
Qualitative data revealed communication gaps between optometrists and those caring for people with
dementia, and between optometrists and other health-care professionals. Ensuring that optometrists know
when they are dealing with someone with dementia would enable them to tailor the examination to meet
individual needs. This includes involving a family member whenever possible, something that family carers
identified as being highly relevant. When individuals having an eye examination are accompanied by a
professional care worker, it is important that the care worker knows the individual and has the relevant
information to hand. Optometrists should ensure that they contact the care home for further information
if necessary.
Tailoring the eye examination, spectacle dispensing and treatment of eye
conditions to meet the needs of the individual
Improving VA, identifying possible causes of VI and referring patients for medical intervention when
necessary are the main responsibilities of the optometrist when examining an older person with dementia.
However, the needs of the individual and quality-of-life issues should be considered by the attending
optometrist and discussed with carers. This may impact decisions regarding the desirability of subjecting an
individual to a full eye examination if this is likely to cause substantial distress, minimising unnecessary
changes when prescribing and dispensing spectacles, and possible referral for cataract surgery.
Professional development and guidance for optometrists
The PrOVIDe study was led by the College of Optometrists, the professional, scientific and examining body
for optometry in the UK, working for the public benefit. More than 70% of UK optometrists are members,
which positions the College to increase professional awareness of eye care for people with dementia by
providing information, guidance and opportunities for professional development.
Recommendations for research
Further improvements to eye care for people with dementia could emerge subject to the outcomes of
further recommended research.
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Development of an eye-care pathway
Research is needed into the development of an eye-care pathway for people with dementia, considering
what should happen in terms of eye care when an individual is diagnosed with dementia. This could
include the following questions:
l What information do individuals and carers need to promote uptake of eye examinations?
l What are the barriers to and facilitators of providing continuity of eye care?
l What modifications are required to the current structure for General Ophthalmic Services sight test
funding in both community and domiciliary practice? This could include establishing minimum
requirements for an ocular health check when there are difficulties completing a full eye examination
and providing adequate remuneration for the extra time often required for the examination of people
with dementia.
l In acknowledgement of the problems regarding spectacles for people with dementia (increased
incidence of spectacles being broken or lost), should there be additional financial support for spectacle
provision? For example, should there be financial subsidies to provide spectacles made from materials
less likely to break?
l Should the threshold for cataract surgery be lower for people with dementia?
The last of these research questions is related to the second area of research recommendations.
Early intervention for cataract
People with dementia interviewed for PrOVIDe said that they would have cataract surgery if needed.
Carers described balancing the risks, burdens and benefits of cataract surgery against the impact on quality
of life. The potential for different outcomes in decision-making depending on who is responsible suggests
that it would be preferable for the decision to be made while an individual has mental capacity to decide.
This generated the second research recommendation, that there should be research into the effects of
early cataract intervention for people in the early stages of cognitive impairment.
The specialist optometric practitioner role
Research is needed to explore the potential of developing the role of a specialist optometric practitioner
for people with dementia. This would include establishing competencies for the role, training requirements
and feasibility. Initial research should consider the level of interest from the optometric profession and
consider if this dementia role could be accommodated within the alternative of a specialty for working
with older people. Research should also explore the role’s positioning in the current mixed economy of
health-care provision: that is, would specialists be independent practitioners or employed by the NHS in
hospital, or in community/domiciliary settings?
Eye care for other vulnerable groups
The PrOVIDe study findings suggest that almost 25% of participants had not had an eye examination in
the previous 2 years and that eye care for people with dementia could be improved. Critically, none of the
participants in stage 1 living in their own homes was aware that a domiciliary sight test was possible.
Therefore, research should also be conducted into the prevalence of undetected/uncorrected VI and
provision of eye care for other vulnerable groups. PrOVIDe study findings regarding the lack of awareness
of domiciliary eye care suggest that one such target group would be older people with chronic illness and
disability who have difficulty accessing community-based optometric practice.
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Chapter 1 Introduction
Dementia and sight loss
Recent estimates of the number of people in the UK with some form of dementia range from 670,0001 to
835,000.2 Dementia prevalence increases with age, rising dramatically from 1.7% of people aged between
65 and 69 years to affect > 40% of people over the age of 95 years.2 It is estimated that by 2021 over
1 million people in the UK will have dementia, a figure expected to rise to over 2 million by 2051,2
reflecting increased longevity. The 2011 Census report Population and Household Estimates for England
and Wales3 indicated that the percentage of the population aged ≥ 65 years was 16.4%, the highest
recorded in any census. There has been a notable increase in the frequency of the oldest-old, with
430,000 residents aged ≥ 90 years in 2011, compared with 340,000 in 2001 and 13,000 in 1911.3
The costs of dementia care in the UK were estimated to be approximately £23B per year in 2010,4 and in
2014 alone dementia cost the UK economy £26B.2
The Royal National Institute of Blind People (RNIB) estimates that almost 2 million people in the UK live
with sight loss that has a significant impact on their daily lives, and predicts that this figure will rise to
almost 4 million by 2050.5 Over 50% of sight loss is avoidable; this figure includes people with sight loss
which, at least in part, is caused by wearing spectacles that are not of the optimum strength. One in four
people aged ≥ 75 years is living with sight loss, and in the population aged > 85 years this rises to one in
three.6 Both dementia and sight loss are increasingly prevalent with age, and the UK’s ageing demographic
will result in many more people living with both dementia and sight loss.
Two-thirds of people with dementia live in private households and one-third live in some form of
institutional care setting.1 Many older people with sight loss live in care homes and there is evidence that
they are subject to a disproportionally high burden of visual loss, with an estimated 30% of those who are
visually impaired living in care homes.7 The proportion of the total UK population living in care homes was
estimated to be 0.55% in 2011 (approximately 350,000 people) and this proportion is likely to rise to
0.85% (600,000 people) by 2031.7
There is increasing evidence of significant disturbances to visual function in Alzheimer’s disease and other
types of dementia, which may affect different aspects of visual performance including contrast sensitivity,
colour vision, spatial awareness and depth perception,8 and hallucinations.9,10 Studies investigating sight
loss and dementia have revealed shared changes in nervous system physiology and suggest that the
prevalence of sight loss in people with dementia is higher than that in the general population of older
people without dementia.10 People with dementia not only suffer the general visual problems associated
with ageing but also experience deficits of higher level visual processing including reading, object
recognition and spatial localisation as a result of the damage to, or degeneration of, the brain,11 which can
make the differential diagnosis of ‘eye problems’ from functional vision loss caused by dementia or, for
example, stroke more difficult. The effects of having both serious sight loss and dementia concurrently are
much more severe than those resulting from either dementia or sight loss alone.10 Dementia alone often
has a significant impact on quality of life; however, the ability of a person with dementia to cope with
visual impairment (VI) is reduced, which can impact significantly on his or her activities of daily living and
cognitive performance.8
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Visual impairment
A variety of definitions of VI have been used in prevalence studies. All of these definitions use criteria for
VI based on levels of visual acuity (VA). VA is determined from the size of the smallest line of letters or
symbols on a chart which a person can read. The definitions all express VA in terms of Snellen’s fraction
(e.g. 6/12, 6/36 or 20/40), where the numerator of the fraction is the standard testing distance (6 metres
in most of the world) and the denominator is a measure of the size of the letters on the line of the
smallest letters that can be read. There is no standardisation regarding the VA level at which an individual
becomes classified as visually impaired.11 Definitions of the degrees of VI and blindness vary from country
to country, with those set by the World Health Organization and those used in the USA and UK
influencing the cut-off points for VA adopted in VI prevalence studies.11
The World Health Organization criterion for VI is poor vision resulting from any cause including
uncorrected refractive error. They differentiate between visual impairment and blindness, and their VA
cut-off points for VI are:
l visual impairment – VA < 6/18 but ≥ 3/60 binocularly with presenting correction [International
Classification of Diseases, Tenth Edition (ICD-10),12 categories 1 and 2]
l blindness – VA of < 3/60 in the better eye with presenting correction (ICD-10,12 categories 3–5) or
visual field of no greater than 10 degrees in radius around central fixation.
In the USA, VI is defined as the best corrected VA < 6/12 (equivalent to < 20/40) in the better-seeing eye.13
Since 2003, people with VI in the UK can be classified as either ‘sight impaired’ or ‘severely sight
impaired’. Prior to 2003, sight-impaired and severely sight-impaired people were referred to as ‘partially
sighted’ and ‘blind’, respectively. There is no legal definition of sight impaired but it is defined in common
use as being ‘substantially and permanently handicapped by defective vision caused by congenital defect,
illness or injury’.14 Guidance is given as to defects of binocular VA and visual field that could lead to
registration as sight impaired:15
l 3/60 to 6/60 with full field
l up to 6/24 with a moderate restriction of the field, opacities or aphakia
l 6/18 or better with a gross field defect.
The definition of blindness (severely sight impaired) in the UK is: ‘So blind as to be unable to perform any
work for which eyesight is essential’.14 Guidance is given as to defects of binocular VA and visual field
which could lead to registration as severely sight impaired:
l acuity < 3/60
l acuity > 3/60 but < 6/60 with significantly contracted field
l acuity > 6/60 but with substantially contracted fields, especially inferiorly.
It should be noted that neither definition nor the associated guidance makes any reference to near vision,
to an individual’s occupation or to any other disabilities they may have.
Common causes of sight loss and visual impairment
An estimated 1.87 million people live with sight loss in the UK. Approximately 360,000 are registered as
sight impaired or severely sight impaired.5,6 Age-related macular degeneration (AMD) is by far the main
cause of registrable VI (sight impaired or severely sight impaired) in the adult UK population.16 Other major
causes are diabetic eye disease and glaucoma. However, 1.64 million of the people with sight loss have
mild or moderate loss, much of which is correctable.6 The primary causes of correctable visual loss are
cataract and uncorrected refractive error.7,11
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Age-related macular degeneration
Age-related macular degeneration can be defined as ageing changes in the central area of the retina
(the macula) occurring in people aged ≥ 55 years in the absence of any other obvious cause.17 AMD is the
leading cause of irreversible severe visual loss in high-income countries in individuals aged > 60 years.18
It is the most common cause of adult blind registration in many high-income countries, including the UK.16
However, those registered are an underestimate of the true prevalence of the condition because many
with early AMD do not qualify for registration and some elect not to opt for registration.
There are many classifications of AMD; one classification is late AMD, geographic atrophy and neovascular
AMD, which have prevalences of 4.8%, 2.6% and 2.5%, respectively, in the UK population aged
≥ 65 years.19 An alternative classification is into two types: dry (non-exudative) or wet (exudative). Dry AMD
is a slow progressive disease which accounts for 90% of cases. The wet type is much less common but can
be more devastating. All useful central vision can be lost within days of wet AMD developing. As a result
of recent developments in wet AMD treatment, some resultant VI can now be successfully treated.7
Approximately 1.5 million people are living with the early stage of AMD.20
Cataract
Cataract is loss of transparency of the crystalline lens. Age-related cataract is the most common form.21
A classic symptom is a slow, gradual, painless progressive reduction in the quality of vision.22 Not all
cataract types are equally deleterious to vision; for example, posterior subcapsular opacities develop
near the posterior pole of the lens and can have a dramatic effect on vision owing to their location.23
Age-related cataract is the most common cause of reversible blindness worldwide. The prevalence of
cataract increases with age, with an increased number of advanced cataracts in the older population.24,25
Acquired cataracts and dementia are both common age-related problems and it is, therefore, likely that
they will coexist.26
Cataract prevalence estimates depend on the definition of when the normal ageing and opacification of
the crystalline lens reaches the point at which it becomes sufficient to bring a diagnosis of cataract.
Often this point is based on when the cataract causes a significant effect on some aspect(s) of visual
performance, normally standard VA measurements. In a study in North London in 1998,27 significant
cataract was defined as VA < 6/12, attributable to cataract, in one or both eyes. In this sample of
1547 people aged > 65 years, prevalence of cataract for the whole sample was 30%. Cataract prevalence
(including aphakia or pseudophakia) increased with age from 16% (65–69 years) to 24% (70–74 years),
42% (75–79 years) and 59% (80–84 years), to 71% in people aged ≥ 85 years.
Visual impairment resulting from cataract is potentially remediable via surgical removal of the existing lens,
replacing it with an intraocular implant. Cataract surgery is now the most commonly performed surgical
intervention carried out on the NHS in England,28 with an increase of almost 100,000 cases per annum
compared with a decade ago. In England in 2011/12, a total of 337,000 cataract operations were
performed as day cases, with the mean age of those undergoing the cataract surgery being 74.4 years.29
Referral for cataract surgery can be initiated by either the optometrist or the general practitioner (GP).
Action on Cataracts30 suggested direct optometrist referral according to locally agreed protocols and there
are now many such projects with audited outcomes and high conversion rates from referral to surgery.
Diabetic retinopathy
Diabetic retinopathy, a complication of diabetes, is a chronic, progressive, potentially sight-threatening
disease of the retinal microvasculature.31 Retinopathy which affects the macular region of the eye,
responsible for providing optimum VA, is often separately referred to as diabetic maculopathy. There are
a number of different classifications of diabetic retinopathy, often with overlap between the different
classifications. All refer to the two basic mechanisms which can lead to visual loss: that is, the risk of new
vessel growth in retinopathy and the risk of damage to the central part of the macula, known as the
fovea.31 If abnormal new vessels are present, the retinopathy is described as proliferative retinopathy,
while in the absence of new vessels it is known as non-proliferative or background retinopathy.
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A population screening study in Liverpool reported the prevalence of diabetic retinopathy to be 25.3%
in type 1 diabetes and 45.7% in type 2 diabetes.32 In 2010, an estimated 748,000 people were living
with background diabetic retinopathy and 85,000 would be classified as falling into non-proliferative
and proliferative diabetic retinopathy combined (the more advanced stages of background diabetic
retinopathy).20 Diabetic maculopathy, which can lead to sight loss more rapidly, was expected to be
present in 188,000 people in 2010.20 When studies are stratified for duration of eye disease and age,
there is an increase in diabetic retinopathy in older people and in those with long-standing disease.33
There is clear evidence that sight-threatening diabetic retinopathy has a recognisable latent or early
symptomatic stage.32 Regular monitoring and vigilant treatment can help to prevent the disease
progression which can lead to blindness. All those with diabetes, either type 1 or type 2, are offered an
annual appointment for screening for diabetic retinopathy as part of the NHS diabetic eye screening
programme. The screening can be carried out in hospital, GP or optometric practice locations and involves
taking a fundus photograph which is subsequently graded.33
Glaucoma
Glaucoma, or, more correctly, the glaucomas, is a group of eye diseases that have in common progressive
structural damage to the optic nerve head, resulting in a characteristic glaucomatous optic neuropathy,
with functional loss of the corresponding visual field and which can lead to blindness if left untreated.
Glaucoma is second to AMD as the most common cause of severe sight impairment (blindness) in adults in
the UK and Ireland.15,16,34,35 Primary open-angle glaucoma (POAG) is a chronic, generally bilateral, although
asymmetrical, disease, characterised by progressive damage of the optic nerve shown by glaucomatous
changes affecting the optic disc, the retinal nerve fibre layer and/or the visual field.36 POAG accounts for
75–95% of glaucoma among people from white ethnic groups37 and is the most common form of
glaucoma in the UK. The prevalence of POAG in the UK population aged > 40 years is estimated to be
2.0%. Prevalence rises steeply with age, from 0.3% at 40 years of age to 3.2% at 70 years.38 Based on a
Bayesian meta-analysis, the pooled prevalence of open-angle glaucoma was estimated to be 6% in white
populations, 16% in black populations and 3% in Asian populations.39
In 2010, there were estimated to be 266,000 people living with detected glaucoma20 and an additional
191,000 people with undetected glaucoma in the UK.29 A pooled prevalence analysis estimated the
number with undetected disease to be as high as 380,000.40 A further 513,000 people were estimated to
have ocular hypertension (OHT), which is elevated intraocular pressure (IOP) in the eye without any other
signs of glaucoma but which increases the risk of subsequently developing glaucoma.20 The prevalence of
OHT in those aged > 50 years has been estimated to be between 3.7% and 7.6%.41
UK community optometrists provide the majority of primary eye care and are responsible for approximately
95% of referrals for suspected glaucoma to secondary care.42 Late presentation with advanced disease
is a risk factor for blindness from glaucoma.43 Late detection may result from patients not engaging with
community eye care, from a failure of health professionals to identify the disease at an early stage or from
unusually rapid disease progression. The VI caused by glaucoma is irreversible but the disease is treatable,
although successful management is more difficult with late-stage presentation.36
Uncorrected or undercorrected refractive error
The term refractive error refers to errors in the optical performance of the eye resulting in a distorted or
defocused image on the retina. Refractive error is usually not constant throughout life. One reason for
recommending that people have regular optometric sight tests is to identify and correct those changes
in refractive error that occur over time. People may not be wearing the required lens powers in their
spectacles to fully correct their current refractive error. This can occur for various reasons, including people
leaving too long an interval between sight tests, people declining to have the recommended prescription
for their refractive error made up into spectacles or failing to wear the correct pair of spectacles. People
who are not wearing the appropriate strength of lenses to correct their refractive error are referred to as
having undercorrected or uncorrected refractive errors. These can be resolved using appropriate spectacles
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following an eye examination by an eye health professional. The prevalence of undercorrected or
uncorrected refractive errors in the UK older population has been reported to be between 9%27 and
40%44 for VI defined as VA < 6/12. However, this 40% figure was obtained from a small, enriched sample
of patients admitted to a department of geriatric medicine with acute illness and was unrepresentative of
older people in general. The most recent of these studies was published in 1998 and there is a need for
updated estimates of undercorrected or uncorrected refractive error to reflect changes in clinical practice,
in health and social care policy, and in the life-course of individuals in the population.
Summary of common causes
A review of studies into correctable VI in older people estimated that 20–50% of older people have
undetected reduced vision.11 This wide range of estimates reflects, in part, the different criteria and cut-off
points used in studies to define VI.45 The majority of people with undetected reduced vision in these studies
had reduced vision resulting from undercorrected (or uncorrected) refractive error and cataract, and hence
their visual loss is potentially correctable following an optometric sight test by the provision and use of a
pair of spectacles or contact lenses of the appropriate prescription, or cataract extraction, respectively.11
Dementia and causes of sight loss develop independently. As people age, they are at an increased risk of
developing dementia and having serious sight loss, and hence there will inevitably be people with
both conditions.10
The Prevalence of Visual Impairment in Dementia (PrOVIDe) study limited its scope to the five conditions
listed above, as these are the most common eye-related conditions associated with sight loss. Many other
eye conditions and non-ocular conditions lead to significant sight loss, notably stroke, head injuries and
other neurological conditions. These conditions, particularly those more common in older age, can also
make significant contributions to visual dysfunction. However, these conditions fall outside the remit of the
current study.
Provision of eye-care services in the UK
The vast majority of UK optometrists work in primary care community optical practices, hospitals or
domiciliary settings. Most optometrists work in community optical practices, from where they are the major
providers of primary eye-care services. Optometrists are trained to perform sight tests, which include
refraction and detection of signs of injury, disease or abnormality in the eye.
Secondary eye care is delivered by the Hospital Eye Service (HES). Secondary eye care is usually provided
by a team of eye-care professionals including ophthalmologists, optometrists and orthoptists. There is
increasing integration between primary and secondary eye care, with primary care optometrists involved in
enhanced schemes to provide a range of services within a community-based setting, often in conjunction
with GPs and ophthalmologists, in order to case-find and monitor eye conditions.46–49
Provision of General Ophthalmic Services and NHS eye examinations in the UK
The vast majority of primary care optometrists have a contract with the NHS via local Clinical
Commissioning Groups to provide sight tests to eligible persons. The provision of General Ophthalmic
Services (GOS) was largely uniform across the UK until the introduction of devolved powers to Wales and
Scotland. This, together with NHS restructuring, created a more diverse provision, with the emergence of a
less rigid approach to the provision of primary eye care in some parts of the UK. Examples that illustrate
these changes are the Welsh Eye Care Initiative, introduced in 2003, which has evolved into the Eye Health
Examination Wales, and the new GOS contract in Scotland, which commenced in 2006. The PrOVIDe
study is limited to England, where change to the GOS provision has been more limited.
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The GOS regulations require practitioners to be satisfied that a NHS sight test is clinically necessary.47 In
general, people aged between 16 and 70 years at the time of the sight test will not normally have their
sight tested under the GOS more frequently than every 2 years. Similarly, people aged ≥ 70 years will not
normally have a sight test more frequently than every 12 months. However, under certain circumstances
the practitioner can carry out a sight test at a shorter interval than stated above ‘either at the practitioner’s
initiative for a clinical reason, or because the patient presents him/herself to the practitioner with
symptoms or concerns which might be related to an eye condition’.50 These recommended minimum sight
test intervals are reduced for certain patients; for example, for a diabetic patient of any age the minimum
interval between sight tests is reduced to 1 year.50
In 2012/13, there were 12.3 million NHS-funded sight tests in England,51 with 5.5 million (44.4%) of these
carried out for patients aged ≥ 60 years.51 Private sight tests are an option and an estimated 5.6 million of
these were carried out in 2011/12.52 A section of a survey by the RNIB of people aged > 60 years asked
how regularly they had sight tests; 53% reported having annual sight tests, 35% reported having a sight
test every 2 years and 11% reported having sight tests less frequently.53 It has been suggested that the
uptake of eye examinations among people with dementia is considerably lower than that in the population
without dementia of a similar age.8,54 A telephone survey by Shah et al.55 found that 93% of optometrists
stated willingness to examine people with dementia, but evidence of the uptake and quality of vision care
in this group of the population is lacking.
Provision of domiciliary sight tests
The majority of NHS sight tests are conducted on ophthalmic practitioners’ premises. In 2012/13, 3.2% of
NHS tests were domiciliary examinations, conducted in the individual’s place of residence or at a day
centre.51 Anyone eligible for a NHS sight test qualifies for a domiciliary sight test if they are unable to
attend a high-street practice unaccompanied because of physical or mental illness or disability.50 The
number of domiciliary sight tests has risen steadily since 2002/3, and the 2012/13 total of 407,000 was an
increase of almost 60% compared with a decade earlier. This increase could be attributed to the ageing
UK population, with more older people seeking eye examinations in their own home, although there is no
evidence to directly support this.51
Prevalence of visual impairment in people with dementia
Literature searches for the prevalence of VI and eye disease in the elderly, and for the prevalence of VI in
people with dementia, revealed a lack of good-quality prevalence data on the topics.
Search strategy
A PubMed search for prevalence of VI and eye disease in the elderly was conducted using the following
search strategy: (elderly[tiab] OR “aged”[MeSH Terms] OR geriatric[tiab] OR older) AND (“eye diseases”
OR “eye disease” OR “eye diseases” OR “visual acuity” OR “vision disorder” OR “vision disorders” OR
“visual impairment” OR “refractive error” OR “refractive errors” OR glaucoma OR presbyopia OR myopia
OR astigmatic OR astigmatism OR cataract OR cataracts OR “retinal diseases”[MeSH Terms] OR
“retinal diseases”[All Fields] OR retinopathy OR retinopathies OR “diabetic eye disease” OR “macular
degeneration” OR “low vision”) AND ((“epidemiology”[Subheading] OR “prevalence”[All Fields] OR
“prevalence”[MeSH Terms]) OR epidemiology[tiab]).
The search was initially carried out in 2011, prior to submission of a formal proposal to the National
Institute for Health Research (NIHR), and identified 9035 papers. It has been updated regularly, most
recently in April 2014 when 11,104 papers were identified. These studies vary as to whether the study
deals with a single eye disease, or several; whether it only addresses eye disease prevalence or includes it
in a study of several pathologies. Only a small number of papers found via this search, and from reference
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list searches of review articles and reports, specifically address the prevalence of VI in a large sample of
elderly people in the UK, although a wider body of international prevalence data exists.
A search of PubMed was conducted for papers dealing with the prevalence of eye disease and/or VI in
people with dementia using the following terms: (dementia OR alzheimer’s[tiab]) AND (“eye diseases”
OR “eye disease” OR “eye diseases”[MeSH Terms] OR “visual acuity” OR “vision disorder” OR “vision
disorders” OR “visual impairment” OR “refractive error” OR “refractive errors” OR glaucoma OR
presbyopia OR myopia OR astigmatic OR astigmatism OR cataract OR cataracts OR retinopathy OR
“retinal disease” OR “diabetic eye disease” OR “macular degeneration” OR “low vision”) AND
(“epidemiology”[Subheading] OR epidemiology[tiab] OR prevalence[tiab] OR prevalence[MeSH Terms]).
The search retrieved 295 papers in April 2014. Approximately 10 were prevalence studies and none of
these were UK papers.
Review of population-based UK studies into prevalence of visual
impairment in older people
Table 1 summarises the key features of the most relevant studies. Although the studies are few in number,
comparisons between them are made difficult by the variations in population and methods used. The
cut-off point in terms of VA employed to define VI was ‘worse than 6/12’ in some studies and ‘worse than
6/18’ in others, with prevalences for both criteria reported in some studies. There were also variations in
the methods used for recording VA; presenting VA was always measured but sometimes binocularly only,
sometimes monocularly (with best monocular VA recorded as presenting acuity), and sometimes both
monocularly and binocularly. Nor was it always used in the prevalence estimates.59 Older studies used
Snellen VA charts,44,58 while more recent studies have used logarithm of minimum angle of resolution
(logMAR) charts of various types. Testing distances varied between the standard 6-m distance and 3m.
Settings varied from broadly national56,57 to local.27,44,58 Sample sizes ranged from > 14,00056 to around
200.44,58 The sample ages were generally ≥ 65 years, although the Medical Research Council (MRC) study
investigated a sample aged ≥ 75 years.56
Some people with dementia will have been included in the sample for most studies, as cognitive
impairment was not an exclusion criterion. However, only two studies assessed cognitive impairment:
Jack et al.44 specifically excluded those with severe cognitive impairment, while the National Diet and
Nutrition Survey (NDNS)’s study analysed those with cognitive impairment separately.57 Only two studies
separately analysed data from a subgroup of participants who lived in care homes.44,57
Study 1
The MRC study was a large cluster randomised trial taking place in 106 general practices with participants
aged ≥ 75 years. VA data were obtained from 14,403 participants and VA was measured using the logMAR
Glasgow acuity cards at 3m.56 Presenting VA was measured first binocularly and then monocularly. Where
presenting VA was worse than 0.5 (equivalent to < 6/18) in either eye, VA was remeasured with a pinhole
disc. The pinhole disc is an opaque disc into which a small hole (the pinhole) has been drilled. The effect of
the pinhole is to reduce the effective pupil size of the participant. If the participant’s loss of vision is the
result of an out-of-focus image on the retina (which should be correctable with the appropriate prescription
in the participant’s spectacles), the pinhole can improve the participant’s vision by reducing the size of the
blur circles on the retina. All participants with pinhole VA of worse than 0.5 were referred to an
ophthalmologist. VA of the better eye was used if binocular VA was not available.
l Using the criterion of binocular presenting VA < 6/18, 12.4% [95% confidence interval (CI) 10.8% to
13.9%] of the sample had VI.
l With a pinhole, the prevalence of VI in the better eye was 10.2% using the ‘worse than 6/18’ criterion.
The pinhole could only be used successfully on 62% of those with presenting VA < 6/18 in either eye.
l Using the criterion of binocular presenting VA < 6/12, 19.9% (95% CI 17.8% to 22.0%) of the sample
had VI.
l The prevalence of VI was higher in women and rose steeply with age.
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l The main causes of VI were extracted from GP notes or hospital records.45
l When refractive error is excluded from the list, the main causes become AMD (52.9%), cataract
(35.9%), glaucoma (11.6%), diabetic eye disease (3.4%) and myopic degeneration (4.2%).
Comment
l This study had a large sample size covering many areas of Britain and was representative of the UK in
terms of mortality and deprivation.
l No refraction was carried out.
l Visual acuity was recorded by trained nurses and may not be as accurately recorded as would be the
case with optometrists, ophthalmic nurses or ophthalmologists.
TABLE 1 Prevalence of VI from a range of UK studies
Survey (year),
reference
Location
(sample size);
age range
Method of
recording VA
Sample size for
VA testing
VA cut-off
point
defining VI
Prevalence (%)
aged ≥ 65 years
(95% CI)
Prevalence (%)
aged ≥ 75 years
(95% CI)
Study 1: MRC trial
(1995–8), Evans
et al., 200256
Great Britain
(n= 15,126);
aged ≥ 75 years
Presenting
binocular VA
14,600 < 6/12 N/A 19.9
(17.8 to 22.0)
< 6/18 12.4
(10.8 to 13.9)
Pinhole
corrected
< 6/18 10.2a
Study 2: Jack
et al., 199544
Liverpool, UK
(n= 200); aged
≥ 65 years
Presenting
binocular
VA (Snellen)
200 < 6/12 50.5a N/A
Study 3: North
London Study
(1995–6), Reidy
et al., 199827
North London,
UK (n= 1547);
aged ≥ 65 years
Presenting
monocular
VA. Pinhole-
corrected
VA (logMAR)
1547 < 6/12 30.2
(24.8 to 35.5)
N/A
Study 4: NDNS
(1994–5), van der
Pols et al., 200057
Mainland, UK
(n= 2060);
aged ≥ 65 years
Best
monocular
VA, with or
without
a pinhole
1362 (not
cognitively
impaired)
< 6/12 28.3a 39.3a
1362 (not
cognitively
impaired)
< 6/18 14.3a 21.0a
125
(cognitively
impaired)
< 6/18 64.8a N/A
Study 5: Wormald
et al., 199258
London, socially
deprived area,
UK (n= 207);
aged ≥ 65 years
Presenting
binocular VA
(Snellen) and
monocular VA
207 < 6/12 14.5
(10.3 to 20.0)
26.4
(18.9 to 35.6)
207 < 6/18 7.7
(4.5 to 12.2)
14.2
(7.5 to 20.8)
Study 6: Melton
Mowbray, Lavery
et al., 198859
Melton
Mowbray, UK
(n= 677); aged
> 75 years
Best
monocular
VA (Snellen)
529
Post-refraction
data
< 6/12 N/A 26.2a
CI, confidence interval; N/A, not applicable; NDNS, National Diet and Nutrition Survey.
a No CIs reported.
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Study 2
Jack et al.44 conducted a prospective study of 200 consecutive mentally competent patients aged
≥ 65 years (mean age 80 years) admitted to hospital with an acute illness. Binocular VA was measured
with a Snellen chart at 6m. Patients with VA of ≤ 6/18 had a full ophthalmic assessment from an
ophthalmologist, and a decision was made as to the main cause of VI if more than one potential cause
was found.
l Using the criterion of binocular presenting VA < 6/12, 50.5% of the sample had VI.
l Of those with VI, 40% were caused by refractive errors and 37% by cataract; a total of 79% were
considered as being due to reversible causes.
l A total of 76% of those admitted to the hospital following a fall had VI.
Comment
l The last line read correctly on the Snellen chart was taken as the participant’s VA. This was common
practice in those studies reported here which used Snellen charts and is a weakness of such studies.
A participant able to read most of the letters on a line will not have those successes counted towards
their overall VA, which will be determined by a line of larger letters which was read correctly in its
entirety. With modern logMAR charts, not available for these early studies, every letter read correctly by
the participant counts towards the VA recorded, even if these letters are from a line on the chart that
was not read correctly in its entirety. Choosing the last line read correctly on a Snellen chart will tend
to underestimate VA and overestimate VI.
l Patients with severe cognitive impairment were excluded from the study. The sample was an enriched
one comprising a selective population of patients admitted to a department of geriatric medicine with
an acute illness.
l The eye examination by the ophthalmologist was carried out only on those with VI. A full refraction
was performed on a proportion of those with VI but the number is not stated.
l An unstated but small number of participants lived in care homes. No effect of location was found
when comparing prevalence of VI in participants living in care homes and participants living in their
own homes.
Study 3
Reidy et al.27 conducted a cross-sectional survey using two-stage cluster random sampling in north London.
Participants were recruited from general practices and 1547 were examined. Monocular VA was recorded
with a logMAR chart at 6m and was repeated with a pinhole. An autorefractor was used to determine
refractive error. VA, autorefraction and visual fields were assessed by trained ophthalmic nurses and a
comprehensive eye examination was performed by ophthalmologists.
l With a criterion of bilateral presenting VA of < 6/12, 30.2% (95% CI 24.8% to 35.5%) of the sample
had VI.
l A total of 72% of those with VI as defined above were classed as potentially remediable.
l The population prevalence of refractive error causing VI in one or both eyes was 9% (95% CI 7.0%
to 11.4%).
l The age-standardised prevalence of poor vision was significantly higher in residents of the most
underprivileged areas.
l The prevalence of cataract causing VI in one or both eyes was 30% (95% CI 25.1% to 35.3%).
l The prevalence of open-angle glaucoma and suspected glaucoma was 3% (95% CI 2.3% to 3.6%)
and 7% (95% CI 5.4% to 8.4%), respectively.
l Reasons given for the high level of undetected and untreated morbidity in the population included low
levels of attendance at the primary care optometrists or failure to purchase corrective spectacles;
suboptimal integration of vision checks into the general primary care of older people; and people’s
perceptions of the extent to which their vision has gradually diminished and the point at which help
should be sought.
DOI: 10.3310/hsdr04210 HEALTH SERVICES AND DELIVERY RESEARCH 2016 VOL. 4 NO. 21
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Bowen et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
9
Comment
l The examination of each participant by an ophthalmologist is a strength of this study.
l Unusually, the proportion of VI reported was bilateral VI, rather than the more common binocular VI or
VI based on the acuity of the better eye.
l Results on socioeconomic background of the sample were described as ‘tentative’, but the association
between the degree of underprivilege and cataract and uncorrected/undercorrected refractive error
is informative.
l A potential strength of the study is the use of an autorefractor to determine refractive error. However,
it is unclear how the autorefractor results were used. There is no indication that the current/habitual
spectacle correction was measured using a focimeter, so the autorefractor findings could not be used
to estimate the change in refraction from the current spectacles. Nor does the VA appear to have been
recorded with the participant wearing the autorefractor result. Instead, it seems likely that the pinhole
VA recorded monocularly was used to identify VI resulting from uncorrected/undercorrected
refractive error.
Study 4
A randomised cross-sectional survey of people living in their own homes or in care homes was carried out
as part of the NDNS.57 Participants were recruited from 80 randomly selected postcode areas of mainland
Britain. Acuity measurements were made by a trained nurse in the participant’s place of residence. VA was
measured in 1487 participants (1362 not cognitively impaired and 125 cognitively impaired) who received
a nurse visit. LogMAR monocular distance VA was measured using the Glasgow acuity card test at 3m,
without any spectacle correction, and repeated with a pinhole. Monocular VAs were then recorded again,
both with and without a pinhole, but with the participant now wearing any distance spectacles.
l With a criterion of best monocular VA of < 6/12, 28.3% of the sample had VI.
l With a criterion of best monocular VA of < 6/18, 14.3% of the sample had VI.
l Visual impairment showed a strong positive linear trend with age.
l Visual impairment was more common in participants living in care homes, with an age-adjusted odds
ratio (OR) of 2.59 (95% CI 2.23 to 2.96).
l Visual impairment was more common in women, with an age-adjusted OR of 1.55 (95% CI 1.21 to 1.89).
l Of the cognitively impaired participants, 64.8% had VI when the ‘VA worse than 6/18 in the better
eye’ criterion was applied.
l Visual acuity improved by 0.2 logMAR units with a pinhole in 21.2% of participants in the
non-cognitively impaired group.
Comment
l A short memory questionnaire was used to identify participants with cognitive impairment to identify
those potential participants for whom proxy consent was needed. There is no indication that any
subjects were excluded on the basis of the assessment.
l This was a national survey which is unusual in including both participants living in their own homes and
those living in care homes.
l Visual acuity measurements were recorded by trained nurses in participants’ homes rather than by
optometrists, ophthalmic nurses or ophthalmologists. Standardisation of lighting conditions was not
possible and variations would affect the accuracy of results.
l No refraction was carried out and no causes of VI, apart from those where uncorrected/undercorrected
refractive error was suspected, were identified.
l This is the only study reviewed to have included an analysis of people with cognitive impairment as a
subpopulation of the sample.
l The paper states that ‘The highest Glasgow Acuity Card score from any of the measurements in the
better eye is defined here as the best visual acuity’.57 These measurements include the pinhole VA.
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Study 5
A 1992 cross-sectional random sample survey by Wormald et al.58 recruited 207 participants aged
≥ 65 years from an inner-London general practice. Binocular VA was recorded using a Snellen chart at 6 m,
and monocular VA was recorded using a Sonksen Silver chart at 3m, with a pinhole if 6/9 was not
achieved. An improvement of greater than one line in VA monocularly or binocularly was taken as
evidence of potential benefit from refraction. The cause of VI was identified by a consultant
ophthalmologist, and where participants had more than one possible cause for their visual loss, a clinical
decision was made as to the main cause.
l Using a criterion of presenting VA of < 6/18 in either eye, 7.7% (95% CI 4.5% to 12.2%) of the
sample had low vision.
l A total of 27% of subjects would have benefited from refraction, based on the pinhole results.
l Cataract was responsible for 63% of VI based on better eye VA of < 6/12 and excluding uncorrected/
undercorrected refractive error.
l A small number (n= 17) of examinations were conducted in participants’ own homes, and 41% of
these participants were found to be visually impaired.
l The prevalence of clinically obvious predisposing changes at the macula associated with visual loss in at
least one eye was 25%.
Comment
l The last line read correctly on the Snellen chart was taken as the VA. No refraction was carried out,
with best corrected VA estimated with a pinhole.
l With a criterion of best presenting acuity of < 6/12, 14.5% (95% CI 10.3% to 20.0%) were calculated
to have VI.
l One strength of the study is the assessment of each participant by an ophthalmologist and the
identification of the cause of VI.
l The high prevalence of cataract will reflect the much lower numbers of cataract surgery procedures
carried out in the early 1990s than today.
l This study is one of the few to record near VA; failure to achieve N6 in a subject with good distance
vision served as an indication of the need for a new prescription for reading spectacles.
Study 6
This early 1980s study of residents of Melton Mowbray59 aged > 75 years comprised 529 participants.
Monocular VA was recorded with existing spectacles (if any) and unaided vision in each eye was recorded
for all subjects using a Snellen chart at 6m. Best monocular VA was recorded following a full refraction by
an optometrist. Subjects also received an ophthalmological examination.
l Using the criterion of post-refraction best monocular acuity of < 6/12, 26.2% had VI.
l Of the sample, 11.2% were unable to read N8 post refraction.
l Of the sample, 10.4% were examined at home or in hospital.
Comment
l The last line read correctly on the Snellen chart was taken as the VA.
l A notable strength of the study is that all of the VA measurements and the determination of refractive
error were undertaken by an optometrist.
l Although both the VA with any current spectacles and the unaided vision were recorded on
presentation, only unaided vision data are stated in the paper. Neither the proportion of participants
presenting with VI nor the undercorrected element of VI were stated.
l Another strength of the study is the recording of near VA (NVA) with what was presumably the
post-refraction correction.
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The studies reviewed above are 15–40 years old and reveal inconclusive data on prevalence, largely owing
to methodological differences and definitions of VI. However, it is clear that many cases of VI in older
people can be either prevented or successfully treated. Evans and Rowlands11 concluded that there is
overwhelming evidence that a very large proportion of older people do not receive appropriate eye care
and many of these people could be helped by cataract surgery or appropriate refractive correction
(spectacles). Improvement in VA is not the only benefit from refractive correction, as behavioural and
psychological problems in people with dementia are reduced when VI is prevented or corrected, with a
corresponding positive impact on quality of life.60 Data from older people with dementia have rarely been
analysed separately in population studies of VI. The exception is the NDNS, in which 64.8% of the
cognitively impaired participants had VI using the ‘VA worse than 6/18 in the better eye’ criterion.57
A meta-analysis of the prevalence and causes of blindness and low vision in the UK highlighted
the urgent need for improved UK epidemiological data, particularly for visual loss among the
non-community-dwelling older population.7 Care home residents were excluded from one VI population
study;56 in others, they were possibly included but not separately analysed,27,58,59 or made up a very small
proportion of an already small sample.44 Only the NDNS study included a large care home residency
subsample (23.8%), and these residents were more likely to have VI, with an OR of 2.59 when compared
with people living in the community.57
Review of population-based international studies into prevalence of visual
impairment in older people
Methodological and sample differences between UK and international population studies, plus health-care
variations between countries, make comparisons between studies difficult. A methodological strength of
a number of international population studies is the measurement of best corrected VA, obtained after a
subjective refraction.61–64 For presenting VI using the criterion of best VA of < 6/12, prevalences vary from 6.9%
in the SEE study of those aged 65–84 years (binocular VA),63 to 7.3%, calculated from the Melbourne study for
those aged ≥ 60 years (best monocular VA),61 and to 11.7% in the Baltimore Eye Survey of those aged
≥ 40 years (best monocular VA).65 For VI defined by best monocular presenting VA of < 6/18, the prevalence
calculated from the Melbourne study data was 2.7%.61 All of these prevalences are lower than those from UK
studies, with the younger age of the international cohorts likely to be a major contributory factor.
For best-corrected VI for VA of < 6/12, the prevalences calculated for those aged ≥ 60 years from the two
Australian studies (both best monocular VA) were 2.7% for Melbourne61 and 6.5% for Blue Mountains,62
with 5.8% reported in the Rotterdam study of those aged ≥ 55 years.64 The only UK study using
comparable methodology was Melton Mowbray, in which a prevalence of 26.2% was obtained from their
sample aged > 75 years.59 For VA of < 6/18, the best corrected VI prevalences were 1.9% for Melbourne61
and 2.5% for Rotterdam.64
International studies of people living in care homes have reported high prevalences of VI. In Alabama,
USA, the presenting VI based on binocular VA of < 6/12 was 57% in a sample in which those with
Mini-Mental State Examination (MMSE) scores of < 13 were excluded.66 In another US study which, like
PrOVIDe, included people with all levels of cognitive impairment, presenting VI (best monocular VA of
< 6/12) was found in 38% of participants, with best corrected VI of 29%. The sample included 40% who
had severe cognitive impairment (MMSE score of 0–9) and 70% who had MMSE score of ≤ 18. The dearth
of UK VI data from care homes has been highlighted.7
Quality of life and visual impairment
Visual impairment, especially in older people, can lead to functional impairment which may adversely affect
quality of life.67 In a ranking of common chronic conditions, which can affect the ability of older people to
perform essential tasks,68 VI was ranked third, behind arthritis and heart disease. A number of instruments
have been used to measure quality of life. Some assess visual function status (e.g. Visual Function
Index and National Eye Institute Visual Function Questionnaire), some are vision-specific quality-of-life
questionnaires (e.g. Low Vision Quality of Life Questionnaire) and some use generic health-related
INTRODUCTION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
12
quality-of-life instruments (e.g. EuroQol Questionnaire).69 Measurements of VA and other measures of
visual performance, such as contrast sensitivity, are highly correlated with activities of daily living.9
Performance on various tasks of daily living was assessed in a study of > 2500 participants aged between
65 and 84 years, which excluded those with Standardised Mini-Mental State Examination (sMMSE) scores
of < 18 (i.e. those with severe or moderate cognitive impairment).70 For mobility tasks, at least 50% of
participants were disabled [using a cut-off point for disability of one standard deviation (SD) below the
population mean performance] if their VA was worse than logMAR 1.0 (6/60). However, for the more
demanding visual task of face recognition, disability occurred when VA was < 0.3 (6/12).70 Interestingly,
> 90% of those with a VA of < 0.3 (6/12) were disabled for the visually demanding task of reading at
90 words per minute.
A nested trial within the national MRC Elderly Trial collected data using the 25-item National Eye Institute
Visual Function Questionnaire instrument from 1745 participants aged > 75 years. For the analysis, VI was
defined in two ways: either presenting VA in the better eye of < 6/12 or VA in the better eye of < 6/18.
There was a strong association between VI, using either definition, and reported difficulties with general
vision, near activities and social functioning.45 Although there was a strong association between VA and
questionnaire scores, VA accounted for only 20% of a combined score derived from each of the subscales
of vision function. The authors note that psychological factors, such as having an optimistic or pessimistic
outlook on life or adopting coping strategies to help counteract the impact of VI, may impact on the way
people with equivalent levels of sight loss report their general level of visual function. Evidence supporting
this view came from the 21% of those with VA of < 6/18 who reported having no problems with their
general vision. This percentage was lower for specific activities such as near activities, for which only 11%
of those with VA of < 6/18 reported having no problems.
A 2012 RNIB-funded UK study conducted by NatCen Social Research (McManus and Lord71) analysed many
aspects of the circumstances of adults with sight loss, using data from two Britain-wide surveys: the Life
Opportunities Survey and the Understanding Society Survey. Comparisons were made between participants
with self-reported sight loss and the remainder of the population after controlling for differences in age
and sex. Notably, 31% of participants with sight loss reported being dissatisfied with life overall, compared
with 10% of those without sight loss. A greater proportion of participants with sight loss (94%)
experienced some kind of restriction to their ability to take part in society than those without sight loss
(83%). Respondents with sight loss were more likely to have experienced difficulty accessing health
services (33% of the subsample) than those without sight loss (18%).
Mental well-being
Sight loss is frequently associated with negative feelings including frustration, anger and feeling low.
These feelings are part of the normal grieving process, with grief in this context being for loss of sight.
Studies in the USA and Canada estimate the prevalence of depression in people attending low-vision
clinics with AMD, the leading cause of registrable VI in the older UK population, to be approximately
30%.60,72,73 A typical study examined 151 adults aged > 60 years (mean age 80 years) with VI living in the
community. The definition used for VI was presenting better eye VA of ≤ 6/18, together with VA of
≤ 6/30 in the other eye. The proportion of participants with depression, as determined by standard criteria
using a validated instrument for diagnosis of depression (Structured Clinical Interview for Diagnostic and
Statistical Manual of Mental Disorders-Fourth Edition74 Disorders), was 32.5%, which is approximately
twice the prevalence of depression in the general population using similar diagnostic methods.73 The
authors noted that the prevalence of depression in their sample of people with VI was similar to
prevalences of depression found in patients with life-threatening diseases, such as cancer.
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In the UK, the MRC trial of the assessment and management of older people in the community collected
data on depression and anxiety, in addition to measuring VA in order to identify participants with VI.56
The instruments used to assess depression and anxiety were the Geriatric Depression Scale and the anxiety
subscale of the General Health Questionnaire, respectively. VI was defined as presenting binocular VA of
< 6/18 and depression by a GDS score of ≥ 6. Participants with VI had slightly raised levels of anxiety
compared with participants who were not visually impaired when only age and sex were controlled. Control
of other confounders removed any association between anxiety and VI. The prevalence of depression in the
VI subgroup was 13.5% and was statistically significantly greater than in those without VI (4.6%;
p< 0.001).75 This 13.5% prevalence of depression was lower than that found in other studies, but the MRC
trial had a sample drawn from the general population rather than from low-vision and outpatient clinics.
The OR, following adjustment for age and sex, for depression with VI was 2.69 (95% CI 2.03 to 3.56),
which reduced to 1.26 (95% CI 0.94 to 1.70) when other confounders, notably activities of daily living,
were controlled. Although VI is one factor contributing to depression in people with sight loss, depression
can be attributed to other factors, notably impairment to functional activities of daily living. It was
suggested that VI leads to difficulties with functional activities, which can then result in depression.75
Another UK study investigated the visual and psychosocial factors, including depression and adjustment to
sight loss, which influenced participants with VI who had self-reported difficulties with a range of visual
activities.76 The instruments used to assess the participants’ depression and the level of adjustment to their
sight loss were the Geriatric Depression Scale and the 19-item Acceptance and Self-Worth Adjustment
Scale. The 100 participants with VI had an average age of 81 years. Visual parameters, including distance
VA, NVA and contrast sensitivity, accounted for 28–50% of the variance in self-reported limitations in
visual activities. However, depression and levels of adjustment were also statistically significant contributors
to limitations in activities, with depression notably accounting for 17% of the variance in self-reported
mobility function.
There is evidence that interventions to enhance visual performance can contribute to a reduction in
depression symptoms. A sample of 95 adults with a mean age of 77 years (range 65–89 years) with VI
were assessed before and after a rehabilitation package, which included provision of low-vision services
and optical aids. After controlling for other factors, the rehabilitation package accounted for 10% of the
variance in depression, with both the low-vision clinical service and the optical aids remaining statistically
significant contributors60 to the reduction in depression symptoms over time.
The 2012 RNIB NatCen study compared many aspects of well-being in those with and those without sight
loss, after controlling for age and sex differences.71 Participants with sight loss (14%) were more likely than
those without sight loss (2%) to have been feeling unhappy or depressed a lot more than usual. A loss of
self-confidence, that occurred a lot more often than usual, was more prevalent in those with sight loss
(11%) than in those without (1%). There was a fourfold difference in the proportion of participants
reporting dissatisfaction in their health between those with sight loss (57%) and those without sight loss
(14%). Participants with sight loss were approximately twice as likely to have fewer than three people to
whom they felt close (15% compared with 8%). An overall well-being index was calculated using the
Short Warwick–Edinburgh Mental Well-being Scale, which gave a score of between 7 and 35 for each
individual, where the higher the score the better the individual’s well-being. Participants with sight loss had
a lower mean score (22.70) than those without sight loss (25.86).
The National Institute for Health and Care Excellence (NICE) guideline on depression in adults with a
chronic physical health problem recommends that primary care practitioners, who presumably include
optometrists, should screen high-risk groups for depression and initiate a referral to the GP for those who
screen positive for depression.77 The association between VI and depression is complex, with the VI
contributing to the depression and the depression contributing to the functional disability associated with
the VI.72 There is widespread agreement that a holistic approach involving collaborative care should be
adopted for patients with moderate to severe depression who also have a chronic physical health problem
such as VI.56,72,77
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Falls
The National Institute for Health and Care Excellence reports that 30% of people aged > 65 years and
50% of people aged > 80 years fall at least once per year. Falls are estimated to cost the NHS more than
£2.3B per year.78 Older people living in care homes or in sheltered housing are more likely to fall than
those living in their own homes.79,80 This increased risk results in part from care home residents often being
frailer and more likely to have more of the other fall-related risk factors than those living in their own
homes.81 In a study of > 9000 participants, those with a cognitive impairment had an OR for falls of
2.3 when compared with those with no cognitive impairment.82
There is considerable evidence that VI, measured in various ways and defined using acuity cut-off
points for VI of < 6/12 or < 6/18, is a significant and independent risk factor for falls, with an OR of
approximately 2.5.44,81,83,84 This reflects the significant input provided by vision, both central and peripheral,
to balance control.85,86 Balance when standing was significantly impaired in AMD compared with controls
when a mental arithmetic secondary task was introduced.86 The visual system also provides vital
information regarding the location and size of hazards that may lie in the path of people as they
ambulate.80 In a UK cross-sectional study of patients aged ≥ 65 years who had undergone hip fracture
surgery, those with presenting VI (binocular VA of < 6/18) were compared with the non-VI group.
Significantly more of the participants with VI had fallen in the previous 5 years. Participants with VI were
also less likely to have had an optometric eye examination in the 3 years prior to their fall and less likely to
have been wearing their glasses at the time of the fall.87
Although NICE guideline 161 states that vision assessment and referral has been a component of
successful multifactorial falls prevention programmes, NICE found no evidence that referral for correction
of vision as a single intervention for older people living in the community is effective in reducing the
number of people falling.78 Elliott81 notes that this conclusion was based largely on the results of two
randomised controlled trials, and identifies several possible sources of bias, including non-representative
participants and potential bias introduced by the trials not being double-blind, both of which could have
affected the results of these and other clinical trials.
There are many possible causes of falls, some specific to the person who falls, suggesting that programmes
designed to prevent falls should be tailored to the individual.88 Most falls result from a combination of
contributory factors, one of which can be VI. Specialised falls services are provided nationally in the UK,
offering advice, providing rehabilitation services and aiming to prevent further falls in those with a history
of falling. As part of their assessment, the majority of falls services carry out a vision check, but these vary
in terms of frequency and methods used. Reciprocal referral between optometrists and local falls services
is recommended to improve continuity of care.85 It is important to consider the role played in falls by
elements of visual performance other than VA, including factors such as reduced contrast sensitivity, visual
fields and binocular vision.88
Reporting standards
Strengthening the Reporting of Observational Studies in
Epidemiology statement
The study endeavoured to comply wherever possible with the Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) statement, which contains recommendations to improve
the quality of reporting of observational studies.89 The STROBE checklist, with annotations giving details of
PrOVIDe’s compliance with each item on the checklist, is available in Appendix 1.
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Standards for reporting and measurement of visual impairment
A report, The Prevalence of Visual Impairment in the UK: A Review of the Literature,45 commissioned
by the RNIB, concluded with a section on the standards for reporting and measurement in studies
investigating the prevalence of VI. The following recommendations were made and have been followed
insofar as they were feasible in PrOVIDe:
The Working Group recommended that vision assessment in population-based studies should include a
measurement of visual acuity using logMAR charts at distance and near under standardised conditions.
Information collected should record: (i) monocular and binocular distance presenting visual acuity,
whether a method of vision correction is used (e.g. spectacles) and, if so, the type and power of vision
correction device; (ii) monocular and binocular near presenting visual acuity at 40 cm, whether a
method of vision correction is used (e.g. spectacles) and, if so, the type and power of vision correction
device; (iii) monocular and binocular best-corrected visual acuity at distance and near, following
refraction using an age-appropriate addition for near acuity.
We recommend the use of validated questionnaires or scales for measuring self reported vision
problems or vision related quality of life. We emphasize the need to thoroughly test all questions
before use in surveys.
Reproduced with permission from RNIB45
Aims and objectives
Previous research suggests that VI, often preventable, is not uncommon in the UK older population.
The risks of VI and dementia both increase with age, suggesting that a proportion of people with
dementia will also have undiagnosed VI, but evidence to support this is lacking owing to a dearth of
research. This, together with evidence of the effects of VI on general well-being, prompted identification
of the main research questions and associated objectives.
The main research questions are:
What is the prevalence of a range of vision problems in people with dementia aged 60–89 years and to
what extent are these conditions undetected or inappropriately managed?
The four primary objectives of the study were:
1. to measure the prevalence of a range of vision problems in people with dementia
2. to compare the prevalences found in objective 1 with the published data on the general population in a
comparable age range
3. to identify and describe reasons for any underdetection or inappropriate management of VI in people
with dementia
4. to recommend interventions to improve eye care for people with dementia and further research in
this area.
The secondary objectives of the study were:
1. to identify any differences in the level of undetected or inappropriately managed VI between those
living in their own homes and those living in care homes
2. to determine estimates for the percentages of those with dementia likely to be able to perform
successfully elements of the eye examination
3. to relate vision problems in people with dementia to data from functional and behavioural assessments.
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Chapter 2 Methods
Study design
The study had two stages. Stage 1 was a cross-sectional study to establish the prevalence of a range of
vision problems among people with dementia. Stage 2 was a qualitative study that used focus groups and
interviews to explore and describe issues around detection and management of vision problems among
people with dementia from the perspectives of affected individuals, family carers, professional care workers
and optometrists.
Stage 1 was an observational cross-sectional study. PrOVIDe endeavoured to follow the STROBE statement
for reporting of observational studies wherever possible. The STROBE recommendations have been
developed to improve the quality of reporting of observational studies.89 An annotated version of the
STROBE checklist, giving details of PrOVIDe’s compliance with each item, can be found in Appendix 1.
Throughout the report, the term ‘potential participant’ is used to describe individuals who were
approached by a member of the research team for involvement in the study. The term ‘participant’ is used
to describe individuals who were formally recruited into the study. The term ‘family carer’ is used to
describe a family member or friend who cares, unpaid, for their relative or friend. The term ‘care worker’ is
used to describe someone who is employed to support individuals with everyday tasks, in their own homes
or in residential care settings. The term ‘formal consultee’ has been used to describe a personal consultee
who was required to give approval on behalf of individuals who lacked mental capacity to provide
informed consent to participate. The term ‘informal consultee’ refers to a family member or personal carer
whose opinion was sought regarding an individual’s participation in the study; this was applicable for
individuals who had the capacity to provide informed consent to participate. An informal consultee role
was sought for all potential participants and participants to provide additional assurance that participation
in the study was supported by an independent source concerned with the interests of the participant.
Setting
Participants were recruited from 20 NHS sites in six regions of England. Sites were selected to ensure the
recruitment of participants living in rural, urban and city locations and to encourage the participation of
people from black and minority ethnic groups. It was originally envisaged that sites in four regions would
be included: East Anglia, the North East, North Thames and Thames Valley. Two more regions, Yorkshire
and the Humber and the North West, were added later when recruitment rates were lower than predicted
in the original regions and concerns were raised that the recruitment target might not be achieved within
the time scale. The regions referred to were those defined by the NIHR Dementias and Neurodegenerative
Diseases Research Network (DeNDRoN), which subdivided England into nine regions.
Regions and sites were selected in consultation with DeNDRoN. Local network co-ordinators identified
local principal investigators willing to support the study and then advised the research team on the
numbers of participants that they predicted could be recruited in the time frame, and site-specific
recruitment targets were agreed.
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Approvals
The study received NHS ethics approval in September 2012 in advance of the scheduled start date. NHS
research and development approval was sought from the NHS sites including primary care trusts where
participants would be recruited from care homes. The first sites granted approval in November 2012,
with the remaining sites gradually joining the study over the next 3 months. Recruitment began in
November 2012.
The Association of Directors of Adult Social Services (ADASS) was consulted on whether or not social care
research ethics approval was also required for recruitment through care homes. ADASS concluded that
NHS ethics approval was sufficient but advised the study team to write to the directors of adult social care
in all (n= 47) participating local authorities to inform them of the study and offer additional information if
required. One authority declined to support the study.
Sampling
Stage 1
The study sample was people with dementia (any type) aged 60–89 years. To ensure that the spectrum
of care was represented, the sample included people living in their own homes and people living in
residential care (such as care homes and hospital inpatient wards). An additional inclusion criterion was
that, in the case of individuals lacking mental capacity to provide informed consent to participate, a formal
consultee was required who could give approval on the individual’s behalf. The opinion of a family
member or professional carer in the role of informal consultee was sought in respect of all participants as
to whether or not participation would be appropriate. The exclusion criteria were as follows:
l Individuals who had been in hospital in the preceding 2 weeks following an acute illness, or who had
major delirium or a major infection.
l Individuals unable to understand English, as consent procedures and the eye examination were
conducted in English.
l Individuals unable to comply with the requirements of the eye examination; although it was expected
that some participants would not be able to comply with all elements of the examination, individuals
were excluded if they were unable to co-operate with the simplest procedures.
l Individuals participating in a clinical drugs trial, because the eye examination involved the administration
of tropicamide eye drops (Mydriacyl, Alcon Laboratories Ltd, Surrey, UK) and all of the potential drug
interactions could not be determined. This exclusion criterion was added on completion of the pilot study.
Sample size
As described in Chapter 1, the prevalence of conditions causing VI has been estimated to be as high as
50%.44 For the stage 1 cross-sectional study, a sample size of 385 was required to allow detection of an
estimated prevalence of 50% with 5% precision and 95% confidence. If the prevalence of a condition
was greater than or less than 50%, the study would have required a sample size smaller than 385. It was
anticipated that some participants would be unable to perform all of the tests undertaken in a standard
optometric examination, but there were no published data on the percentages of those with dementia
who would be unable to perform individual elements of the examination. In the absence of published
data, a decision was made to assume a worst-case scenario that up to 50% of the subjects might be
unable to complete a particular test. This increased the maximum sample for stage 1 to 770 (385 × 2).
This led to a decision to divide the sample into two groups: group 1 was people living in their own homes
and group 2 was people living in care. Although the group sizes were not defined to specifically support
‘between-group’ comparisons, the use of equal numbers in the two groups would provide scope for some
comparative analysis between groups 1 and 2. With the determined sample size, there would be at least
80% power to detect a difference between proportions of 50% and 42% (or less) in two equal-sized
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groups. The initial sampling strategy for both groups was to stratify by age and sex to match as closely as
possible the best estimates available at the time for the general dementia population. In both group 1 and
group 2 the PrOVIDe target sample was one-third male and two-thirds female; 30% of males were aged
between 60 and 74 years and 70% of males were aged between 75 and 89 years; and 15% of females
were aged between 60 and 74 years and 85% of females were aged between 75 and 89 years.
Stage 2
The population under study in stage 2 was extended beyond people with dementia to include family
carers, care workers working in care settings and optometrists. This process of triangulation – posing
similar questions to different sources – was employed to increase the validity of findings. Stage 1
participants who had mental capacity to consent themselves into the study and who were able to
participate in an interview were considered for inclusion in stage 2. Purposive sampling was applied to
identify participants across the age range, of both sexes, and to include individuals who might be
particularly informative because of a history of eye disease.
Family carers were also identified through their involvement in stage 1 in that they were the named next
of kin or the informal consultee of stage 1 participants. The method of data collection with family carers
was focus groups, and the named carers of stage 1 participants living in an area where focus groups were
planned were invited to participate. Similarly, the care workers approached for stage 2 worked in care
homes that had assisted with recruitment of stage 1 participants.
Optometrists were sampled using the membership of the College of Optometrists (CoO). The College had
10,086 members representing in excess of 70% of the members of the profession registered to practise.
The method of data collection used for optometrists was focus groups. All College members living or
working in an area where focus groups were planned were invited to participate.
Recruitment of participants
In stage 1, the initial approach to potential participants was made by a member of the direct care team, a
member of DeNDRoN, local co-ordinating research staff or a member of the CoO research team. The aim
of this initial contact was to inform the potential participant and carers of the study and its remit. This was
achieved by direct face-to-face contact (e.g. in a clinic), by telephone or by letter. Potential participants and
carers were provided with written information on the study’s purpose, methods and risks, and what was
required of participants.
Subsequently, potential participants and personal and professional carers were contacted by either a
DeNDRoN staff member or a member of the research team to determine if the potential participant and
family member/carer were willing to be involved in the study. They were also given the opportunity to ask
any questions or raise any concerns they might have had at that stage. Potential participants were given a
minimum of 1 week to consider their possible participation in the study. If the potential participant and
carer felt confident and comfortable to participate in the study, consent forms were completed.
Ethically, and for validity of the findings, it was important and appropriate to include participants who
lacked mental capacity to consent within the tenets of the Mental Capacity Act (2005).90 In recognition of
the complexities surrounding informed consent and capacity in people with dementia, all research workers
involved in the study received formal NIHR Clinical Research Network training in good clinical practice,
informed consent, the ethics of consent and the Mental Capacity Act.90 In the case of individuals unable to
consent for themselves, a formal consultee (family member/dependant/friend) was asked for their opinion.
The formal consultee was asked to take into account any advance decisions or previously expressed wishes
and feelings, and consider the potential participant’s best interests. In group 1, 67.9% of participants were
able to consent themselves into the study and 32.1% required a consultee. In group 2, 27.6% were able
to consent themselves into the study and 72.4% required a consultee. The consultee was provided with an
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information sheet, containing the same information as that for a participant able to consent for
themselves, and was asked to sign a consultee declaration form. As an additional measure to safeguard
participants’ interests, for participants with the capacity to consent an informal consultee was asked to
give their opinion on the potential participant’s suitability to take part in the study.
In stage 2, potential participants were contacted by a member of the research team. During stage 1, the
examining optometrist assessed participants for their ability to cope with an interview, and those who
were considered to be able to do so were asked if they were willing to be contacted about stage 2.
Individuals who were subsequently selected through purposive sampling were initially telephoned by a
member of the research team to check their willingness to consider participation in stage 2. This was
followed by a letter of invitation and further written information about what the interview would entail.
A second telephone call was made at least 1 week later to answer any questions and, if the individual
agreed, to set a date and time for the interview to take place. The appointment was confirmed with a
follow-up letter. Formal consent was obtained on the day of the interview prior to commencing
data collection.
Potential focus group participants (family carers and optometrists) were sent a letter of invitation and an
information sheet about the focus groups. The sheet included details of how to contact the research team
with any queries. Those wishing to attend the focus groups indicated this by returning a contact form
(by fax, e-mail or prepaid reply envelope). On receipt of this form, an acknowledgement was sent to the
participant, together with further details about the focus group venue. Non-responders were not
contacted again.
Early pilot work suggested probable difficulties in recruiting care home care workers to attend focus
groups. Only one focus group was arranged, with the assistance of a care home group manager.
Additional data from care workers were collected through interviews. With assistance from stage 1
recruiters, purposive sampling was used to identify and target care homes that might be willing to take
part. The initial invitation to participate in stage 2 was made by a letter accompanied by a participant
information sheet. Formal consent to take part in focus groups or interviews was taken on the day of the
data collection procedure, prior to any data collection taking place.
Data collection
Stage 1
Stage 1 comprised three elements:
1. a sMMSE
2. functional and behavioural assessment questionnaires completed by a carer
3. an eye examination, that is, a full optometric examination in line with requirements of the GOS sight
test and the CoO guidance document C4.91
Standardised Mini-Mental State Examination
The MMSE is a tool used by clinicians to help them diagnose and assess dementia. It was originally
developed by Marshall Folstein92 in 1975. The MMSE is available in several versions. A standardised version
(sMMSE) of the test was used for the PrOVIDe study. The sMMSE consists of a series of 12 questions or
tests designed to assess orientation, memory, attention and calculation, recall and language. Each element
is scored and a maximum score of 30 is possible. The study recruiter carried out sMMSE on the day that
the participant was consented into the study, once consent had been obtained.
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Functional and behavioural assessment questionnaires
Two questionnaires were used to provide background information on the participant’s functional and
behavioural state. This allowed comparison between cases with and without VI, as well as providing
background information on individuals for whom it was not possible to perform certain elements of the
eye examination.
The two questionnaires employed were established tools: the Bristol Activities of Daily Living Scale (BADLS)93
and the Cambridge Behavioural Inventory – Revised (CBI-R).94 The BADLS was selected as it is a well-established,
validated, carer-rated instrument. It was selected as a means of gathering additional information about the
extent to which participants’ dementia impacted their day-to-day life. It was considered to offer scope for some
evaluation of the interactions between dementia, vision and daily living activities. The BADLS assesses the
performance of 20 activities of living, using four statements describing different levels of performance and a
fifth ‘not applicable’ option. The respondent is asked to select the statement that most closely describes the
individual’s performance over the preceding 2 weeks.
The CBI-R was selected to provide scope to conduct analyses to explore the possible relationships between
vision, vision problems and the levels of cognitive impairment encountered within the sample population.
The CBI-R describes behavioural changes using 45 items arranged into 10 sections. It is designed to be
completed by a carer who states the frequency of a behaviour using a five-point scale ranging from ‘never’
to ‘constantly’. If a question does not apply, a ‘not applicable’ response should be used.
The eye examinations
Each optometrist aimed to perform a full optometric examination in line with the requirements of the GOS
sight test and professional guidance.91 Participants were offered a choice between having their eye
examination in an optometric practice (normal community setting) and having it in their own home
(domiciliary examination). A number of community optometrists volunteered to assist with the study by
performing practice-based eye examinations. However, the number was small for the wide geographical
spread of the recruitment area, which meant that most study participants would have been required to
travel some distance to their appointment if they wished to have an examination in an optometric practice.
All study participants chose to have a domiciliary eye examination.
Examinations were carried out by an optometrist from The Outside Clinic (TOC), a company specialising
in providing domiciliary eye care nationwide. During recruitment of optometrists, a number of TOC
optometrists expressed interest. TOC was willing to support its optometrists interested in working on
PrOVIDe; it extended this support to allow the study to use TOC software to gather participants’ data from
the eye examinations and its experienced logistics team to co-ordinate the arrangement of appointments.
Further factors that contributed to the research team’s decision to involve TOC included the rigorous
training its staff undergo, the clearly evidenced and rigorous audit and clinical governance mechanisms
used by the company, its bespoke tablet-based electronic patient data-management system, and its
familiarity with working in Clinical Commissioning Groups across England. The strong clinical governance
framework in place at TOC provided assurance that the research data collected were reliable, valid,
comprehensive and consistent. The record-keeping system for clinical records was electronic, facilitating
data extraction and analysis for the study.
The Outside Clinic’s optometrists are trained and experienced in dealing with people with illness or
disability, including people with dementia, and all had the necessary and specialised equipment for
conducting eye examinations in the home. Following several meetings and a review of TOC’s processes,
systems and clinical governance framework, it was determined that working with TOC and its optometrists
would offer significant advantages to PrOVIDe.
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Fourteen optometrists were recruited to perform the eye examinations and data collection for the study.
Three optometrists were required in each of the initial four regions to cover the wide geographical areas in
which participants lived. Two more were recruited later to cover the recruitment of participants from the
two additional regions. The optometrists received additional training from the PrOVIDe project manager
on study-specific requirements. Additional tests that the optometrists were required to perform on study
participants included using the logMAR chart for recording vision and VA and the use of a specific cataract
grading scale when grading cataracts.
Participants and family members/care workers received advance notice of the optometrist’s visit. They
were contacted 3–5 days before the appointment to confirm the suitability of the appointment date.
If the date was not suitable, TOC sent another appointment date by post. On the day of the examination,
the examining optometrist telephoned the named point of contact approximately 1 hour before the
appointment to give an accurate time of arrival.
On arrival at the participant’s place of residence, the optometrist introduced him- or herself to the
participant and family member or carer, explaining who they were and the reason for their visit. The
optometrist set up his or her equipment in the room allocated for the eye examination (in care homes) or
in the most appropriate available room (in the participant’s own home). Where there was a choice of
rooms, the ability to achieve dim illumination was a major factor in the final selection.
Prior to the eye examination commencing, participants were asked if there were any tasks (vision related)
that they found particularly difficult. Where a participant was unable to respond appropriately, advice was
taken from carers and/or care home staff as to the cognitive and other abilities of the patient. The tests
constituting the eye examination were normally conducted in the order described in Figure 1, but
the over-riding principle was that the optometrist should adopt a flexible approach throughout, and the
order of tests was adapted as required to suit the individual patient. The examinations were performed
according to the cognitive and physical abilities of the participant, with the emphasis on objective
assessments and omitting tests (both objective and subjective) as required by the needs of individual
participants. This approach was consistent with the current CoO professional guidance on examining
patients with dementia,91 although not all examination data were required for the PrOVIDe study.
Tests carried out in a typical PrOVIDe eye examination
History and symptoms
These were obtained from the participant and/or the carer. For care home residents, the optometrist
requested access to the participant’s care record or asked a member of staff to provide the relevant
information from the record. Where necessary, input was sought from the carer or care home staff
regarding the participant’s history and symptoms. Information was gathered regarding the participant’s
current visual status and spectacle wear, their general health, previous ocular history and family
general health.
Vision and visual acuity
Distance vision Distance vision and VA were recorded using either the Thomson Test Xpert 3Di Test chart
(Thomson Software Solutions, Welham Green, UK) or TOC’s own computerised test chart. Both test
charts allow the presentation of letters using either logMAR or Snellen progression of letter sizes. The
optometrist would normally use a 3-m testing distance, and if shorter testing distances were required both
test charts would adjust the letter size to compensate for the distance at which the chart was used. No
mirror was used during VA testing in this study. LogMAR VA was assessed using letters from the Roman
alphabet, with five letters on each line of letters presented. However, the optometrist would attempt to
obtain vision and VA measurements using symbols if standard letters did not prove successful. Vision and
VA were measured on a letter-by-letter basis.
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Visual fields test if 
clinically necessary.
Test carried out on 
another day
History and symptoms
Obtained from participant and/or carer
Presenting VA
Distance VA and NVA measured
Assessment of binocular function
Not part of the PrOVIDe study data collection
Assessment of pupil reactions
Not part of the PrOVIDe study data collection
Tonometry: measurement of IOP
Using the ‘Icare’ tonometer
Objective assessment of refractive error
Using retinoscopy
Subjective assessment of refractive error
Recording of post-refraction VA
Distance VA and NVA measured
Pupils dilated with tropicamidea
Ocular health examinationa
Using hand-held direct ophthalmoscope
Referral to GP or local HES if required
Advice given to participant/carer
Dispensing of new spectacle prescription, if 
required and requested. Provision of relevant
clinical treatments if required/requested
FIGURE 1 Elements of the eye examination. a, The ocular health examination and pupil dilatation were able to be
carried out at any of the points indicated by the dashed arrows: their place in the order of examination elements
was not rigidly fixed.
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The procedure followed by the research optometrists when deciding when to terminate the acuity
measurement is described in the following example. The participant in this illustrative example correctly
identified three of the five letters on the smallest line of letters that they could read (i.e. all of the letters
on the next smallest line of letters were read incorrectly or could not be read at all). The optometrist would
then present a different line of five letters of the same size and check how many letters the participant
could read on this second line. If this number was again three letters out of five, the acuity measurement
would terminate at that point for that eye. However, if the participant read a different number of letters
on this second line of letters of the same size, for example four letters, the optometrist would present
a third line of five letters of the same size. If three letters were read on this third line, the acuity
measurement would be terminated, and three letters on this line would contribute to this participant’s VA.
If four letters were read on this third line, the acuity measurement would be terminated and four letters on
this line would contribute to this participant’s VA. In summary, the optometrist would always check the
ability of the participant to correctly identify letters on the lowest line of letters that they could read by
presenting a second line of letters of the same size, and would present a third line (or more) of letters of
that size if required and if co-operation allowed. The aim of this approach was to seek confirmation of the
number of letters the participant correctly identified on the lowest line of letters they could read. However,
with the PrOVIDe participant base it was unlikely that these methods would be successful with every
participant. Co-operation levels would vary between participants, and could vary in a single participant
during the eye examination. Therefore, the optometrist was instructed to take a pragmatic approach to the
recording of vision and VA, using their professional judgement to decide when a test should be terminated
if co-operation was no longer adequate to justify further assessment.
Whenever participant co-operation permitted, the optometrist measured the distance vision (if no
previous spectacles were available) or distance VA with the participants’ existing spectacles and with the
prescription determined during the PrOVIDe examination. The optometrists recorded vision and VA for
the right and left eyes separately. This allowed the prevalence of VI to be calculated based on best
monocular VA.
Near vision NVA was measured by means of a conventional eye examination approach using a standard
Faculty of Ophthalmologists near-vision chart. The near-point scale used in these charts does not have a
consistent progression between sizes of print, and in this respect it is similar to Snellen charts used for
distance VA measurement. For example, the difference in size between N6 print and N5 print on the near
vision chart is 1.2×, while the difference between N24 and N18 is 1.33×.
Near visual acuity was recorded as the smallest print size a participant could read at their preferred reading
distance. Angular near vision reading acuity, which would require measurement of the smallest print size
read at a fixed working distance with a fixed addition, was not recorded in this study. Rather than specify
a particular number of words or lines of print that had to be read in order to give credit for that print size,
the optometrists regarded the participant as being able to read a line of print if that line of print could be
read fluently. All participants were encouraged to read the smallest size of print possible. The optometrist
always aimed to provide optimum NVA at the preferred near working distance. Letters were available on
the back of the near vision chart for those participants unable to read words.
Whenever participant co-operation permitted, the optometrist also measured NVA with the participants’
existing spectacles for near vision. The optometrists recorded NVA for the right and left eyes separately.
This allowed the prevalence of presenting near-vision loss to be calculated based on best monocular VA.
Binocular function
This was assessed using the cover test and by testing ocular motility. The cover test is a dissociation test in
which each eye is covered in turn while the patient fixates on a specified target at a given distance. The
practitioner observes the eye movements and diagnoses the anomaly, if any. The ocular motility test is
used to assess the extraocular muscles and their associated neural pathways. These tests were included in
the eye examination but were not part of the PrOVIDe study.
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Pupil reactions
The integrity of the pupillary pathways is assessed by shining a torch into each of the participant’s eyes in
turn. Testing pupil reactions was included in the eye examination but was not part of the PrOVIDe study.
Tonometry
This is performed to measure the IOPs in the eyes. Tonometry is an objective measurement during which
the only requirement from the participant is to keep their eyes open and maintain reasonably steady
fixation. This test is used as part of a battery of tests (the others being visual field examination and optic
nerve head examination) to detect glaucoma. The Icare tonometer was used (Icare Finland Oy, Vantaa,
Finland). The Icare is a contact technique (i.e. involves contact between the tonometer probe and the
cornea) that can be performed without the use of a topical anaesthetic. A comparison between the Icare
tonometer and the Goldmann applanation tonometer (Haag Streit AG, Bern, Switzerland), the current
reference standard method of measuring IOP, concluded that there is a good agreement between the two
methods of IOP measurement. In addition, the Icare tonometer is easy to use and records consistent
readings rapidly, with minimal training required.95 The TOC optometrists working on the study were all
familiar with the Icare and used this device routinely prior to their participation in the project.
The objective and subjective determination of refractive error
This allows the strength of the spectacle prescription to be determined. Retinoscopy is an objective
technique used by optometrists to determine the refractive error of the eye by observing the movement
of light reflected from the fundus. It was attempted in all the study examinations to determine the
prescription objectively. Wherever possible, the retinoscopy result was modified subjectively using a
conventional monocular subjective refraction with the patient reading letters or symbols presented on the
logMAR test chart.
On completion of the determination of each participant’s refractive error (their spectacle prescription), the
distance VAs for the right and left eyes were recorded (whenever participant co-operation permitted) and,
in most cases, a binocular VA (VA with both eyes together) was also recorded. The participant’s working
distance for doing near tasks was recorded and informed the determination of the near addition, which is
the extra element of power required by older people to provide comfortable, clear vision for near visual
tasks. This initial estimate of near addition was refined, where possible, and NVAs were recorded.
Ocular health examination
At this stage in the test the participant’s pupils were dilated using tropicamide eye drops to facilitate the
examination of the eye’s structures behind the iris, notably the lens, the retina and other back-of-the-eye
structures. Both 0.5% and 1% Tropicamide Minims® (Bausch+ Lomb, Surrey, UK) (single-dose containers)
were available to the optometrist, who chose the concentration based on their clinical assessment of the
participant. An examination of the anterior eye (eyelids, cornea, conjunctiva and iris) would take place prior
to examination of the posterior surfaces of the eye. Prior to pupillary dilatation, the likelihood of the pupil
dilatation provoking an acute angle-closure glaucoma (ACG) attack (see Glossary) was assessed using the
pen light test for anterior chamber depth estimation.96 The risk of provoking an acute ACG attack with
tropicamide is very low, with zero cases of ACG reported in almost 4000 dilatations.97 However, participants
judged at risk of an ACG attack were not dilated and were examined through undilated pupils.
Following the instillation of tropicamide eye drops, the participant’s pupils were normally sufficiently dilated
after approximately 20 minutes. Tropicamide is a drug that can reduce accommodation (the ability to alter
the focus of the eyes) but PrOVIDe participants were aged > 60 years and would therefore have no
accommodation. Once the pupils were fully dilated, the examination of the fundus followed, using a direct
hand-held ophthalmoscope. As a further check on the possibility of a dilatation-induced acute ACG attack,
post-dilatation IOPs were measured using the Icare tonometer. A significant increase in IOP could be an
indicator of a pending ACG attack, and if this was suspected the optometrist remained and monitored the
participant for a further hour.
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Optometrists use a variety of methods to grade the severity of AMD, diabetic retinopathy and cataract.
For this study, AMD was classified into dry and wet (neovascular) AMD and then graded as mild, moderate
or severe. Diabetic retinopathy was graded as background diabetic retinopathy; mild, moderate or severe
non-proliferative retinopathy; proliferative retinopathy; and diabetic maculopathy. When calculating the
prevalence of AMD, diabetes and glaucoma in this study, a participant was considered as being positive
for the condition irrespective of the severity recorded by the optometrist.
Optometrists regularly detect and monitor patients with different types and grades of cataract. The three
most common types of age-related cataract (nuclear, posterior subcapsular or cupuliform, and cortical) are
often graded by community optometrists as mild, moderate or severe. In addition to this grading, a sketch
of the lens changes observed may form part of the clinical record. Some community optometrists use
more sophisticated slit-lamp based grading systems for cataract, such as The Lens Opacities Classification
System (LOCS) III.98 Systems such as LOCS III, also often used in research studies, require the use of a
slit-lamp biomicroscope. The slit lamp normally used in community optometric practices is a bulky piece of
equipment, unsuitable for domiciliary use, and was not available for PrOVIDe.
PrOVIDe optometrists used the cataract grading section of the Optometric Grading Scale (Figure 2) as the
main method for grading cataract for PrOVIDe participants. The research team contacted the designer,
Mr RM Pearson, for approval to use the Optometric Grading Scale99 when grading cataracts in study
participants. Free-text descriptions and diagrams were also used if necessary.
Visual fields
This was by far the most demanding of the tests attempted in the study eye examination. In the first half
of the recruitment and data collection period, optometrists were advised to request this test for all
participants for whom the test was clinically necessary or if the optometrist felt that the participant would
be able to understand and complete the test. This requested test was carried out by a member of TOC’s
field staff team on a different day from the actual eye examination. The visual field tests were conducted
using either the Humphrey® Frequency Doubling Technology perimeter (Carl Zeiss Meditec AG,
FIGURE 2 Optometric Grading Scale for grading age-related cataract.99 © Richard M Pearson. Reproduced
with permission.
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Jena, Germany) or the OCULUS Easyfield® perimeter (OCULUS Optikgeräte GmbH, Wetzlar, Germany). In
the second half of the data collection period, optometrists were advised to return to their normal practice
of requesting the test only when it was clinically necessary, owing to practical and logistical difficulties
encountered when arranging the fields appointments and the additional burden on participants of having
a second visit.
Conclusion
The examination concluded with verbal and written advice to the participant and/or carer based on the
optometrist’s findings. This included advice on any referral required, on the use of the participant’s existing
or any new spectacles or other treatments advised, and on the recommended date of the next eye
examination. Information explaining the effects of the tropicamide drops, including the symptoms and
signs of an ACG attack and advice on the action to take in the unlikely event of this occurring, were
printed on the form containing the spectacle prescription.
Where participant co-operation was poor, the optometrist moved the ocular health examination forwards
in the eye examination. This allowed the optometrist to focus on ophthalmoscopy through dilated pupils
whenever possible, which is the key test for detection of eye disease and does not require high levels of
participant co-operation.
Optometrists asked carers for their views on whether or not the extent to which a participant was able to
co-operate with the examination reflected his or her usual state. These views were noted on the
record card.
Participants, their relatives and carers were informed in writing of how to raise any concerns they might
have regarding the study or any aspect of the eye examination. Concerns were reported initially to the
PrOVIDe research team, who liaised with TOC and recruiters as required. All concerns or complaints were
documented and addressed.
Pilot study
Recruitment of participants for the pilot study commenced at the end of November 2012 and the main
study began on 15 February 2013. The pilot largely involved group 1 participants, as there were some
outstanding approvals relating to group 2 participants. Data from the pilot are not presented separately
in this report. Feedback from recruiters during the pilot study led to minor changes being made
to procedures relating to arranging and scheduling eye examinations, but no changes were made to
data collection.
A recruiter query arose during the pilot study about whether or not to include subjects who were already
taking part in other studies involving clinical drug trials of pharmaceutical products. This was discussed at
the Steering Group meeting held at the end of the pilot study; the group agreed a modification to the
exclusion criteria to exclude those participating in clinical trials, because the possible interactions between
trial drugs, particularly if a new product, and the tropicamide eye drops were unknown.
Main study
As there were no changes to data collection after the pilot study, the eye examination data collected from
the 21 participants who took part in the pilot were used in the main study; therefore, the eye examination
data collection period began in December 2012 and finished in April 2014.
Stage 2
Qualitative data collection techniques were employed in stage 2 through a combination of focus groups and
interviews. Focus groups are particularly useful when the aim of data collection is to bring together individuals
with a shared knowledge to explore common or contrasting opinions and experiences.100 For this reason,
focus groups were employed with two populations: family carers of people with dementia, and optometrists.
With any population a minimum of three focus groups is recommended to reduce selection bias,101 and in
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this study there was a total of 10 focus groups from these two populations: five with family carers and five
with optometrists.
Each focus group lasted for between 1 and 1.5 hours. The key question areas were the frequency and
relevance of sight tests for people with dementia, reported experiences of eye care and barriers to eye
care. The focus group question schedules are in Appendix 2.
Focus groups were also planned with professional carers. The recommended number of participants is a
minimum of four and a maximum of 12, but pilot work with care homes indicated that there would be
difficulties in recruiting a sufficient number of participants. Indeed, it was possible to arrange only one
focus group, and so interviews were used to elicit the views of additional care home representatives. Each
interview was conducted face to face by the same interviewer using a semistructured interview schedule,
which can be found in Appendix 3.
Interviews were also used to collect the views of people with dementia. Data saturation can usually be
achieved with around 30 interviews.102 In this study, 36 interviews were conducted with an equal number
of male and female participants, covering the full sample age spectrum of 60–89 years. Interviews took
place in participants’ homes and participants were invited to have a carer present if they wished. Nearly
all interviewees (n= 30) exercised this option, which proved to be helpful, as carers were able to answer
recall questions which participants found difficult. Carers often also offered their own contributions to the
interview discussion, thereby providing additional data. The length of interviews varied but usually ranged
between 15 and 30 minutes; the variation was largely dependent on the individual’s ability to respond as a
result of their cognitive state and the extent of the carer’s contribution to the discussion. Focus groups and
interviews were audio-recorded and then transcribed in preparation for data analysis.
Interviews with people with dementia were conducted over a 12-month period between May 2013 and
April 2014. Two focus groups were arranged in November 2013 to facilitate the piloting of the sampling
and recruitment procedures and the focus group schedule. The remaining eight focus groups with family
carers and optometrists took place between February and May 2014. Data collection with care workers
was completed in June 2014.
Stage 1 data analysis plan
Study outcomes
Distance vision
The calculation and analysis of the prevalence of the different types of VI in our sample addressed several
of the PrOVIDe study objectives, namely primary objectives 1 and 2, and secondary objectives 1, 2 and 3
(see Chapter 1, Aims and objectives). In PrOVIDe, the three types of VI investigated were as follows:
1. Presenting VI, based on best monocular VA recorded with the participant wearing their current distance
spectacles or unaided if no spectacles were worn for distance vision.
2. Post-refraction (or best corrected) VI, based on best VA recorded with the participant wearing the
prescription determined by the PrOVIDe optometrist.
3. Uncorrected or undercorrected VI, which includes those participants who had presenting VI but who
were not visually impaired wearing the prescription determined by the PrOVIDe optometrist.
As discussed in Chapter 1 (see Visual impairment), a variety of definitions of VI have been used in
prevalence studies. All of these definitions use criteria for VI based on levels of VA as recorded on Snellen
progression VA charts. The two most commonly used cut-off points used to define VI in terms of VA are
(1) VA < 6/12 Snellen and (2) VA < 6/18 Snellen. The logMAR equivalent of 6/12 Snellen is 0.30, so a VA
of < 6/12 is equivalent to 0.32 or worse logMAR acuity, and this was one of the cut-off points taken in the
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PrOVIDe study to define VI. There is no full logMAR line equivalent to 6/18 Snellen; reading all of the
letters of a 0.5 logMAR line is equivalent to 6/19 Snellen, and reading all the letters on the 0.4 logMAR
line is equivalent to 6/15 Snellen. The logMAR equivalent of 6/18 Snellen is 0.4771, so in mathematical
terms a logMAR acuity of 0.48 is worse than 6/18 Snellen. Therefore, 0.48 or worse logMAR acuity was
the second cut-off point used in the PrOVIDe study to define VI.
For distance vision, our data analyses included descriptive statistics of VI prevalence in the whole sample
and for groups 1 and 2 separately, with tests for differences in proportions between groups. Multivariable
ORs were calculated for each type of VI by age, sex and group, and for uncorrected/undercorrected
VI by sMMSE score. Prevalence data were presented using descriptive statistics for our four target eye
conditions (AMD, cataract, diabetic retinopathy and glaucoma) for the whole sample and for groups 1 and
2 separately, with tests for differences in proportions between groups. Multivariable ORs were calculated
for each eye condition by age, sex and group. The clinically determined causes of post-refraction VI were
presented using descriptive statistics. The proportion of carers providing support to the participant with
dementia during the eye examination was tabulated for the whole sample and for groups 1 and 2
separately, with tests for differences in proportions between groups. Improvements in VA between pre and
post refraction were presented for the sample as a whole and for groups 1 and 2 separately, with tests for
the statistical significance of any improvements between groups.
Near vision
The two cut-off points in terms of NVA used to define impaired near vision were (1) best monocular NVA
of worse than N8 and (2) best monocular NVA of worse than N10. Our analyses included descriptive
statistics of the prevalence of near vision loss in the whole sample and for groups 1 and 2 separately, with
tests for differences in proportions. Multivariable ORs were calculated for each type of near vision loss by
age, sex and group, and for uncorrected/undercorrected VI by sMMSE score. Improvements in NVA
between pre and post refraction were presented for the sample as a whole and for groups 1 and 2
separately, with tests for the statistical significance of any improvements between groups.
Ability of participants to complete individual elements of the
eye examination
This was secondary objective 2 of the study (see Chapter 1, Aims and objectives). Our data analyses
included descriptive statistics of the proportions of the whole sample able to complete each key test in the
eye examination, and proportions for groups 1 and 2 separately, with tests for differences in proportions
between groups. Multivariable ORs were calculated for each key test with age, sex and group as covariates
to assess their independent associations with the completion of each examination component. Any
association between participants’ level of cognition, as assessed by their sMMSE score, and their ability to
complete key elements of the eye examination was summarised using descriptive statistics and
multivariable ORs calculated for each test, with age, sex and group as covariates.
Patient management on completion of the eye examination
Descriptive statistics were presented for the proportions of the sample referred to participants’ GP or to
the HES.
Analysis of the effects of visual impairment on function (Bristol Activities of
Daily Living Scale) and behaviour (Cambridge Behavioural Inventory – Revised)
The results from the visually impaired and non-visually impaired participants were compared for both
instruments and ORs were derived, with age, sex and group as covariates. This was secondary objective 3 of
the study (see Chapter 1, Aims and objectives).
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Statistical methods
In stage 1, for descriptive statistics, the mean and SD were used to describe data that were close to
normally distributed, and the median and interquartile range (IQR) were used to describe data that were
strongly non-normally distributed. All relevant data reported in the text of Chapter 3 are in the following
style ‘count/percentage (95% CI)’ and will appear as ‘N/N, PP% (PP to PP)’. When data are stated as
proportions in tables, the 95% CI is given. Pearson chi-squared tests were performed to test the difference
between group proportions, using Yates’ continuity correction when appropriate (two-group comparisons),
and through Monte Carlo simulation (empirical distribution) when the number of cases in a given group
was low. When the results of chi-squared tests are reported, the degrees of freedom have been recorded
where appropriate. Logistic regression was used to calculate adjusted ORs when attempting to control for
covariates and when investigating independent effects on binary outcomes. For our exploratory analyses
of VI and behavioural and functional ability, ordinal logistic regression was used in some of the item
responses to the BADLS and CBI-R instruments. We have used ‘binary logistic regression’ and ‘logistic
regression’ synonymously, as is conventional, with an extra qualification for ordinal logistic regression for
the analyses indicated. Initial analyses as described above were performed on complete cases: that is, only
on participants in whom all relevant data were present for a particular tabulation, estimate, model or test.
For all tests, p< 0.05 was considered significant, with the Bonferroni correction applied when required.
All data were analysed using SPSS version 21 (IBM Corporation, Armonk, NY, USA) and R (an open-source
programming package from the R Foundation for Statistical Computing, Vienna, Austria).
Missing data plan
For all proportion estimates, and for all regression analyses, examining the independent associations of
age, sex, sMMSE scores (where appropriate) and residential status (living in residential care or own home)
with study outcomes (i.e. VI status, near vision loss, presence of eye conditions and the effects of VI on
behaviour and function), the primary analysis was a complete-case analysis (i.e. it included only participants
in each analysis in whom the relevant variables were fully observed).
Given that different study outcomes would be missing in different participants and for varying reasons
(e.g. some participants might not have been able to complete the recording of presenting or post-refraction
VA at distance and/or near vision, while for others dilatation of the pupil might not have been possible),
this may lead to some inconsistency in our separate analysis of each study outcome. Complete-case analysis
also leads to less efficient estimates, because it does not use the partial information available on participants.
Perhaps most crucially, it may lead to bias in unadjusted estimates if the data are not missing completely at
random. For example, our VI rate estimates from complete cases would be unbiased only if those participants
in whom we did/could not measure VA were expected to have the same rate of VI as those with observed
VA. That assumption seems implausible. Missing data can even lead to bias in regression modelling on
complete cases if the causes of missing data are not fully explained by the covariates in each model (missing
at random assumption).103 This assumption is unlikely to be realistic given that our regression models adjust
only for age, sex, sMMSE (where appropriate) and residential status.
To improve the plausibility of our prevalence estimates and our regression analysis assumptions, a multiple
imputation procedure employing chained equations104,105 was performed as a sensitivity analysis. Simply
stated, under multiple imputation, observed values of variables are used to predict missing values in other
variables. For our data, we used age, sex, location (living in residential care or own home), region, site and
examining optometrist as predictor variables, all of which were fully observed in the sample. Other
variables with some missing data included in the imputation model were time since last eye examination;
presenting and post-refraction distance and NVA; sMMSE score; presenting and post-examination AMD;
glaucoma and diabetes; post-examination diabetic retinopathy; presenting cataract and post-examination
cataract severity (left and right eye); BADLS total score; and CBI-R total score. Thus, for each variable with
missing data, the observed values of all other variables in this set would be used to predict the missing
values. A total of 30 multiply imputed data sets were generated and the estimates in each imputed data
set were pooled to obtain a result, the standard error of which accounted for the random variation across
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data sets owing to the uncertainty from missing data. All proportion estimates and their standard errors
were calculated on the logistic scale within each imputation and combined similarly.
Additionally, for cognitive performance, we operated under the assumption that missing sMMSE scores were
indicative of lower cognitive performance and were informatively missing.103 Thus, even if two participants had
similar characteristics but one had missing and the other had non-missing sMMSE scores, we would expect
there to be a difference in their cognitive performance. To address this, we performed a pattern mixture
model with a conditional expectation difference of 10 units between observed and missing sMMSE scores.
Extrapolating prevalence to the UK dementia population
Prevalence estimates for VI and its causes in the wider UK population of those aged 60–89 years with
dementia were calculated by comparing the estimated distributions of characteristics in this target population
with the PrOVIDe sample characteristics and calibrating estimates of rates of VI and of ocular conditions
(AMD, cataract, diabetic retinopathy and glaucoma) accordingly. The two-stage clustered sampling of
six regions and then 20 sites used in PrOVIDe was accounted for in this prevalence estimation, as was
the stratified sampling by age (60–74 years, 75–89 years), sex and location in each site (see Chapter 3,
Demographics and characteristics of the sample, Recruitment). The use of clustered sampling would result in
larger standard errors and wider CIs of estimates from the so-called design effect, whereas stratification acts
to reduce sampling variability and, in effect, reduce the standard error and the width of CIs.106
Post-stratification population calibration weights were derived using the estimate counts of the
population aged between 60 and 89 years with dementia in various strata. Two reliable joint distributions
(cross-tabulations) of the population were obtained2 and used for calibration: (1) age group and sex;
and (2) age group and residency (residential care or own home). Age groups were in 5-year bands –
60–64 years, 65–69 years, 70–74 years, 75–79 years, 80–84 years and 85–89 years – and residency was
dichotomised as ‘living in the community’ (own home) or ‘living in care’ (residential care). A raking
procedure107 was performed to derive weights to calibrate on these two population distributions
(age–sex and age–residency). Multiply imputed data were used (see Missing data plan) to account for
non-completion of components of the eye examination or other sources of missing data in outcomes
within the sample. Thus, a single weight factor could be calculated for all outcomes, with the imputation
addressing representativeness in the sample. All proportions and their standard errors were calculated on
the logistic scale within each imputation108 and combined using Rubin’s rules.109
All analyses were performed using the survey package in R.110
Comparison of prevalence with other UK studies of visual impairment in
older people
Using a similar approach to the prevalence estimation for the wider UK dementia population, estimated
rates of VI in PrOVIDe were also reweighted for greater comparability with two nationally representative
studies of VI in the elderly.56,57 This was achieved by applying post-stratification weights to the PrOVIDe
data. Rather than being derived using estimated distributions of characteristics from the UK population
aged 60–89 years with dementia, these weights were instead derived from the distributions of participant
characteristics in the NDNS and MRC studies.
The NDNS reported the cross-tabulations of age–sex and age–residency, where age groups were in bands
of 65–74 years, 75–84 years and ≥ 85 years, and residency was ‘community’ or ‘institution’ (the latter has
been interpreted as equivalent to living in residential care). The MRC study reported cross-tabulations of
age–sex, where age groups were in bands of 75–79 years, 80–84 years, 85–89 years and ≥ 90 years, and
participants lived in the community only. NDNS and MRC participants in age categories that fell outside the
age range of PrOVIDe were excluded for these comparative analyses (≥ 85 years for NDNS and ≥ 90 for
MRC), as were participants living in residential care for the MRC comparison. In turn, participants not in the
age ranges of NDNS or MRC were excluded in each respective comparison. Thus, the age range used when
comparing NDNS and PrOVIDe was 65–84 years and the age range used when comparing MRC and
PrOVIDe was 75–89 years.
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An alternative approach would have been to simply examine the rate of VI in each age–sex stratum
available; however, these strata become increasingly small, and estimates within them become increasingly
imprecise, with additional issues of multiple testing. Both of these issues would limit the ability to conclude
whether or not any differences were credible. The rationale, therefore, was to compare as large an
overlapping sample as possible for each of these two comparator studies in order to maximise the power
to detect any meaningful differences, while using weighting in the PrOVIDe estimates to control for
differences in sampling proportions of age and sex (and residency for NDNS).
From a statistical perspective, both comparator studies had differences in estimating and reporting VI
prevalences. The MRC reported that non-response was higher in females than in males, and in older
age groups than in younger age groups, but did not adjust for this in estimates. The NDNS used a
weighting factor to adjust and report overall prevalence to reflect the UK population, but this was not
accompanied by a CI to assess its precision. The NDNS did not report any CIs for any of their estimated
prevalences, whereas the MRC reported CIs with an adjustment for the clustered sampling of the study.
For the comparison of PrOVIDe estimates with the NDNS in the comparable/overlapping age group of
65–84 years, it was only possible to use VI rates and CIs calculated crudely from reported counts in age
strata and there was no information on the weights in the subset of age strata. From reported MRC
estimates the mean VI rate in those aged 75–89 years was calculated and combined with the
cluster-adjusted standard errors across the three relevant age strata to obtain approximate cluster-adjusted
CIs on the rate of presenting VI for distance vision.
Stage 2 data processing and qualitative analysis
In stage 2, audio recordings of the interviews and focus group discussions were transcribed and then
analysed using framework analysis.111 The process consists of five stages:
1. Familiarisation with the data – key ideas and recurrent themes are listed.
2. Identifying a thematic framework – data are sifted and sorted into key issues, concepts and themes.
3. Indexing – systematic application of the framework to the data while judging the significance and
meaning of the data.
4. Charting – lifting the data from the original source into charts.
5. Mapping and interpretation of the chart contents – perceptions, accounts and experiences are
compared and contrasted, patterns and connections are sought and explanations for differences
are considered.
Reliability and validity were achieved through independent analysis of the data by several members of the
research team. There was public and participant involvement (PPI) in data analysis: transcripts, data
interpretation and reporting were reviewed by the PPI member of the Project Steering Group.
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Chapter 3 Stage 1 results
Demographics and characteristics of the sample
Recruitment
Study recruitment began in November 2012 and was closed in February 2014, by which time
808 participants had been recruited (Table 2). Recruitment targets were stratified by age and sex
to reflect the age/sex distribution of the UK dementia population at that time. The median age of
the whole sample was 81 years (IQR 76–85 years); the median ages for participants living in their
own homes (group 1) and in care homes (group 2) were 80 years (IQR 74–84 years), and 83 years
(IQR 79–86 years), respectively.
The peak period of recruitment of group 1 participants occurred between February and July 2013, while
for group 2, care home participants, the peak period of recruitment was between September 2013 and
January 2014. The study profile is illustrated in Figure 3.
TABLE 2 Demographics (age, sex and group) of participants recruited
Demographics
Group 1 Group 2
TotalMale Female Total Male Female Total
Age (years) 60–74 75–89 60–74 75–89 60–74 75–89 60–74 75–89
Recruited 66 126 53 198 443 25 95 26 219 365 808
Withdrawn 11 13 2 28 54 5 15 1 25 46 100
Study participants 55 113 51 170 389 20 80 25 194 319 708
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Table 3 shows a comparison between the age, sex and group profile of the final PrOVIDe sample and the
2014 UK population data from the Alzheimer’s Society.2 Compared with these UK population data, the
PrOVIDe sample has a lower percentage of males and females in the 60–64 years, 65–69 years, 70–74 years
and 75–79 years ranges, a higher percentage of males and females in the 75–79 years category and a
higher percentage of females, but a lower percentage of males, in the 85–89 years category. For place of
residence, those participants living in their own homes were under-represented in the PrOVIDe sample
compared with the Alzheimer’s Society data for all age ranges apart from the 85–89 years range, in whom
the PrOVIDe sample was oversampled by 2.7%. There was better sampling agreement for those living in
care homes, apart from the 80–84 years range, who were oversampled in PrOVIDe by 7.7%.
Geographical distribution of participants
Six regions, with multiple sites in each region (a total of 20 sites), were involved in the recruitment of
potential participants. Figure 4 shows the locations of participating sites.
Each site proposed its own recruitment targets for group 1 and group 2 participants based on various
factors, including the size of the trust, geographical location, and local support for ENRICH (Enabling
Research in Care Homes) and access to care homes.
Recruitment was co-ordinated by the central DeNDRoN team. Table 4 presents the number of participants
recruited, the number of participants who withdrew and the number of participants who completed the
eye examination for each of the six regions.
Target study sample
(n = 770)
(group 1, n = 385; group 2, n = 385)
Recruited
(n = 808)
Study sample
(n = 708)
Total eye
examinations
attempted
(n = 708)
Group 1
Living in own homes
(n = 389)
Group 2
Living in care homes
(n = 319)
Withdrawals
(n = 100)
Group 1
(n = 54)
Group 2
(n = 46)
FIGURE 3 Study profile: stage 1.
STAGE 1 RESULTS
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FIGURE 4 Locations of participating recruitment sites.
STAGE 1 RESULTS
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Withdrawals from the study
The 100 out of 808 potential recruits who withdrew from the study before the eye examination represent
12.4% of recruits. One-third of withdrawals were attributable to death (16%) or to deterioration in
the health of the participant or carer (17%). One-quarter of withdrawals (25%) were attributable to the
participant and/or carer changing their mind after consenting. One-fifth of withdrawals (20%) were
attributed to difficulties in appointment scheduling. Four individuals were withdrawn from the study
because they were found to be ineligible. The remaining 18 individuals who withdrew from the study did
not report a specific reason.
Levels of cognitive impairment in the sample
Participants’ level of cognition was assessed using the sMMSE instrument. It was not possible to complete
the sMMSE instrument for 54 out of 708 participants, 52 of whom lived in care homes. These participants
mainly comprised those for whom no coherent responses were obtained when attempting the test,
and so could not be assessed using the sMMSE, and a small number who were unavailable, asleep or
unco-operative on the day of recruitment, and so the test was not carried out. From logistic regression,
after adjusting for age and sex, there is a statistically significant group effect on the probability of being
unable to obtain a sMMSE score, with the OR for those in care homes of 42.7 (95% CI 12.9 to 264.3;
p< 0.001). As a result of the small number of participants in group 1 in whom it was not possible to
obtain a sMMSE score (only two participants with missing sMMSE scores), the precision of the OR is low,
hence the wide CI. There was a statistically significant age (per year) effect [OR 0.95 (95% CI 0.91 to
1.00); p= 0.04] but no evidence for an independent sex effect [OR 0.63 (95% CI 0.31 to 1.21); p= 0.18].
The mean total sMMSE score, out of a maximum of 30, for the sample as a whole was 16.7 (95% CI 16.1
to 17.3). The mean score for group 1 was 19.8 (95% CI 19.2 to 20.5) and for group 2 was 12.1 (11.2 to
13.1), with a statistically significant group effect from linear regression when adjusted for age and sex:
–7.6 (95% CI –8.8 to –6.5; p< 0.001). There was no evidence for independent age or sex effects, with the
estimated differences (95% CI) per year of 0.03 (–0.05 to 0.11; p= 0.49) and between males and females
of 1.09 (–0.05 to 2.24; p= 0.06).
TABLE 4 Number of participants who were recruited, who withdrew and who completed the eye examination in
each region
Region
Group 1 Group 2
Recruited Withdrawn Participants Recruited Withdrawn Participants
East Anglia 73 8 65 45 4 41
North East 118 18 100 117 15 102
North Thames 147 11 136 88 13 75
Thames Valley 100 15 85 65 6 59
North West 5 2 3 8 0 8
Yorkshire 0 0 0 42 8 34
Study total 443 54 389 365 46 319
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For the analysis of the range of sMMSE scores in our sample (Tables 5 and 6), each participant was
allocated to one of five levels of cognitive impairment based on their total sMMSE score: severe cognitive
impairment (sMMSE score of 0–9), moderate cognitive impairment (10–20), mild cognitive impairment
(21–24), very mild cognitive impairment (25–27) and no cognitive impairment (28–30). In the context of
the PrOVIDe study, the term mild cognitive impairment is being taken to include people in the sMMSE
range of 21–24, although mild cognitive impairment has a different meaning in the general literature,
where it often refers to people without dementia but who have a performance of 1.5–2 SDs lower on
cognitive (usually memory) testing than age-matched norms. People in this group typically have subtle
cognitive and functional impairment and are an ‘at risk’ group for future development of dementia.
It should be noted that sMMSE scores do not equate to dementia severity. They only give a measure of
cognitive function, which may be influenced by many factors, including education, motor ability and
vision.112 Similarly, treatments for dementia, notably cholinesterase inhibitors, may have improved sMMSE
scores in some of our participants to levels within the more normal range. Other participants may have, at
the time of their assessment, achieved a score on the sMMSE in the relatively normal range but will still
have significant functional impairment as a consequence of their cognitive impairment. As a result of these
functional impairments, not detectable using the relatively insensitive sMMSE, these participants still have
clinically defined dementia. Nor does sMMSE pick up on executive dysfunction particularly well, so
relatively normal scores may be found in people with frontal variants of dementia.
The principal reason for analysing numbers/percentages of participants in different categories of dementia
was to establish that the PrOVIDe sample included an adequate distribution of severity of cognitive
impairment across the sMMSE range, and the data presented in Table 5 demonstrate that this aim was
achieved. Almost 40% of the sample (260/654) had moderate cognitive impairment (sMMSE score of
10–20), with approximately 20% in each of the mild and severe groups (145/654 and 138/654,
respectively). At the time of assessment, 4.3% of the sample (28/654) revealed no cognitive impairment,
scoring 28, 29 or 30 on the sMMSE instrument. The difference between distributions of non-missing
sMMSE categories in groups 1 and 2 was statistically significant (χ12 p< 0.01).
TABLE 5 Level of cognitive impairment as assessed by sMMSE
sMMSE score
(degree of
cognitive
impairment)
Full sample (N= 654)a Group 1 (N= 387) Group 2 (N= 267) Difference in
proportions
between groups 1
and 2, %b
(95% CI); p-value% (n) 95% CI % (n) 95% CI % (n) 95% CI
0–9 (severe
cognitive
impairment)
21.1 (138) 18.1 to 24.5 9.3 (36) 6.7 to 12.8 38.2 (102) 32.4 to 44.3 –28.9 (–35.7 to –22.1);
< 0.01
10–20 (moderate
cognitive
impairment)
39.8 (260) 36.0 to 43.6 34.9 (135) 30.2 to 39.9 46.8 (125) 40.7 to 53.0 –11.9 (–19.9 to –4.0);
< 0.01
21–24 (mild
cognitive
impairment)
22.2 (145) 19.1 to 25.6 30.5 (118) 26.0 to 35.4 10.1 (27) 6.9 to 14.5 20.4 (14.2 to 26.5);
< 0.01
25–27 (very mild
cognitive
impairment)
12.7 (83) 10.3 to 15.5 18.1 (70) 14.5 to 22.4 4.9 (13) 2.7 to 8.4 13.2 (8.3 to 18.2);
< 0.01
28–30 (no
cognitive
impairment)
4.3 (28) 2.9 to 6.2 7.2 (28) 4.9 to 10.4 0 (0) 0 to 1.8 7.2 (4.3 to 10.1);
< 0.01
a No sMMSE scores were measured for 54 participants (7.6%): 2 (0.5%) in group 1 and 52 (19.5%) in group 2.
b Chi-squared test of difference of proportions (χ1
2).
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The variations in the proportions of our sample with different categories of dementia with age are
presented in Table 6. There is a difference in the distribution of non-missing cognitive impairment
categories with age (overall chi-squared test, using Monte Carlo adjustment for small cell counts,
p< 0.001). This trend is also evident in the scatterplot of sMMSE score versus age in Figure 5. The curved,
dashed line in the scatterplot is a ‘Friedman super-smoother line’, a non-parametric regression estimator
based on local linear regression with adaptive bandwidths. It is essentially a fitted line following the mean
of y at a given x, which is required to be smooth but allowed to curve upwards and downwards.113
Eye examination data
Eye examination data were collected by 14 TOC optometrists. The average number of eye examinations
performed by each optometrist was 51 (SD 35, range 11–131). Location was a major factor affecting the
number of eye examinations by each optometrist, as each worked in a specific region.
Optometrists were able to perform an eye examination, although not necessarily a full eye examination,
on all participants living in their own homes (group 1; n= 389). Optometrists were unable to perform any
part of the eye examination on eight participants living in care homes (group 2; n= 319). The ages and
sMMSE scores for these eight participants were: 85 years, sMMSE= 13; 63 years, sMMSE= 0; 82 years,
sMMSE= 7; 85 years, sMMSE= 16; 87 years, sMMSE= 19; 80 years, sMMSE= 5; 85 years, sMMSE not
possible; and 73 years, sMMSE not possible. Hence an eye examination, albeit often not a full eye
examination, was performed on the remaining 311 participants in group 2. A full eye examination was
sometimes not possible because optometrists were unable to perform one or more elements of the eye
examination on the participant (see Ability of participants to complete individual elements of the eye
examination). Eleven participants were examined twice by TOC optometrists, in line with TOC policy for
situations in which the first examination failed to yield adequate results, or if the patient or carer requested
a second attempt, or in instances where a recheck examination was indicated (e.g. if a participant failed
to adapt well to new spectacles). It is unlikely that a second examination would have been attempted in
most of these cases had the participant been examined as part of normal optometric domiciliary care, and
therefore only data from the participant’s first eye examination have been included in the analysis.
30
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FIGURE 5 Scatterplot of sMMSE score vs. age.
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Prevalence of visual impairment
Prevalence of VI (Table 7) is described in terms of:
l presenting VI, based on best monocular VA recorded with the participant wearing their current
distance spectacles or unaided if no spectacles were worn for distance vision
l post-refraction (or best corrected) VI, based on best VA recorded with the participant wearing the
prescription determined by the PrOVIDe optometrist
l uncorrected or undercorrected VI, which includes those participants who have presenting VI but who
were not visually impaired wearing the prescription determined by the PrOVIDe optometrist.
TABLE 7 Prevalence of VI for both VA criteria for presenting VI (with any spectacles worn), post-refraction VI
(up-to-date prescription worn), and uncorrected/undercorrected VI (those with presenting VI who remain visually
impaired with their up-to-date prescription)
Type of VI
Full sample (N= 708) Group 1 (N= 389) Group 2 (N= 319) Difference in
proportions
between groups 1
and 2%a (95% CI);
p-value% (n) 95% CI % (n) 95% CI % (n) 95% CI
VA < 6/12
Presenting 32.5 (191) 28.7 to 36.5 21.8 (82) 17.8 to 26.4 51.4 (109) 44.5 to 58.3 –29.6
(–37.9 to –21.3);
< 0.001Missing data 16.9 (120) 3.3 (13) 33.5 (107)
Uncorrected or
undercorrected
14.3 (84) 11.7 to 17.5 10.6 (40) 7.8 to 14.3 21.0 (44) 15.8 to 27.2 –10.4
(–17.0 to –3.6);
< 0.01
Missing data 17.2 (122) 3.3 (13) 34.2 (109)
Post refraction 18.1 (107) 15.2 to 21.5 11.4 (43) 8.4 to 15.1 30.2 (64) 24.2 to 36.9 –18.8
(–26.1 to –11.5);
< 0.001Missing data 16.7 (118) 2.8 (11) 33.5 (107)
VA < 6/18
Presenting 16.3 (96) 13.5 to 19.6 10.6 (40) 7.8 to 14.3 26.4 (56) 20.7 to 33.0 –15.8
(–22.8 to –8.7);
< 0.001Missing data 16.9 (120) 3.3 (13) 33.5 (107)
Uncorrected or
undercorrected
7.7 (45) 5.7 to 10.2 5.1 (19) 3.2 to 7.9 12.4 (26) 8.4 to 17.8 –7.3
(–12.7 to –2.0);
< 0.01
Missing data 17.2 (122) 3.3 (13) 34.2 (109)
Post refraction 8.6 (51) 6.6 to 11.3 5.6 (21) 3.6 to 8.5 14.2 (30) 9.9 to 19.7 –8.6
(–14.2 to –3.0);
< 0.001Missing data 16.7 (118) 2.8 (11) 33.5 (107)
a Chi-squared test of difference of proportions (χ1
2).
Note
> 95% of the ‘missing’ data were categorised as ‘could not be measured’ as a result of poor participant co-operation.
Presenting VA was missing for three participants and there were no missing data for post-refraction VA measurement.
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Flow charts that illustrate the stages involved in identifying each of the three types of VI, and which
present the numbers of visually impaired for each type of VI, are given in Figure 6 for the VI criterion of VA
< 6/12, and in Figure 7 for VA < 6/18.
l Presenting VI It was not possible to measure the presenting best monocular VA in 117 out of 708
participants (16.5%, 95% CI 13.9% to 19.5%), with 11 out of 389 (2.8%, 95% CI 1.5% to 5.2%) in
group 1, and 106 out of 319 (33.2%, 95% CI 28.1% to 38.7%) in group 2. In 0.4% (3/708) of
participants, the presenting best monocular VA data were missing. The overall prevalence of VI defined
by the criterion of VA < 6/12 was 191 out of 588 (32.5%, 95% CI 28.7% to 36.5%) and for VA
< 6/18 was 96 out of 588 (16.3%, 95% CI 13.5% to 19.6%) (see Table 7).
l Post-refraction VI Post-refraction VAs could not be recorded in 118 out of 708 participants (16.7%, 95% CI
14.2% to 19.7%). The overall prevalence of VI for VA < 6/12 was 107 out of 590 (18.1%, 95% CI 15.2%
to 21.5%) and for VA < 6/18 was 51 out of 590 (8.6%, 95% CI 6.6% to 11.3%).
l Uncorrected or undercorrected VI The prevalence of uncorrected or undercorrected VI was 84 out of
586 (14.3%, 95% CI 11.7% to 17.5%) for VA < 6/12 and 45/586 (7.7%, 95% CI 5.7% to 10.2%) for
VA < 6/18.
l Group 1 versus group 2 Differences in prevalence between groups 1 and 2 were statistically significant
for both the 6/12 and 6/18 criteria for presenting, uncorrected or undercorrected and post-refraction VI
(see Table 7).
Measurement of
presenting VA attempted
(n = 708)
VA could not be
measured
(n = 117)
VA measured
(n = 588)
VA < 6/12
Presenting VI
(n = 191)
VA > 6/12
Not VI
(n = 397)
Missing data
(n = 3)
Eye examination attempted
(n = 708)
VA < 6/12
Post-refraction VI
(n = 107)
VA > 6/12
Not VI
(n = 483)
Includes
uncorrected or undercorrected VI
(n = 84)
VA could not be
measured
(n = 118)a
FIGURE 6 Identification of presenting VI, post-refraction VI and uncorrected/undercorrected VI for best monocular
VA < 6/12 criterion. a, Includes one participant for whom VA could not be measured post refraction but presenting
VA could be measured.
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Factors associated with visual impairment
The variation in prevalence with age for each type of VI (VA < 6/12 and VA < 6/18) is shown in Table 8.
The highest prevalences for presenting and post-refraction VI were in the 80–84 years and 85–89 years
age groups, with a more even distribution of prevalences across the age bands for uncorrected or
undercorrected VI. The variation in prevalence with category of severity of cognitive impairment for VA
< 6/12 is shown in Table 9 and for VA < 6/18 is shown in Table 10. Prevalences for presenting and
post-refraction VI for both cut-off points were highest in the severe category for cognitive impairment,
with prevalences tending to reduce with lesser degrees of cognitive impairment. There was a similar trend
for uncorrected/undercorrected VI for VA < 6/18. However, for uncorrected/undercorrected VI for VA
< 6/12, there was a more even distribution of prevalences across the categories of cognitive impairment.
The data in Tables 8–10 were analysed by logistic regression analysis, summarised in Table 11.
Measurement of
presenting VA attempted
(n = 708)
VA could not be
measured
(n = 117)
VA measured
(n = 588)
VA < 6/18
Presenting VI
(n = 96)
VA > 6/18
Not VI
(n = 492)
Missing data
(n = 3)
Eye examination attempted
(n = 708)
VA < 6/18
Post-refraction VI
(n = 51)
VA > 6/18
Not VI
(n = 539)
Includes
uncorrected or undercorrected VI
(n = 45)
VA could not be
measured
(n = 118)a
FIGURE 7 Identification of presenting VI, post-refraction VI and uncorrected/undercorrected VI for best monocular
VA < 6/18 criterion. a, Includes one participant in whom VA could not be measured post refraction but presenting
VA could be measured.
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Relationship between Standardised Mini-Mental State Examination score and
visual acuity
An alternative method of presenting the relationship between participants’ level of cognitive impairment,
as measured by sMMSE score, and their visual performance as defined by their level of VA, is shown in the
box and whisker plots in Figure 8. Participants with best monocular VA of > 6/12 have been classified as
‘level 0’, participants with VA between 6/12 and 6/18 as ‘level 1’, and those with VA worse than 6/18 as
‘level 2’. There is a trend for presenting VA to decline with decreasing sMMSE score. For post-refraction
VA, sMMSE scores are higher in level 0 participants than in those in either level 1 or level 2. Figure 8c
illustrates the change in VA level plotted against sMMSE score; for example, a participant who improved
from < 6/18 (level 2) to > 6/12 (level 0) would be classified as –2 in terms of change in VA level. There
is a trend for those participants with the greatest changes in level (improvement in VA) to have lower
sMMSE scores.
Logistic regression analysis
For both presenting and post-refraction VI there were statistically significant independent age and group
differences for both the VA < 6/12 and VA < 6/18 criteria (see Table 11), with adjusted OR estimates
(per year) of between 1.05 and 1.10 (p≤ 0.01). There was little evidence for consistent independent sex
differences on VI.
TABLE 11 Multivariable (adjusted) ORs for each type of VI by age, sex, group, and by sMMSE for uncorrected/
undercorrected VI
Type of VI Variable OR p-value 95% CI
VA < 6/12
Presenting VI Age (per year) 1.05 < 0.01 1.02 to 1.08
Sex (male) 0.71 0.08 0.48 to 1.04
Group 2 3.19 < 0.001 2.19 to 4.66
Post-refraction VI Age (per year) 1.07 < 0.001 1.03 to 1.12
Sex (male) 0.80 0.35 0.50 to 1.27
Group 2 2.71 < 0.001 1.74 to 4.26
Uncorrected/undercorrected VI Age (per year) 1.00 0.83 0.97 to 1.04
Sex (male) 0.69 0.16 0.41 to 1.14
Group 2 2.19 < 0.01 1.30 to 3.73
sMMSE (per unit score) 1.00 0.87 0.97 to 1.04
VA < 6/18
Presenting VI Age (per year) 1.05 0.01 1.01 to 1.10
Sex (male) 0.93 0.78 0.58 to 1.50
Group 2 2.52 < 0.001 1.59 to 4.03
Post-refraction VI Age (per year) 1.10 < 0.01 1.04 to 1.17
Sex (male) 1.84 0.05 1.00 to 3.37
Group 2 2.26 0.01 1.23 to 4.20
Uncorrected/undercorrected VI Age (per year) 0.99 0.56 0.94 to 1.04
Sex (male) 0.45 0.04 0.21 to 0.92
Group 2 1.99 0.05 0.99 to 4.02
sMMSE (per unit score) 0.95 0.03 0.91 to 1.00
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FIGURE 8 Box and whisker plots of sMMSE score for VA defined by VA > 6/12 (level 0), for VA between 6/12 and
6/18 (level 1), and for VA < 6/18 (level 2), for (a) presenting VA; (b) post-refraction VA; and (c) box and whisker plot
of sMMSE score for change in VA level between presenting and post-refraction measurement. (continued )
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For uncorrected/undercorrected VI defined by VA < 6/12, there was no evidence for any independent
age or sex effects (see Table 11). After adjusting for age, sex and group there was no evidence for any
independent effect of sMMSE score, OR 1.00 (95% CI 0.97 to 1.04; p= 0.87). After adjusting for age, sex
and sMMSE score there was a statistically significant group difference, with the OR for those participants
living in care homes compared with those living at home being 2.19 (95% CI 1.30 to 3.73; p< 0.01).
For uncorrected/undercorrected VI defined by VA < 6/18, there was no evidence of any independent
change with age (p= 0.56). Sex, sMMSE score and group all exhibited statistically significant independent
differences on the prevalence of VI with OR estimates of 0.45 (male vs. female, p= 0.04), 0.95 (sMMSE, per
unit score, p= 0.03) and group 1.99 (care homes vs. own homes, p= 0.05) (see Table 11).
Time elapsed since last eye examination
Data were gathered on the time that had elapsed since each participant’s last eye examination. Although
some participants were able to give an exact date (usually taken from the form on which their last
spectacle prescription was written), for the majority of participants this was an approximate date. Figure 9
shows these data for groups 1 and 2 separately, presented as a bar chart. No data on the time since last
eye examination could be obtained from 7 out of 708 participants, all of whom lived in care homes.
30
(c)
25
20
15
sM
M
SE
 s
co
re
10
5
0
+1 level No
change
–1 level
Change in VA level
–2 level
FIGURE 8 Box and whisker plots of sMMSE score for VA defined by VA > 6/12 (level 0), for VA between 6/12 and
6/18 (level 1), and for VA < 6/18 (level 2), for (a) presenting VA; (b) post-refraction VA; and (c) box and whisker plot
of sMMSE score for change in VA level between presenting and post-refraction measurement.
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These data are presented as a histogram in Figure 10. The research optometrists recorded the time since
last eye examination using the following non-linear scale: 0–1 month, 1–2 months, 2–3 months,
3–4 months, 4–5 months, 5–6 months, 6–12 months, 12–24 months, 24–36 months, 36–48 months,
48–60 months, 60–72 months, 72–84 months, 84–96 months, 96–108 months and 108–120 months.
35
30
25
20
15
Pe
rc
en
ta
g
e 
o
f 
p
ar
ti
ci
p
an
ts
10
5
0
0–6
months
30
32
2728
19
18
14
15
3
1
2 1 1 0 1 0 0 0
3
2
0
2
0 0
6–12
months
1–2
years
2–3
years
3–4
years
4–5
years
5–6
years
Time since last eye examination
6–7
years
7–8
years
8–9
years
9–10
years
Not
possible
Group 1
Group 2
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Predictors of time since last eye examination
The time since last eye examination was recorded in intervals that varied from 0–1 month and 1–2 months,
up to 108–120 months, with the time intervals becoming increasingly coarse as time increased. The
independent (of age, sex and sMMSE score) associations of the time interval since the last eye examination
were examined using two different regression analyses that included age, sex, sMMSE score and group
(participants living in care homes or living in their own homes) as covariates. These were (1) a continuous
‘coarse’ regression with a log-link function, modelling times within intervals using a latent model and
giving rate ratios114 and (2) an ordinal logistic regression model giving ORs for a change from one time
interval to a later one. Analysis 1 estimated a rate ratio of 0.78 (95% CI 0.65 to 0.93) for group, implying
a reduction of 22% in the time since the last eye examination in care home residents, compared with
those living in their own homes. Analysis 2 estimated an OR of 0.70 (95% CI 0.51 to 0.97) for group,
implying an increased probability for a shorter time interval between eye examinations for care home
residents than for those living in their own homes. Neither analysis provided evidence for an association
of time since last eye examination with age, sex or sMMSE score. In summary, living in a care home is
independently (of age, sex and sMMSE score) associated with a shorter interval since last eye examination
than living at home.
Independent association between time since last examination and
uncorrected/undercorrected visual impairment
The time interval since last eye examination was examined as a predictor for uncorrected/undercorrected VI.
The mid-points of all time intervals were calculated and time since last examination was then added
as a continuous covariate to the primary model for uncorrected/undercorrected VI, including age,
sex, group and sMMSE scores. For VI defined as VA of < 6/12, there appeared to be no association
(independent of age, sex, sMMSE score and group) between the time since last eye examination and the
probability of having uncorrected/undercorrected VI, with an OR of 1.04 (95% CI 0.89 to 1.19). However,
for VI defined as VA of < 6/18, there was evidence of an association (independent of age, sex and group)
between the time since last eye examination and the probability of having uncorrected/undercorrected VI,
with an OR of 1.23 (95% CI 1.04 to 1.42). Here, ORs were expressed as the increase in odds for VI for every
year increase in the time since last eye examination.
The independent association of group (participants living in care homes or their own homes) with VI in this
analysis had adjusted ORs of VI of 2.24 (95% CI 1.32 to 3.82) for VA of < 6/12 and 2.34 (95% CI 1.14
to 4.86) for VA of < 6/18 in those living in care homes versus those living in their own homes. Thus, an
individual living in a care home was more likely to have uncorrected/undercorrected VI than an individual
living in their own home, even if both had the same time interval since their last eye examination. These
ORs were slightly increased compared with the model when it does not include the time since last eye
examination: 2.19 (95% CI 1.30 to 3.73) for VA of < 6/12 and 1.99 (95% CI 0.99 to 4.02) for VA of
< 6/18. This finding reflects the shorter time since the last eye examination in those living in care homes
versus those living in their own homes.
Prevalence of specified eye conditions
Before the reporting of the prevalence of eye conditions, it should be pointed out that optometrists use a
variety of methods to grade the severity of AMD, diabetic retinopathy and cataract. For this study, AMD
was classified into dry and wet (neovascular) AMD and graded as mild, moderate or severe. Diabetic
retinopathy was graded as background diabetic retinopathy; mild, moderate or severe non-proliferative
retinopathy; proliferative retinopathy; and diabetic maculopathy. When calculating the prevalence of AMD,
diabetic retinopathy and glaucoma in this study, a participant was considered as being positive for the
condition irrespective of the severity recorded by the optometrist.
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The prevalences of the four specified conditions (AMD, cataract, diabetic retinopathy and glaucoma) are
presented in Table 12. Some participants had more than one of these conditions. A total of 185 out of
695 participants (26.6%) (108/388, 27.8%, of group 1 participants, and 77/307, 25.1%, of group 2
participants) already had an intraocular lens (IOL) in at least one eye following cataract surgery. Currently
these participants have been classified in this table as not having cataract, even if there was cataract in one
eye. The rationale for this decision was that for these participants cataract was not impairing their vision
under binocular conditions. For a more detailed analysis of participants with IOLs see Factors associated
with the PrOVIDe specified conditions.
Factors associated with the PrOVIDe specified conditions
Cataract, glaucoma and AMD all become more prevalent with increasing age in the general UK
population. Table 13 presents prevalence data for each condition, with our age range (60–89 years)
subdivided into six equal 5-year ranges. This subdivision also facilitates comparison with published studies
(see Discussion), which include participants in a variety of age groups. The cataract grading scale
(see Chapter 2, Data collection, Stage 1) grades cataract from 0 to 5, according to the density of the
opacification, where grade 0 is no cataract visible to the PrOVIDe optometrist on ophthalmoscopy.
Grades 1–5 are visible to the optometrist and the prevalence of these cataracts is presented in Table 13.
Grade 1 cataract is unlikely to have a significant effect on the participants’ VA, unlike grades 2–5.
Therefore, the prevalences of cataracts of grades 2–5 are also given in Table 13.
Cataract prevalence increases initially with age but then reaches a plateau, which reflects the increasing
proportion of participants who have undergone cataract surgery and had an IOL implant in one or both
eyes with age. For ease of interpretation of the data we have until now regarded participants who have an
IOL in one eye as not having cataract on presentation. A more detailed breakdown of the crystalline lens
status of the sample is given in Table 14.
TABLE 12 Prevalence data for the four conditions
Condition
Full sample (N= 708) Group 1 (N= 389) Group 2 (N= 319) Difference in
proportions
between groups 1
and 2, %a (95% CI);
p-value% (n)
95% CI
(missing %) % (n)
95% CI
(missing %) % (n)
95% CI
(missing %)
AMD 17.7 (123) 15.0 to 20.8
(2.0)
18.3 (71) 14.7 to 22.6
(0.3)
17.0 (52) 13.1 to 21.8
(4.1)
1.3 (–4.7 to 7.3);
0.73
Cataractb 59.0 (410) 55.2 to 62.7
(1.8)
55.9 (217) 50.8 to 60.9
(0.3)
62.9 (193) 57.2 to 68.2
(3.8)
–7.0 (–14.6 to 0.7);
0.08
Diabetic
retinopathy
2.0 (14/699) 1.1 to 3.4
(N/A)
2.0 (7/389) 0.8 to 3.8
(N/A)
2.3 (7/310) 1.0 to 4.8
(N/A)
–0.3 (–2.9 to 1.9);
0.79
Glaucomac 7.1 (49/694) 5.3 to 9.3
(2.0)
8.0 (31/388) 5.6 to 11.3
(0.3)
5.7 (18/306) 3.6 to 9.3
(4.1)
2.3 (–2.0 to 6.2);
0.35
N/A, not applicable.
a Chi-squared test of difference of proportions (χ1
2).
b The presence of cataract is defined as cataract sufficient to be graded on the TOC cataract grading scale. Participants
with an intraocular lens in one eye have currently been classified in this table as not having cataract.
c These figures are an estimate. The prevalence figures for glaucoma have been calculated by adding an estimated half of
the total number of patients referred to the HES as suspect glaucoma cases to the number of patients already diagnosed
with glaucoma. This is based on the assumption that 50% of the suspect glaucoma referrals will be true positives.
Note
All ‘missing’ data were ‘could not be measured’ as a result of poor participant co-operation.
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The influence of IOLs on the prevalence of cataract with age is illustrated in Figure 11, with the proportion
of participants with IOLs almost doubling between 75–79 and 85–89 years, while the proportion of
participants with cataract actually falls in the oldest age group.
The results of the multivariable logistic regression analysis on the presence of each condition are presented
in Table 15. After adjusting for sex and group there was a statistically significant age effect for AMD,
cataract grades 1–5 and cataract grades 2–5 (p< 0.001). There is weak evidence for an independent age
effect on diabetic retinopathy and no evidence for one on glaucoma/OHT, with OR estimates of 0.93
(per year, p= 0.06) and 1.01 (per year, p= 0.51), respectively.
There was a statistically significant sex effect for diabetic retinopathy (male vs. female OR 3.69) when
adjusted for age and group (p= 0.03). However, there were only 14 participants in the sample with
diabetic retinopathy, so all the OR estimates for this condition should be interpreted with caution. There is
little evidence of an independent sex effect for AMD (p= 0.31), cataract grades 1–5 (p= 0.35), cataract
grades 2–5 (p= 0.22) or glaucoma/OHT (p= 0.18).
After adjusting for age and sex, there was a statistically significant group effect for AMD (group 2 vs.
group 1, OR 0.59; p= 0.01). There was no evidence for an independent group effect for cataract grades
1–5 (p= 0.66) and cataract grades 2–5 (p= 0.83), and weak evidence for a group effect on diabetic
retinopathy and glaucoma/OHT with OR estimates (group 1 vs. group 2) of 1.90 and 0.68, respectively
(p= 0.26 and p= 0.17).
Causes of visual impairment
A total of 102 out of 708 participants were classified post refraction as visually impaired based on their VA
being < 6/12; 47 out of 708 participants were classified post refraction as visually impaired based on their
VA being < 6/18. Binocular VA was used, with best monocular substituted when binocular VA was not
available, to facilitate comparison with other UK studies.44,56 Any VI resulting from uncorrected or
undercorrected refractive error has now been corrected, so refractive error has been eliminated as a
possible cause. The eye condition(s) identified by the examining optometrist as being the cause(s) of their
VI are given in Table 16. For some participants two possible causes were recorded, and in these cases both
causes have been included in Table 16.
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FIGURE 11 Prevalence of cataract and IOLs stratified into six age categories.
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TABLE 15 Multivariable (adjusted) ORs for AMD, cataract, diabetic retinopathy and glaucoma/OHT by age, sex
and group
Condition Variable OR p-value 95% CI
AMD Age (per year) 1.18 < 0.001 1.13 to 1.24
Sex (M) 0.79 0.31 0.50 to 1.24
Group 2 0.59 0.01 0.38 to 0.90
Cataracta (grades 1–5) Age (per year) 1.14 < 0.001 1.10 to 1.18
Sex (M) 0.80 0.35 0.51 to 1.28
Group 2 0.90 0.66 0.56 to 1.45
Cataracta (grades 2–5) Age (per year) 1.11 < 0.001 1.08 to 1.14
Sex (M) 0.81 0.22 0.57 to 1.14
Group 2 0.96 0.83 0.68 to 1.36
Diabetic retinopathy Age (per year) 0.93 0.06 0.87 to 1.00
Sex (M) 3.69 0.03 1.19 to 13.80
Group 2 1.90 0.26 0.62 to 5.89
Glaucoma or OHT Age (per year) 1.01 0.51 0.98 to 1.06
Sex (M) 1.43 0.18 0.85 to 2.39
Group 2 0.68 0.17 0.39 to 1.16
M, male.
a The cataract category includes those participants who have had their cataract removed and an IOL implanted.
TABLE 16 Causes of VI (post refraction) resulting from each of the four specified eye conditions, alone and
in combination
Condition(s)
VA < 6/12 (N= 102) VA < 6/18 (N= 47)
% (n) 95% CI % (n) 95% CI
AMD alone 16.7 (17) 10.3 to 25.6 19.1(9) 9.6 to 33.7
Cataract alone 44.1 (45) 34.4 to 54.3 31.9 (15) 19.5 to 47.3
Diabetic retinopathy alone 0 0.0 to 4.5 0 0.0 to 9.4
Glaucoma alone 2.0 (2) 0.3 to 7.6 4.3 (2) 0.7 to 15.7
Cataract and AMD 20.6 (21) 13.5 to 30.0 29.8 (14) 17.8 to 45.1
Cataract and diabetic retinopathy 1.0 (1) 0.1 to 6.1 0 0.0 to 9.4
Cataract and glaucoma 4.9 (5) 1.8 to 11.6 0 0.0 to 9.4
Glaucoma and AMD 2.9 (3) 0.8 to 9.0 4.3 (2) 0.7 to 15.7
Other 7.8 (8) 3.7 to 15.3 10.6 (5) 4.0 to 23.9
Cases of VI in which the cause could not be attributed to one of the four specified conditions have been included
under ‘other’.
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To facilitate comparison with other studies, the data in Table 16 have been re-presented in Table 17
but with the totals for each of the four conditions presented alone. The total is more than 100%, as
approximately 30% of participants had more than one potential cause for their loss of vision.
An alternative approach to the analysis of causes of VI is for a clinician to make a forced choice of the
single condition most likely to be the cause of the visual loss is shown in Table 18. The process adopted to
identify a single cause was for two researchers (RS and DE) to review each visually impaired participant’s
eye examination record and independently identify a single causative condition for each participant. Any
differences in opinion were resolved by discussion. Two cases required discussion for clarification, following
which RS and DE agreed on the single causative condition for each case.
Cataract was the primary cause in 49 out of 102 (48.0%, 95% CI 38.1% to 58.1%) of cases of post-refraction
VI (for VA of < 6/12 criterion). This VI is potentially remediable. AMD was the primary cause in 37 out of 102
(36.3%, 95% CI 27.2% to 46.4%) cases. For the VA of < 6/18 criterion, AMD was the cause in 23 out of 47
(48.9%, 95% CI 34.3% to 63.7%) cases and cataract in 17 out of 47 (36.1%, 95% CI 23.1% to 51.5%) cases.
Fundus examination and dilatation
Optometrists were requested to attempt a dilated fundus examination on all suitable participants. However,
participants were not dilated unless full informed consent was given by the participant or personal or
professional carer. Sixty-seven per cent (476/708) of participants had dilated fundus examinations and
28.2% (200/708) of participants were not dilated. The reasons for not dilating are given in Table 19.
Pupillary dilatation was not possible in a further 4.5% (32/708) of participants because the optometrist was
unable to measure the IOP before dilatation, a requirement of TOC examination protocol.
TABLE 17 Causes of VI (post refraction) resulting from each of the four specified eye conditions
Condition
VA < 6/12 (N= 102) VA < 6/18 (N= 47)
% (n) 95% CI % (n) 95% CI
AMD 40.2 (41) 30.8 to 50.4 53.2 (25) 38.2 to 67.6
Cataract 70.6 (72) 60.6 to 79.0 61.7 (29) 46.4 to 75.1
Diabetic retinopathy 1.0 (1) 0.1 to 6.1 0 0.0 to 9.4
Glaucoma 9.8 (10) 5.1 to 17.7 8.5 (4) 2.8 to 21.3
Other 7.8 (8) 3.7 to 15.3 10.6 (5) 4.0 to 23.9
The percentages add up to more than 100% as visual loss has been attributed to more than one condition in
approximately 30% of participants.
TABLE 18 Causes of VI resulting from each of the four specified eye conditions (a single cause for visual loss has
been identified for each participant)
Condition
VA < 6/12 (N= 102) VA < 6/18 (N= 47)
% (n) 95% CI % (n) 95% CI
AMD alone 36.3 (37) 27.2 to 46.4 48.9 (23) 34.3 to 63.7
Cataract alone 48.0 (49) 38.1 to 58.1 36.1 (17) 23.1 to 51.5
Diabetic retinopathy
alone
1.0 (1) 0.1 to 6.1 0 (0) 0.0 to 9.4
Glaucoma alone 6.9 (7) 3.0 to 14.1 4.3 (2) 0.7 to 15.7
Other 7.8 (8) 3.7 to 15.3 10.6 (5) 4.0 to 23.9
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Registration as sight impaired and severely sight impaired
Nine out of 687 participants (1.3%) were registered severely sight impaired (blind) or sight impaired
(partially sighted). Eight were registered severely sight impaired (four in each group) and one group 2
participant was registered sight impaired. Optometrists were unable to obtain information on registration
from 21 participants.
Support for participant during the eye examination
Presence of a carer during the eye examination
Although the presence of a carer (personal or professional) was desirable during the eye examination,
in some cases no one was present to support the participant (Table 20). Optometrists were unable to
perform any part of the eye examination on eight participants living in care homes and hence this
information was not recorded in these eight cases. There was a statistically significant difference between
the proportions in group 1 and group 2 for the presence of a relative, for the presence of a professional
carer and for nobody being present to provide support during the eye examination (χ12 p< 0.001).
Notably, no carer was present in one-quarter of eye examinations, with 8.5% of examinations in group 1
conducted without a carer and 43.4% in group 2 conducted without a carer.
TABLE 19 Reasons for not dilating study participants
Reasons for not dilating
% of participants (n)
(N= 200)
Raised IOP or a large IOP difference between the two eyes 4.5 (9)
Pre-existing glaucoma 8.5 (17)
Narrow anterior chamber angles 4.5 (9)
Participant declined dilatation 16 (32)
Lack of informed consent to dilate 14 (28)
Poor co-operation 14 (28)
Reasons for not dilating not explained or unclear 27 (54)
Other (e.g. adequate fundus view obtained without dilatation) 12 (24)
TABLE 20 Support for participant during the eye examination
Support present
during eye
examination
Sample for which eye
exam attempted
(N= 700) Group 1 (N= 389) Group 2 (N= 311)
Difference in
proportions
between
groups 1 and
2, %a (95% CI)% (n) 95% CI % (n) 95% CI % (n) 95% CI
Relative (personal carer) 64.0 (448) 60.3 to 67.5 89.5 (348) 85.9 to 92.2 32.2 (100) 27.1 to 37.7 57.3
(51.0 to 63.6)
Staff (professional carer) 12.0 (84) 9.7 to 14.7 2.1 (8) 1.0 to 4.2 24.4 (76) 19.8 to 29.7 –22.3
(–27.6 to –17.1)
Nobody present 24.0 (168) 20.9 to 27.4 8.5 (33) 6.0 to 11.8 43.4 (135) 37.9 to 49.1 –34.9
(–41.4 to –28.5)
a Chi-squared test of difference of proportions (χ1
2).
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Contribution of carer to successful completion of key elements of the
eye examination
The presence or absence of a carer was analysed for successful and unsuccessful completion of five key
elements of the eye examination. These were: (1) objective assessment of refractive error; (2) subjective
assessment of refractive error; (3) VA measurement; (4) fundus examination by ophthalmoscopy; and
(5) tonometry. For each of these elements, the unadjusted rate ratios (95% CI) were as follows:
1. objective refraction: OR 1.3 (0.7 to 2.5)
2. subjective refraction: OR 1.5 (0.6 to 4.0)
3. VA measurement: OR 1.9 (1.2 to 3.0)
4. ophthalmoscopy: OR 1.6 (0.9 to 2.9)
5. tonometry: OR 1.7 (0.8 to 3.8).
From this analysis, the presence of a carer was associated with a statistically significant positive impact on
the ability of the participant to successfully complete VA measurement. For the other four tests, although
failing to reach statistical significance, the point estimates are all positive, and for tonometry and
ophthalmoscopy are close in magnitude to that for VA measurement.
Change in distance visual acuity from pre to post refraction
Mean improvement in distance visual acuity
The mean improvement in VA (using best monocular VA before and after refraction) for the sample as a
whole was 0.09 logMAR units (SD 0.15 logMAR units, range –0.10 to 1.40 logMAR units). The mean
improvement in VA for group 1 participants was also 0.09 logMAR units (SD 0.15 logMAR units, range
–0.10 to 1.40 logMAR units), with an improvement of 0.10 logMAR units (SD 0.17 logMAR units, range
–0.02 to 1.20 logMAR units) for group 2. This improvement is equivalent to reading a further five letters,
or one line extra, on the logMAR chart. The improvements in VA were statistically significant (Wilcoxon) for
the sample as a whole (p< 0.01), for group 1 (p< 0.01) and for group 2 (p< 0.01) participants.
The mean VA and mean improvement in VA from presentation to post refraction for the four main
conditions are presented in Table 21.
Improvement in visual acuity post refraction based on lines of improvement
on distance test charts
As an alternative to mean improvements in VA, the change in VA following refraction can be described by
the percentage of the sample for which acuity improved by one or more lines on standard VA charts.
These data are shown in Table 22 for improvements in VA of greater than one line, or greater than or
equal to two or three lines on a logMAR chart (> 0.10, ≥ 0.20 and ≥ 0.30 logMAR units, respectively).
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TABLE 22 Improvement in VA, based on best monocular VA pre- and post-refraction data available for 584 out of
708 participants (82.5%)
Improvement
in VA
Full sample (N= 584) Group 1 (N= 376) Group 2 (N= 208) Difference in
proportions
between groups 1
and 2, %a (95% CI);
p-value% (n) 95% CI % (n) 95% CI % (n) 95% CI
> 0.10
logMAR units
24.8 (145) 21.4 to 28.6 23.1 (87) 19.0 to 27.8 27.9 (58) 22.0 to 34.6 –4.8 (–12.6 to 3.1);
0.24
≥ 0.16
logMAR units
20.4 (119) 17.2 to 23.9 19.1 (72) 15.4 to 23.6 22.6 (47) 17.2 to 29.0 –3.5 (–10.8 to 3.9);
0.38
≥ 0.20
logMAR units
17.8 (104) 14.8 to 21.2 16.5 (62) 13.0 to 20.7 20.2 (42) 15.1 to 26.4 –3.7 (–10.7 to 3.3);
0.26
≥ 0.30
logMAR units
6.8 (40) 5.0 to 9.3 6.1 (23) 4.0 to 9.2 8.2 (17) 5.0 to 13.0 –2.1 (–6.9 to 2.8);
0.35
a Chi-squared test of difference of proportions (χ1
2).
TABLE 21 Mean VA post refraction, using best monocular VA, and mean improvement in VA from pre refraction
(presenting) to post refraction for each condition
Condition (n)
Mean VA
(SD)
Mean improvement
in VA (SD)
Wilcoxon test for
VA improvement
Measurement of
VA not possible Others
AMD (101) 0.27 (0.22) 0.08 (0.10) p< 0.01 8 CF-3
HM-6
NPL-1
Diabetic retinopathy (12) 0.21 (0.12) 0.10 (0.10) p= 0.02 2 –
Glaucoma (49) 0.15 (0.17) 0.13 (0.18) p< 0.01 7 –
Cataract (grades 1–5) (317) 0.19 (0.15) 0.10 (0.17) p< 0.01 62 CF-3
HM-3
LP-1
NPL-1
Cataract (grades 2–5) (209) 0.22 (0.15) 0.11 (0.18) p< 0.01 36 CF-1
LP-1
NPL-1
CF, counting fingers; HM, hand movements; LP, light perception; NPL, no light perception.
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Also included is the percentage of the sample who improved by ≥ 0.16 logMAR units. This criterion was
chosen as it represents an improvement greater than the average change in acuity between two lines on a
Snellen chart, which is 0.154 log units.57 Although all the distance VA measurements in PrOVIDe were
made using charts with logMAR progression of letter sizes, previous studies that have investigated VI
in older people have often used charts with Snellen progression.44,58,59 Snellen charts have several
disadvantages compared with logMAR charts, notably the unequal progression in letter sizes between lines
on the chart. However, to permit comparisons between PrOVIDe results and those obtained in previous
studies that used Snellen charts, the ‘equivalent’ improvement in terms of lines of Snellen acuity has also
been calculated.
Data are presented for groups 1 and 2 separately and there were no statistically significant differences
between the proportions in each group who improved in VA post refraction for each of the chosen acuity
levels. It is notable that in 17.8% of the sample (16.5% in group 1 and 20.2% in group 2) VA improved
by at least two lines on the logMAR chart following refraction.
Loss of near visual acuity
The NVA levels on the standard near vision charts used during the eye examination were N4, N5, N6, N8,
N10, N12, N14, N18, N24 and N48. The median NVA for the sample as a whole pre refraction was N6
(IQR N5–N8), recorded with the participant wearing their current spectacles, if any, for near vision.
Median NVA post refraction was N5 (IQR N5–N6), recorded with the participant wearing the prescription
for near vision found in the PrOVIDe examination. All near acuities recorded were based on best
monocular NVA. The median NVA for group 1 pre refraction was N6 (IQR N5–N8) and N5 (IQR N5–N6)
post refraction. The median NVA for group 2 pre refraction was N8 (IQR N6–N8) and N6 (IQR N5–N8) post
refraction. Figure 12 illustrates the distribution of NVA pre and post refraction for the sample as a whole.
Prevalence of near vision loss
Best monocular pre- and post-refraction NVAs were available for 475 participants. It was not possible to
record NVA in 157 (22.2%) participants. There were missing data pre refraction for 76 (10.7%)
participants. The two cut-off points in terms of NVA used to define impaired near vision were best
monocular NVA <N8 and best monocular NVA <N10. Prevalences of presenting impaired near vision,
uncorrected or undercorrected impaired near vision, and impaired near vision post refraction are presented
in Table 23.
l Presenting near vision loss For the NVA <N8 cut-off point the prevalence of presenting near vision loss
was 16.2%, reducing to 8.4% for NVA <N10. For both criteria the differences in prevalence between
groups 1 and 2 were statistically significant (χ12 p= 0.01).
l Post-refraction near vision loss Following refraction the prevalence of near vision loss had fallen to
5.9% for NVA <N8 and to 1.5% for NVA <N10. There remained a statistically significant difference
between the proportions of those with near vision loss post refraction between groups 1 and 2 for
NVA <N8 but not for NVA <N10 (χ12 p< 0.01 and p= 0.20, respectively). Of the 93 participants who
had a valid post-refraction NVA but no valid presenting NVA, 26 and 15 participants had NVA <N8
and <N10, respectively, giving VI rates of 28.0% and 16.1% compared with the rates in the
‘overlapping’ sample, as per Table 23, of 5.9% and 1.5%.
l Uncorrected or undercorrected near vision loss For the NVA <N8 cut-off point the overall prevalence
of uncorrected or undercorrected near vision loss was 10.3%, with no statistically significant difference
between groups 1 and 2 (χ12 p= 0.70). Similarly, there is no statistically significant difference between
groups 1 (5.4%) and 2 (10.8%) for the <N10 criterion (χ12 p= 0.06).
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Factors associated with near vision loss
For presenting near vision loss, using logistic regression models, statistically significant independent group
differences were found for both the NVA <N8 and NVA <N10 criteria, with adjusted OR estimates of
2.08 and 2.56 (care homes vs. own homes); p< 0.01 (Table 24). There was no evidence for independent
age and sex effects on near vision loss.
For uncorrected/undercorrected near vision loss defined by either criterion, there was no evidence for any
independent age, sex or sMMSE differences. There was a statistically significant group effect for the NVA
<N10 criterion, with estimated adjusted OR of 2.51 (95% CI 1.13 to 5.53; p= 0.02). There was no
evidence for a group effect for the NVA <N8 criterion (p= 0.26).
For post-refraction near vision loss for both the NVA <N8 and NVA <N10 criteria, there was a statistically
significant independent age effect, with OR estimates of 1.06 (per year, p= 0.04) and 1.20 (per year,
p< 0.01), respectively. There was a statistically significant independent group effect for NVA <N8, with the
estimated OR for those participants living in care homes compared with those living at home being 2.71
(95% CI 1.51 to 4.94; p< 0.01), and some evidence for a similar independent group effect for NVA <N10,
with OR 2.32 (95% CI 0.95 to 6.02; p= 0.07). There was no evidence of an independent sex effect.
TABLE 23 Prevalence of near vision loss based on best monocular VA pre- and post-refraction data available for
475 participants
Type of near
vision loss
Full sample (N= 475) Group 1 (N= 336) Group 2 (N= 139) Difference in
proportions
between groups 1
and 2, %a (95% CI);
p-value% (n) 95% CI % (n) 95% CI % (n) 95% CI
Presenting near vision loss
NVA <N8 16.2 (77) 13.1 to 19.9 13.4 (45) 10.0 to 17.6 23.0 (32) 16.5 to 31.1 –9.6 (–18.0 to –1.2);
0.01
NVA <N10 8.4 (40) 6.2 to 11.4 6.3 (21) 4.0 to 9.5 13.7 (19) 8.6 to 20.8 –7.4 (–14.2 to –0.60);
0.01
Uncorrected or undercorrected near vision loss
NVA <N8 10.3 (49) 7.8 to 13.5 9.8 (33) 7.0 to 13.6 11.5 (16) 6.9 to 18.3 –1.7 (–8.4 to 5.0);
0.70
NVA <N10 6.9 (33) 4.9 to 9.7 5.4 (18) 3.3 to 8.5 10.8 (15) 6.4 to 17.5 –5.4 ( –11.6 to 0.80);
0.06
Post-refraction near vision loss
NVA <N8 5.9 (28) 4.0 to 8.5 3.6 (12) 1.9 to 6.3 11.5 (16) 6.9 to 18.3 –7.9 (–14.1 to –1.8);
< 0.01
NVA <N10 1.5 (7) 0.6 to 3.1 0.9 (3) 0.2 to 2.8 2.9 (4) 0.9 to 7.7 –2.0 (–5.4 to 1.50);
0.20
a Chi-squared test of difference of proportions (Monte Carlo).
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There were 233 out of 708 (32.9%) participants with missing NVA data. There were statistically significant
independent group and sMMSE differences in the occurrence of missing data with estimated ORs for
unobserved NVA of 0.87 (95% CI 0.84 to 0.89) (per unit score) for sMMSE (p< 0.001) and 3.21 (95% CI
2.06 to 5.04) for care homes versus own homes (p< 0.001). There was no evidence of an independent
change with age and little evidence of a sex difference (p= 0.07).
Improvement in near visual acuity post refraction based on the number of
lines of improvement on near test charts
The change in NVA following refraction can be described by the percentage of the sample for whom NVA
remained unchanged and the proportion for whom NVA improved by one or more lines on the NVA charts
(Table 25). There was no statistically significant difference between groups for any of the improvements in
NVA (Wilcoxon rank-sum test, p= 0.26).
TABLE 24 Multivariable (adjusted) ORs for near vision loss by age, sex and group, and by sMMSE for uncorrected/
undercorrected near vision loss
Type of near vision loss Variable OR p-value 95% CI
NVA <N8
Presenting near vision loss Age (per year) 1.00 0.98 0.96 to 1.04
Sex (M) 1.00 1.00 0.59 to 1.66
Group 2 2.08 < 0.01 1.23 to 3.51
Post-refraction near vision loss Age (per year) 1.06 0.04 1.01 to 1.12
Sex (M) 0.79 0.45 0.42 to 1.44
Group 2 2.71 < 0.01 1.51 to 4.94
Uncorrected/undercorrected near vision loss Age (per year) 0.98 0.50 0.94 to 1.03
Sex (M) 1.04 0.89 0.56 to 1.91
Group 2 1.48 0.26 0.74 to 2.88
sMMSE (per unit score) 1.01 0.76 0.96 to 1.06
NVA <N10
Presenting near vision loss Age (per year) 1.01 0.73 0.96 to 1.07
Sex (M) 1.01 0.97 0.50 to 1.98
Group 2 2.56 < 0.01 1.30 to 5.05
Post-refraction near vision loss Age (per year) 1.20 < 0.01 1.08 to 1.37
Sex (M) 0.63 0.38 0.20 to 1.67
Group 2 2.32 0.07 0.95 to 6.02
Uncorrected/undercorrected near vision loss Age (per year) 0.98 0.54 0.93 to 1.04
Sex (M) 1.09 0.82 0.51 to 2.27
Group 2 2.51 0.02 1.13 to 5.53
sMMSE (per unit score) 1.01 0.78 0.95 to 1.07
M, male.
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Ability of participants to complete individual elements of the
eye examination
The proportions of the sample who were able to complete key elements of the eye examination (objective
and subjective determination of refractive error, measurement of VA, tonometry, pupil dilatation, visual
fields and the fundus examination) are given in Table 26. The difference in proportions between those in
groups 1 and 2 who were able to complete each of these elements was statistically significant (χ12 p< 0.01).
The visual fields data are from those 116 participants in whom a fields test was attempted, of whom
110 could complete the test. These data should be interpreted with caution as, in addition to these
116 participants, there were 251 participants for whom the optometrists decided that the visual fields test,
although clinically desirable, would not be possible because of the participant’s level of co-operation.
However, some of these 251 participants might have been able to complete the fields test had it been
carried out. Nevertheless, it is probable that the visual fields test would not have been possible in the
majority of these 251 participants. Assuming that none of these 251 participants could have completed the
visual fields test, an estimated 30% of participants (110/367) were able to complete the visual fields test.
Logistic regression models were also used, with age, sex and group (care home or own home) as
covariates to assess their independent associations with the completion of each examination component.
When adjusted for age and sex there was a statistically significant independent group difference for
subjective examination, VA measurement, tonometry and dilatation, with the estimated ORs for those
participants living in care homes compared with those living in their own homes ranging from 0.22 to
0.27 (p≤ 0.03), that is to say living in a care home was likely to be associated with lower completion rates
of these elements of the eye examination. There was some evidence of a group difference in the ability
to complete the fundus examination, with an estimated OR of 0.46 (95% CI 0.19 to 1.02; p= 0.06).
There was little evidence for a group difference in the ability of the participant to complete the objective
determination of refractive error, with an estimated OR for group 2 versus group 1 of 0.64 (95% CI 0.32
to 1.27; p= 0.20).
TABLE 25 Improvement in NVA between pre and post refraction
Improvement
in NVA
Full sample (n= 475) Group 1 (n= 336) Group 2 (n= 139) Difference in
proportions
between groups 1
and 2%,a (95% CI)% (n) 95% CI % (n) 95% CI % (n) 95% CI
No improvement 55.6 (264) 51.0 to 60.1 53.3 (179) 47.8 to 58.7 61.2 (85) 52.5 to 69.2 –7.9 (–18.1 to 2.3)
One line 28.6 (136) 24.7 to 33.0 31.0 (104) 26.1 to 36.2 23.0 (32) 16.5 to 31.1 8.0 (–1.1 to 17.0)
Two lines 9.3 (44) 6.9 to 12.3 10.1 (34) 7.2 to 14.0 7.2 (10) 3.7 to 13.2 2.9 (–3.0 to 8.8)
Three lines 3.4 (16) 2.0 to 5.5 4.2 (14) 2.4 to 7.1 1.4 (2) 0.2 to 5.6 2.8 (–0.7 to 6.1)
More than
three lines
3.2 (15) 1.8 to 5.3 1.5 (5) 0.5 to 3.6 7.2 (10) 3.7 to 13.2 –5.7 (–10.7 to –0.7)
a Wilcoxon rank-sum test used to test for any significant differences between categories (p= 0.26).
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Patient management on completion of the eye examination
As a result of the eye examination, 47 participants (6.7%) were referred to their GP for management or
for onward referral to the HES. The reasons for these referrals are given in Table 27. Three of the four
participants referred to the diabetic medical retina clinic were referred to arrange annual diabetic screening
because the participants were not currently participating in the NHS Diabetic Eye Screening programme.
Three of the five referrals for external eye conditions were to the participants’ GP for their management,
rather than for onward referral to the HES. Almost 60% of referrals were for either possible cataract
extraction/capsulotomy or suspected glaucoma/OHT.
On completion of the eye examination, optometrists advised 700 participants (98.9%) of the
recommended date of their next eye examination. The remaining eight participants who could not be
advised of a recommended date were also those on whom optometrists were unable to perform any part
of the eye examination. The recommended date of next eye examination was 1 year in 576 out of 700
(82.3%) participants and 2 years for the remaining 124 out of 700 (17.7%) participants. A total of 444
out of 700 (63.4%) participants were advised that a new or changed spectacle prescription would
be beneficial, based on improvement in VA and/or subjective improvement in performance with the
new/changed prescription, with 244 out of 700 (34.8%) advised that no change in spectacle prescription
was necessary. A total of 26 out of 700 (3.7%) participants were advised that their current spectacles
were unserviceable owing to fair wear and tear, and hence new spectacles would be beneficial. These
percentages total more than 100% because some participants were advised both that a new or changed
prescription would be beneficial and that their current spectacles were unserviceable, and others were
advised that no change in prescription was necessary but that their current spectacles were unserviceable.
TABLE 27 Reasons for referral to GP or HES
Reason for referral (referral clinic) % (95% CI) of participants with the suspected condition (n) (N= 47)
Cataract 19.1 (9.6 to 33.7) (9)
Diabetic medical retina 8.5 (2.8 to 21.3) (4)
External eye 10.6 (4.0 to 23.9) (5)
Pre-existing glaucoma 8.5 (2.8 to 21.3) (4)
Suspect glaucoma 31.9 (19.5 to 47.3) (15)
OHT 4.3 (0.7 to 15.7) (2)
Laser YAG capsulotomy 4.3 (0.7 to 15.7) (2)
Orthoptic anomaly 4.3 (0.7 to 15.7) (2)
Other medical retina (AMD) 4.3 (0.7 to 15.7) (2)
Not specified 4.3 (0.7 to 15.7) (2)
YAG, yttrium aluminium garnet.
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Some participants were asked, before any new spectacles were prescribed, to compare subjectively the
performance of their current spectacles with the performance of the prescription found by the research
optometrist. Although this was not an obligatory procedure for optometrists from TOC, it was preferred
practice where patient co-operation permitted. However, even when the optometrist decided that
co-operation was sufficient to attempt this procedure, it was not possible for many PrOVIDe participants
to make this comparison because the challenge of remembering the appearance of a letter chart and
comparing that appearance subjectively with a previous appearance of the chart was too demanding,
particularly because this comparison would have been attempted towards the end of the subjective
examination when participant fatigue often impaired performance. Nevertheless, 27.7% of participants
who were advised of a new or changed spectacle prescription voluntarily reported a noticeable subjective
improvement in VA with the new prescription when compared with the old prescription, while 3.2%
found no subjective improvement in VA with the new prescription. Of those participants who were advised
of a new or changed spectacle prescription by the optometrist, 50.5% were dispensed new spectacles at
the time of the eye examination and 39.6% declined new spectacles.
Level of cognition and outcomes of the eye examination
Association between the ability of participants to perform elements of the
eye examination and their level of cognition
An analysis of participants’ ability to complete various elements of the eye examination and their overall
level of cognition as measured by the total sMMSE score is summarised in Table 28. For the objective
determination of refractive error by retinoscopy, there was no statistically significant difference between
the sMMSE scores (Wilcoxon rank-sum test, p= 0.13) for those participants on whom optometrists could
complete retinoscopy and those participants in whom retinoscopy was not possible. However, for the
other elements of the eye examination tested (visual fields was not tested) there was a statistically
significant difference (p< 0.01 for each of the other tests) between the sMMSE scores for participants for
whom the test was possible and those participants for whom the test was not possible. Notably, the mean
sMMSE score was 18.4 in those participants for whom subjective refraction was possible, compared with
6.8 in those for whom subjective refraction was not possible. Similarly, the mean sMMSE score was 18.2 in
those participants for whom VA measurement was possible, compared with 4.9 in those for whom VA
measurements were not possible. The visual fields data are from those 116 participants in whom a fields
test was attempted.
Using logistic regression models, after adjustment for age, sex and group (care home or own home) there
was a statistically significant independent association between sMMSE and participants’ ability to complete
the subjective examination, VA measurement, tonometry, dilatation and fundus examination, with the
estimated ORs for those with lower sMMSE scores ranging from 2.7 to 18.9 per 10-unit score increase of
sMMSE from 0 (p< 0.01 for each) (see Table 28). There was no evidence of an independent sMMSE
association with the ability of the participant to undergo an objective refraction, with an estimated OR of
1.25 (95% CI 0.84 to 1.87; p= 0.27). Logistic regression analysis was not carried out for the visual
fields data.
Potential bias in Standardised Mini-Mental State Examination scoring in
participants with visual impairment
The sMMSE instrument can be modified for participants with a sensory loss that could affect their
performance. In particular, for participants with loss of vision, their performance on the three sMMSE items
which involve participants reading the words ‘close your eyes’, writing a complete sentence and copying a
design could be adversely affected. An alternative version of the instrument, MMSE blind, is often used
with visually impaired participants. With MMSE blind, the three items requiring significant visual input are
omitted and the test is scored out of a maximum of 27 rather than the usual 30. The results obtained out
of a maximum of 27 for MMSE blind are then rescaled to give a score out of 30.
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In PrOVIDe, the sMMSE instrument was used on all participants, both visually impaired and non-visually
impaired. The sMMSE test was delivered at recruitment, at which point the recruiter would, in general, be
unaware if the participant was visually impaired or not. It is possible that there was overestimation of
cognitive impairment through the use of sMMSE in visually impaired participants, who might have been
unable to complete correctly these three items requiring visual input as a result of their VI rather than
because of any cognitive impairment. To investigate the possible bias (underestimation) on the PrOVIDe
sMMSE scores in patients who were visually impaired, a linear regression model was fitted to the sMMSE
scores, adjusting for age, sex, residential status and presenting VI ordered in terms of severity: ‘better than
6/12 (none)’, ‘6/12 to 6/18’ and ‘worse than 6/18’. The coefficient point estimates and statistical
significances were then compared with those of a model of MMSE blind scores (Table 29).
TABLE 28 Standardised Mini-Mental State Examination scores for participants who were able and for those who
were not able to carry out selected elements of the eye examination
Test n Mean sMMSE score (SD) Adjusted ORa (95% CI) OR p-value
Objective assessment
Possible 607 14.8 (8.8) 1.25 (0.84 to 1.87) 0.27
Not possible 47 16.8 (8.0)
Subjective assessment
Possible 557 18.4 (6.9) 4.62 (3.25 to 6.72) < 0.01
Not possible 96 6.8 (6.9)
VA measurement
Possible 578 18.2 (6.9) 18.90 (10.33 to 38.1) < 0.01
Not possible 76 4.9 (6.3)
Tonometry
Possible 634 17.0 (7.9) 2.67 (1.44 to 5.27) < 0.01
Not possible 20 8.0 (7.3)
Dilatation
Possible 613 17.4 (7.7) 4.21 (2.57 to 7.24) < 0.01
Not possible 41 6.5 (6.9)
Visual fields
Possible 110 21.9 (4.9) Not attempted N/A
Not possible 6 16.3 (6.3)
Fundus examination
Possible 613 17.2 (7.7) 2.75 (1.76 to 4.41) < 0.01
Not possible 41 9.0 (9.4)
N/A, not applicable.
a Logistic regression models were used to estimate ORs.
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No substantive differences were observed in the direction and statistical significance of predictors for both
measures of cognitive performance, although there is an indication of higher MMSE blind scores in both
non-visually impaired participants and moderately visually impaired participants. Of the 654 participants
with measured sMMSE scores, 149 had identical MMSE blind scores and 493 were within a single score
difference. The 95% limits of agreement between sMMSE and MMSE blind scores were 1.43 and –1.33,
with a mean difference score of –0.07 (MMSE blind – sMMSE). The correlation between sMMSE scores and
MMSE blind scores was 0.994. A Deming regression (allowing for measurement error in both dependent
and independent variables) was fitted to blind MMSE score with sMMSE score as the only predictor: this
yielded a regression slope estimate with a CI between 0.989 and 1.001, where a slope of 1 with no
variance would indicate perfect agreement between the scores. All of this illustrates that the use of the
sMMSE and not of MMSE blind, even in participants with VI, is not likely to lead to different conclusions
on a population level.
TABLE 29 Results of linear regression models fitted to sMMSE scores and to MMSE blind scores
Coefficient Estimate 95% CI p-value
sMMSE score
Intercept 22.62 16.12 to 29.13 < 0.001
Age (per year) –0.04 –0.12 to 0.04 0.303
Sex: male 0.68 –0.40 to 1.76 0.216
Care home –4.93 –6.10 to –3.76 < 0.001
VA 6/12 to 6/18 –1.70 –2.75 to –0.65 0.002
VA < 6/18 –0.68 –1.90 to 0.53 0.268
MMSE blind score
Intercept 23.34 16.80 to 29.87 < 0.001
Age –0.05 –0.13 to 0.03 0.210
Sex: male 0.81 –0.27 to 1.88 0.143
Care home –4.96 –6.12 to –3.80 < 0.001
VA 6/12 to 6/18 –1.52 –2.58 to –0.47 0.005
VA < 6/18 –0.73 –1.95 to 0.48 0.237
Derived from 654 (92%) of participants with presenting VI and sMMSE scores available.
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Analysis of effects of visual impairment on function
(Bristol Activities of Daily Living Scale) and behaviour
(Cambridge Behavioural Inventory – Revised)
Analysis of Bristol Activities of Daily Living Scale data
The results from the visually impaired and non-visually impaired participants were compared for all
20 activities of the BADLS for both VA < 6/12 (Table 30) and VA < 6/18 (Table 31). ORs were derived from
ordinal logistic regression models, with age, sex and group as covariates, and are estimates of the
independent effect of VI on these function activities. Presenting VA has been used for the analysis, as it
best represents the participants’ visual status when the BADLS data were collected. Correction for multiple
comparisons across the related items (and, thus, related hypotheses) in the BADLS has been applied using
the Bonferroni correction. This modifies the statistical significance cut-off point from 0.05 to 0.05/20 or
0.0025. For VI defined by VA < 6/12, all the BADLS items have estimated ORs > 1.0 (range from 1.11 to
2.19) for participants with VI, compared with participants without VI, indicating an adverse association of
VI with each of these activities. Applying the conservative significance level of 0.0025, only ‘toilet/
commode’, with an estimated OR of 2.19 (95% CI 1.36 to 3.53), and ‘telephone’, with an OR of 1.89
(95% CI 1.26 to 2.85), were statistically significant (p= 0.001 and p= 0.002, respectively). There is some
evidence of an independent VI association with ‘drink’, with an estimated OR of 1.93 (95% CI 1.22 to
3.06), and ‘teeth’, with an OR of 1.86 (95% CI 1.22 to 3.06) (p= 0.005 and 0.004, respectively).
TABLE 30 Odds ratio estimates of the independent associations of VI (VA < 6/12) with BADLS function activity
responses, derived fromordinal logistic regression models with adjustments made for age, sex and group
BADLS function activity Number analysed OR VI vs. non-VI (95% CI) p-value
Food 350 1.50 (0.94 to 2.42) 0.092
Eating 485 1.75 (1.06 to 2.9) 0.029
Drink 396 1.93 (1.22 to 3.06) 0.005
Drinking 487 1.83 (0.84 to 4.04) 0.129
Dressing 480 1.66 (1.11 to 2.49) 0.014
Hygiene 476 1.7 (1.13 to 2.54) 0.011
Teeth 470 1.86 (1.22 to 2.84) 0.004
Bath/shower 466 1.36 (0.91 to 2.02) 0.13
Toilet/commode 474 2.19 (1.36 to 3.53) 0.001
Transfers 479 1.12 (0.68 to 1.84) 0.644
Mobility 477 1.26 (0.83 to 1.89) 0.271
Orientation: time 469 1.11 (0.76 to 1.63) 0.581
Orientation: space 466 1.45 (0.97 to 2.19) 0.071
Communication 478 1.15 (0.75 to 1.77) 0.515
Telephone 416 1.89 (1.26 to 2.85) 0.002
Housework/gardening 352 1.15 (0.73 to 1.81) 0.543
Shopping 364 1.63 (1.03 to 2.61) 0.039
Finances 350 1.7 (1.09 to 2.66) 0.019
Games/hobbies 427 1.17 (0.79 to 1.74) 0.427
Transport 347 1.91 (1.14 to 3.24) 0.014
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For VI defined by VA < 6/18, all items had estimated ORs > 1.0 (range from 1.12 to 2.55), apart from
‘transfers’, which had an estimated OR of 0.66 (95% CI 0.33 to 1.24) (p= 0.21). There is some evidence
of an independent VI association with ‘telephone’, with an estimated OR of 2.08 (95% CI 1.22 to 3.56),
and ‘transport’, with an OR of 2.55 (95% CI 1.29 to 5.08) (p= 0.007 for both).
Analysis of Cambridge Behavioural Inventory – Revised data
Results from the visually impaired and non-visually impaired participants were compared for all 45 items of
the CBI-R for both VA < 6/12 (Table 32) and VA < 6/18 (Table 33). ORs were derived from ordinal logistic
regression models, with adjustments made for age, sex and residential status, and are estimates of the
independent association of VI with these behavioural activities. Presenting VA has been used for the
analysis, as it best represents the participants’ visual status when the CBI-R data were collected. Correction
for multiple comparisons has been applied using the Bonferroni correction. This modifies the statistical
significance cut-off point from 0.05 to 0.05/45 or 0.0011.
For VI defined by VA < 6/12, 75% of behaviours (36/45) have ORs that are > 1.0 (range from 1.01 to 2.27)
for participants with VI, compared with participants without VI, indicating an adverse relationship of VI
with each of these activities. Seven behaviours have ORs < 1.0 (range 0.81–0.98), five of which are from
the ‘motivation’ and ‘stereotypic and motor behaviours’ domains; none of these ORs are statistically
significant (p-values range from 0.30 to 0.94). Applying the conservative 0.0011 cut-off point for statistical
significance, only ‘has difficulties writing (letters, Christmas cards, lists, etc.)’ has an OR that is statistically
significant, with an estimated OR of 2.27 (95% CI 1.50 to 3.45; p< 0.001). There is some evidence of an
TABLE 31 Odds ratio estimates of the independent associations of VI (VA < 6/18) with BADLS function activity
responses, derived fromordinal logistic regression models with adjustments made for age, sex and group
BADLS function activity Number analysed OR VI vs. non-VI (95% CI) p-value
Food 350 1.96 (1.03 to 3.82) 0.044
Eating 485 1.36 (0.71 to 2.49) 0.333
Drink 396 1.87 (1.04 to 3.35) 0.035
Drinking 487 1.21 (0.47 to 2.83) 0.673
Dressing 480 1.2 (0.71 to 2.00) 0.494
Hygiene 476 1.46 (0.86 to 2.45) 0.158
Teeth 470 1.70 (0.99 to 2.9) 0.052
Bath/shower 466 1.46 (0.87 to 2.45) 0.151
Toilet/commode 474 1.28 (0.71 to 2.28) 0.4
Transfers 479 0.66 (0.33 to 1.24) 0.213
Mobility 477 1.24 (0.74 to 2.06) 0.418
Orientation: time 469 1.14 (0.70 to 1.85) 0.605
Orientation: space 466 1.42 (0.85 to 2.39) 0.18
Communication 478 1.24 (0.72 to 2.08) 0.429
Telephone 416 2.08 (1.22 to 3.56) 0.007
Housework/gardening 352 1.62 (0.89 to 2.98) 0.114
Shopping 364 1.94 (1.07 to 3.54) 0.03
Finances 350 1.87 (1.06 to 3.30) 0.03
Games/hobbies 427 1.12 (0.68 to 1.83) 0.662
Transport 347 2.55 (1.29 to 5.08) 0.007
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TABLE 32 Odds ratio estimates of the independent associations of VI (VA < 6/12) with CBI-R behaviour responses,
derived from ordinal logistic regression models with adjustments made for age, sex and group
CBI-R
Number
analysed
OR VI vs. non-VI
(95% CI) p-value
Memory and orientation
CMO 1: has poor day-to-day memory (e.g. about conversations,
trips, etc.)
482 0.92 (0.63 to 1.36) 0.681
CMO 2: asks the same questions over and over again 488 0.89 (0.61 to 1.28) 0.526
CMO 3: loses or misplaces things 468 1.18 (0.8 to 1.73) 0.401
CMO 4: forgets the names of familiar people 490 1.25 (0.87 to 1.81) 0.227
CMO 5: forgets the names of objects and things 478 1.34 (0.92 to 1.94) 0.124
CMO 6: shows poor concentration when reading or watching
television
483 1.39 (0.95 to 2.03) 0.087
CMO 7: forgets what day it is 484 1.24 (0.86 to 1.81) 0.256
CMO 8: becomes confused or muddled in unusual surroundings 483 1.31 (0.9 to 1.89) 0.160
Everyday skills
CES 1: has difficulties using electrical appliances (e.g. television, radio,
cooker, washing machine)
442 1.55 (1.04 to 2.31) 0.03
CES 2: has difficulties writing (letters, Christmas cards, lists, etc.) 448 2.27 (1.5 to 3.45) 0
CES 3: has difficulties using the telephone 441 1.89 (1.27 to 2.82) 0.002
CES 4: has difficulties making a hot drink (e.g. tea/coffee) 429 1.67 (1.08 to 2.57) 0.02
CES 5: has problems handling money or paying bills 398 1.89 (1.2 to 3.02) 0.006
Self-care
CSC 1: has difficulties grooming self (e.g. shaving or putting on
make-up)
479 1.81 (1.24 to 2.66) 0.002
CSC 2: has difficulties dressing self 484 1.66 (1.13 to 2.42) 0.009
CSC 3: has problems feeding self without assistance 477 1.76 (1.1 to 2.8) 0.018
CSC 4: has problems bathing or showering self 473 1.55 (1.05 to 2.28) 0.026
Abnormal behaviour
CAB 1: finds humour or laughs at things others do not find funny 476 1.38 (0.91 to 2.09) 0.132
CAB 2: has temper outbursts 490 1.12 (0.76 to 1.65) 0.549
CAB 3: is unco-operative when asked to do something 481 1.04 (0.71 to 1.54) 0.828
CAB 4: shows socially embarrassing behaviour 485 1.2 (0.79 to 1.82) 0.397
CAB 5: makes tactless or suggestive remarks 477 1.48 (0.97 to 2.25) 0.067
CAB 6: acts impulsively without thinking 485 1.14 (0.77 to 1.69) 0.51
Mood
CMOOD 1: cries 460 1.04 (0.69 to 1.56) 0.855
CMOOD 2: appears sad or depressed 466 1.01 (0.69 to 1.48) 0.944
CMOOD 3: is very restless or agitated 470 1.31 (0.9 to 1.9) 0.152
CMOOD 4: is very irritable 470 1.03 (0.7 to 1.5) 0.883
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TABLE 32 Odds ratio estimates of the independent associations of VI (VA < 6/12) with CBI-R behaviour responses,
derived from ordinal logistic regression models with adjustments made for age, sex and group (continued )
CBI-R
Number
analysed
OR VI vs. non-VI
(95% CI) p-value
Beliefs
CBELIEFS 1: sees things that are not really there (visual hallucinations) 473 1.47 (0.95 to 2.25) 0.08
CBELIEFS 2: hears voices that are not really there (auditory hallucinations) 472 1.4 (0.84 to 2.3) 0.188
CBELIEFS 3: has odd or bizarre ideas that cannot be true 464 1.28 (0.85 to 1.94) 0.237
Eating habits
CEH 1: prefers sweet foods more than before 462 1.16 (0.78 to 1.71) 0.472
CEH 2: wants to eat the same foods repeatedly 464 0.95 (0.61 to 1.46) 0.806
CEH 3: her/his appetite is greater, s/he eats more than before 472 1.6 (1.04 to 2.46) 0.031
CEH 4: table manners are declining, e.g. stuffing food into mouth 469 1.44 (0.9 to 2.3) 0.128
Sleep
CSLEEP 1: sleep is disturbed at night 469 1.43 (0.99 to 2.09) 0.06
CSLEEP 2: sleeps more by day than before (cat naps, etc.) 470 1.45 (1 to 2.11) 0.051
Stereotypic and motor behaviours
CSMB 1: is rigid and fixed in her/his ideas and opinions 461 0.81 (0.54 to 1.2) 0.297
CSMB 2: develops routines from which she or he cannot easily be
discouraged, e.g. wanting to eat or go for walks at fixed times
467 1.03 (0.68 to 1.56) 0.894
CSMB 3: clock watches or appears pre-occupied with time 466 0.92 (0.59 to 1.41) 0.696
CSMB 4: repeatedly uses the same expression or catchphrase 474 0.97 (0.66 to 1.43) 0.891
Motivation
CMOTIVATION 1: shows less enthusiasm for his or her usual interests 470 1.00 (0.68 to 1.45) 0.988
CMOTIVATION 2: shows little interest in doing new things 474 0.88 (0.6 to 1.28) 0.504
CMOTIVATION 3: fails to maintain motivation to keep in contact with
friends or family
462 1.00 (0.67 to 1.48) 0.997
CMOTIVATION 4: appears indifferent to the worries and concerns of
family members
473 1.21 (0.82 to 1.78) 0.328
CMOTIVATION 5: shows reduced affection 472 0.98 (0.64 to 1.51) 0.944
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TABLE 33 Odds ratio estimates of the independent associations of VI (VA < 6/18) with CBI-R behaviour responses,
derived fromordinal logistic regression models with adjustments made for age, sex and group
CBI-R
Number
analysed
OR VI vs. non-VI
(95% CI) p-value
Memory and orientation
CMO 1: has poor day-to-day memory (e.g. about conversations,
trips, etc.)
482 0.72 (0.45 to 1.18) 0.193
CMO 2: asks the same questions over and over again 488 0.81 (0.51 to 1.31) 0.397
CMO 3: loses or misplaces things 468 1.12 (0.69 to 1.82) 0.657
CMO 4: forgets the names of familiar people 490 1.09 (0.69 to 1.74) 0.709
CMO 5: forgets the names of objects and things 478 1.07 (0.66 to 1.73) 0.79
CMO 6: shows poor concentration when reading or watching
television
483 0.88 (0.54 to 1.43) 0.606
CMO 7: forgets what day it is 484 1.17 (0.73 to 1.88) 0.516
CMO 8: becomes confused or muddled in unusual surroundings 483 1.18 (0.74 to 1.87) 0.486
Everyday skills
CES 1: has difficulties using electrical appliances (e.g. television, radio,
cooker, washing machine)
442 1.72 (1.03 to 2.91) 0.038
CES 2: has difficulties writing (letters, Christmas cards, lists, etc.) 448 2.17 (1.24 to 3.89) 0.008
CES 3: has difficulties using the telephone 441 1.61 (0.97 to 2.68) 0.067
CES 4: has difficulties making a hot drink (e.g. tea/coffee) 429 1.34 (0.77 to 2.33) 0.292
CES 5: has problems handling money or paying bills 398 1.77 (0.98 to 3.31) 0.064
Self-care
CSC 1: has difficulties grooming self (e.g. shaving or putting on
make-up)
479 1.55 (0.96 to 2.51) 0.072
CSC 2: has difficulties dressing self 484 1.69 (1.05 to 2.72) 0.03
CSC 3: has problems feeding self without assistance 477 1.49 (0.84 to 2.58) 0.166
CSC 4: has problems bathing or showering self 473 1.61 (0.99 to 2.62) 0.057
Abnormal behaviour
CAB 1: finds humour or laughs at things others do not find funny 476 1.4 (0.84 to 2.29) 0.189
CAB 2: has temper outbursts 490 1.5 (0.93 to 2.42) 0.098
CAB 3: is unco-operative when asked to do something 481 1.6 (0.99 to 2.57) 0.055
CAB 4: shows socially embarrassing behaviour 485 1.07 (0.63 to 1.79) 0.798
CAB 5: makes tactless or suggestive remarks 477 2.14 (1.29 to 3.5) 0.003
CAB 6: acts impulsively without thinking 485 1.35 (0.83 to 2.17) 0.226
Mood
CMOOD 1: cries 460 1.2 (0.70 to 2.04) 0.492
CMOOD 2: appears sad or depressed 466 0.95 (0.58 to 1.57) 0.854
CMOOD 3: is very restless or agitated 470 1.68 (1.04 to 2.70) 0.033
CMOOD 4: is very irritable 470 1.21 (0.75 to 1.94) 0.437
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independent VI association with ‘has difficulties using the telephone’, with an estimated OR of 1.89
(95% CI 1.27 to 2.82; p= 0.002), ‘has problems handling money or paying bills’, with an OR of 1.89
(95% CI 1.20 to 3.02; p= 0.006), and ‘has difficulties grooming self (e.g. shaving or putting on make-up)’,
with an OR of 1.81 (95% CI 1.24 to 2.66; p= 0.002).
For VI defined by VA < 6/18, 75% of behaviours (36/45) have ORs that are > 1.0 (range from 1.05 to 2.17)
for participants with VI compared with participants without VI, indicating an adverse relationship of VI
with each of these activities. Eight behaviours had ORs < 1.0 (range 0.72–0.95), of which two are in the
‘motivation’ domain, two are in the ‘stereotypic and motor behaviours’ domain and three are in
the ‘memory and orientation’ domain; none of these eight ORs is statistically significant (p-values range
from 0.19 to 0.85). Applying the conservative 0.0011 cut-off point for statistical significance, no OR is
statistically significant. There is evidence of an independent VI association with ‘has difficulties writing
(letters, Christmas cards, lists, etc.)’, with an estimated OR of 2.17 (95% CI 1.24 to 3.89; p= 0.008), and
‘makes tactless or suggestive remarks’, with an OR of 2.14 (95% CI 1.29 to 3.5; p= 0.003).
TABLE 33 Odds ratio estimates of the independent associations of VI (VA < 6/18) with CBI-R behaviour responses,
derived fromordinal logistic regression models with adjustments made for age, sex and group (continued )
CBI-R
Number
analysed
OR VI vs. non-VI
(95% CI) p-value
Beliefs
CBELIEFS 1: sees things that are not really there (visual hallucinations) 473 1.52 (0.90 to 2.54) 0.109
CBELIEFS 2: hears voices that are not really there (auditory hallucinations) 472 1.42 (0.75 to 2.58) 0.266
CBELIEFS 3: has odd or bizarre ideas that cannot be true 464 1.46 (0.88 to 2.39) 0.14
Eating habits
CEH 1: prefers sweet foods more than before 462 1.16 (0.71 to 1.88) 0.557
CEH 2: wants to eat the same foods repeatedly 464 1.05 (0.60 to 1.81) 0.862
CEH 3: her/his appetite is greater, she or he eats more than before 472 1.91 (1.14 to 3.18) 0.013
CEH 4: table manners are declining, e.g. stuffing food into mouth 469 1.22 (0.66 to 2.18) 0.511
Sleep
CSLEEP 1: sleep is disturbed at night 469 1.45 (0.92 to 2.31) 0.112
CSLEEP 2: sleeps more by day than before (cat naps etc.) 470 1.4 (0.88 to 2.24) 0.155
Stereotypic and motor behaviours
CSMB 1: is rigid and fixed in her/his ideas and opinions 461 0.89 (0.53 to 1.47) 0.644
CSMB 2: develops routines from which s/he can not easily be
discouraged e.g. wanting to eat or go for walks at fixed times
467 1.39 (0.82 to 2.33) 0.21
CSMB 3: clock watches or appears pre-occupied with time 466 0.93 (0.52 to 1.61) 0.787
CSMB 4: repeatedly uses the same expression or catch phrase 474 1.17 (0.73 to 1.88) 0.506
Motivation
CMOTIVATION 1: shows less enthusiasm for his or her usual interests 470 0.92 (0.57 to 1.48) 0.73
CMOTIVATION 2: shows little interest in doing new things 474 1 (0.62 to 1.61) 0.994
CMOTIVATION 3: fails to maintain motivation to keep in contact with
friends or family
462 1.26 (0.76 to 2.08) 0.366
CMOTIVATION 4: appears indifferent to the worries and concerns of
family members
473 1.15 (0.70 to 1.88) 0.572
CMOTIVATION 5: shows reduced affection 472 0.88 (0.49 to 1.54) 0.663
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Missing data sensitivity results
The primary variables, VA and sMMSE score, exhibited considerable rates of missingness owing to
participants being unable to complete either or both components. Presenting distance VA was
unmeasured (missing) in 120 participants (17%), and for presenting NVA this figure was 232 (33%)
participants. The sMMSE score was unmeasurable (missing) in 54 (7%) participants. In 43 participants
(6%), all three of these variables were unmeasured. There was a strong association between missingness
on distance VA and missingness on sMMSE scores, missingness on NVA and missingness on sMMSE
scores, and missingness on distance VA and missingness on NVA (all p< 0.001). Table 34 shows the
combinations of missingness on these three variables.
For the primary results relating to distance VI, ocular conditions and near vision loss, which have been
presented for complete cases in Tables 7, 12 and 23, the overall sample estimates of prevalence
(accounting for missing data using multiple imputation) are given in Table 35. It is apparent that the
prevalence of distance VI and near vision loss are greater than estimated from the complete-case analysis,
reflecting that the prevalence of VI is higher by location, and by age, and that these factors are also
associated with difficulty obtaining VA measurements; therefore, participants with missing data are
more likely to have poorer VA. Prevalences of ocular conditions are similar to those reported in the
complete-case analysis in Table 12, reflecting that these assessments were mostly without missing data
compared with the measurements of distance and NVA.
For the regression results relating to VI presented in Table 11, there was no change in the substantive
conclusions under the imputation model. Compared with the complete-case analysis, the independent
associations of age, sex, sMMSE score (where investigated) and location with VI (presenting VI,
post-refraction VI or uncorrected/undercorrected VI) were all unchanged in direction and statistical
significance. Point estimates tended to be slightly increased for the OR of presenting and post-examination
VI in participants in residential care versus community resident participants. These ORs for uncorrected/
undercorrected VI in participants in residential care versus participants resident in their own homes were
slightly attenuated in the multiple imputation analysis compared with the complete-case analysis, but the
differences were small: approximately a 10% reduction in the ORs.
Similarly for results relating to Table 15 for the four target eye conditions (AMD, cataract, diabetic
retinopathy and glaucoma) there were no changes in the substantive conclusions under the imputation
model compared with our initial findings. The independent associations of age, sex and location
with each ocular condition were unchanged in direction and statistical significance compared with the
complete-case analyses. In addition, for our findings relating to NVA presented in Table 24, there
were no substantive changes in conclusions under the multiple imputation model compared with the
complete-case analysis.
Tables reporting the ORs and inferences relevant to Tables 11, 15 and 24, but under the multiple
imputation model, can be found in Appendix 4 for further detailed comparisons.
TABLE 34 The extent of missing data for all possible combinations of presenting distance VA, presenting NVA and
sMMSE score
Presenting distance VA Presenting NVA
sMMSE
Not missing Missing
Not missing Not missing 463 (65.4%) 8 (1.1%)
Not missing Missing 114 (16.1%) 3 (0.4%)
Missing Not missing 5 (0.7%) 0 (0.0%)
Missing Missing 72 (10.2%) 43 (6.1%)
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Extrapolating prevalence to the UK dementia population
The methods used to calculate the weights assigned to each stratum were described in Chapter 2
(see Stage 1: data analysis plan, Extrapolating prevalence to the UK dementia population). These weights
are given in Table 36; higher weights indicate calibration addressing undersampling relative to the target
population, and lower weights indicate oversampling. The weights, normalised such that they sum to the
PrOVIDe sample size, range from 0.44 to 2.86 (a ratio of 6.50) exhibiting large differences in sampling
probabilities across these strata.
The extrapolated prevalence estimates for each outcome for the UK population of those aged 60–89 years
with dementia are given in Table 37.
Further prevalence estimates of distance VI for the populations with dementia aged 60–74 years,
65–89 years and 75–89 years are provided in the additional tables in Appendix 5.
The prevalences for distance VI and near vision loss are generally higher in these population estimates,
and CIs are wider, than in the PrOVIDe sample rates, reflecting the design effect and the large variation in
calibration weights.
TABLE 35 Estimated prevalence (with 95% CIs) of distance VI, near vision loss and ocular conditions in the full
PrOVIDe sample using multiply imputed data for missing observations
Acuity status/ocular condition
Imputed prevalence (%)
Estimate 95% CI
Distance VI
Presenting (VA < 6/12) 37.7 33.3 to 42.3
Presenting (VA < 6/18) 21.9 18.4 to 25.8
Post refraction (VA < 6/12) 24.8 19.2 to 31.4
Post refraction (VA < 6/18) 13.4 10.1 to 17.7
Under-/uncorrected (VA < 6/12) 14.5 11.3 to 18.4
Under-/uncorrected (VA < 6/18) 8.7 6.1 to 12.2
Ocular conditions
AMD 18.4 15.7 to 21.5
Cataract (1–5, no IOL) 58.6 54.9 to 62.2
Cataract (2–5, no IOL) 37.7 34.2 to 41.4
Diabetic retinopathy 2.4 1.4 to 4.0
Glaucoma 8.8 6.8 to 11.2
Near vision loss
Presenting (NVA <N8) 27.9 24.2 to 31.9
Presenting (NVA <N10) 19.9 15.4 to 25.4
Post refraction (NVA <N8) 19.6 16.1 to 23.7
Post refraction (NVA <N10) 9.2 6.5 to 12.9
Under-/uncorrected (NVA <N8) 11.4 9.0 to 14.3
Under-/uncorrected (NVA <N10) 13.1 9.6 to 17.8
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TABLE 36 Sampling weights applied to each observation within each stratum: defined by age, sex and group
Age group (years)
Living in own home Living in care home
Female Male Female Male
60–64 1.77 1.22 2.86 1.98
65–69 2.18 1.38 0.69 0.44
70–74 1.04 1.22 0.94 1.1
75–79 1.18 1.05 1.06 0.95
80–84 1.24 1.08 0.57 0.49
85–89 0.72 0.97 1.00 1.35
TABLE 37 Projected prevalence (with 95% CIs) of distance VI, near vision loss and ocular conditions in the
population of people with dementia in the UK aged between 60 and 89 years old
Acuity status/ocular condition
Extrapolated population prevalence (%)
Estimate 95% CI
Distance VI
Presenting (VA < 6/12) 34.6 29.3 to 40.3
Presenting (VA < 6/18) 20.3 16.7 to 24.6
Post refraction (VA < 6/12) 22.4 16.4 to 29.9
Post refraction (VA < 6/18) 12.2 8.8 to 16.6
Under-/uncorrected (VA < 6/12) 13.6 10.5 to 17.4
Under-/uncorrected (VA < 6/18) 8.3 5.9 to 11.6
Ocular conditions
AMD 17.7 14.7 to 21.0
Cataract (1–5, no IOL) 57.7 52.4 to 62.9
Cataract (2–5, no IOL) 36.7 32.5 to 41.1
Diabetic retinopathy 2.3 1.2 to 4.4
Glaucoma 8.4 6.5 to 10.7
Near vision loss
Presenting (NVA <N8) 25.9 22.1 to 30.1
Presenting (NVA <N10) 17.8 13.2 to 23.6
Post refraction (NVA <N8) 17.5 13.1 to 23.0
Post refraction (NVA <N10) 8.0 5.2 to 12.0
Under-/uncorrected (NVA <N8) 11.1 8.7 to 14.1
Under-/uncorrected (NVA <N10) 11.9 8.3 to 16.7
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Comparison of prevalence with other UK studies of visual
impairment in older people
The methods used to reweight the estimated rates of VI in PrOVIDe to allow greater comparability with
two nationally representative studies of VI in the elderly were described in Chapter 2 (see Stage 1: data
analysis plan, Comparison of prevalence with other UK studies of visual impairment in older people). In the
NDNS,57 the crude (unweighted, unclustered) rates of VI defined by VA < 6/12 and VA < 6/18 in those
aged 65–84 years were calculated as 17.9% and 7.4%, respectively. In the MRC study,56 the crude rates
of VI defined by VA < 6/12 and VA < 6/18 in those aged 75–89 years were calculated as 18% and 11.0%,
respectively. Reweighted PrOVIDe estimates are given alongside these comparative estimates in Table 38.
Point estimates of presenting VI rates are higher for PrOVIDe than for the NDNS subsample for both
definitions of VI, suggesting a meaningful difference between these populations, although there is only
weak evidence to rule out no difference between prevalence rates. For presenting distance VI defined by
VA < 6/12, the point estimates of prevalence are meaningfully lower in the MRC subsample than in the
age-similar participants of PrOVIDe who are living in their own homes. Although this difference of 10.7%
is imprecisely estimated, there is some evidence of a difference between true prevalence rates. For
presenting VI defined by VA < 6/18, estimates are slightly higher in the MRC subsample than in the
age-similar participants of PrOVIDe who are living in their own homes, but these differences are neither
statistically significant nor very large in magnitude.
It should be noted that even though age, sex and residency differences in the samples have been largely
accounted for, there may of course be systematic differences between the samples even after reweighting.
In particular, how participants were recruited and how representative they are of certain regions cannot be
addressed. It may be that participants of the same age, sex and residency relative to their own populations
(dementia for PrOVIDe, non-dementia for the main NDNS sample and mixed for MRC) were generally
healthier or less healthy in MRC or NDNS than those in PrOVIDe, or that their health-care access was
better. NDNS participants were sampled by postcodes directly through residential addresses, whereas
PrOVIDe and the MRC study participants were sampled by regional clusters through public health services,
and this may have led to differences in those recruited.
TABLE 38 Reweighted estimates of VI in PrOVIDe and comparator study subsamples according to age-sex-residency
distributions of NDNS and age-sex distribution of MRC
Distance VI
Comparator
study
Age range
overlap
(years)
n
PrOVIDe
n
comparator
PrOVIDe reweighted
VI rate (%)
Comparator VI rate
(%)a
Estimate 95% CI Estimate 95% CI
Presenting
(VA < 6/12)
NDNS 65–85 486 1027 23.7 20.0 to 27.7 17.9 15.6 to 20.4
Presenting
(VA < 6/18)
NDNS 65–85 486 1027 11.9 8.5 to 16.3 7.4 5.9 to 9.2
Presenting
(VA < 6/12)
MRC 75–89 283 13,819 28.7 21.3 to 37.4 18.0 14.5 to 21.5
Presenting
(VA < 6/18)
MRC 75–89 283 13,819 10.4 7.1 to 15.1 11.0 9.3 to 12.7
a Visual impairment rate estimates and CIs are unadjusted for weights/non-response bias in comparator subsample.
Bold text highlights numbers that are the main comparators.
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Key findings from stage 1
l Optometrists usually recommend that people have annual sight tests from the age of 70 years and
every 2 years before that unless there are clinical reasons for more frequent testing. In the PrOVIDe
study, 22% reported not having had a test in the past 2 years: this included 19 participants who had
not been tested in the past 10 years.
l The prevalence of presenting VI was 32.5% (95% CI 28.7% to 36.5%) and 16.3% (95% CI 13.5% to
19.6%) for VA < 6/12 and 6/18 respectively, in people aged 60–89 years, generally higher than in
comparable data from prevalence studies on the general population after adjustment for age and sex.
Notably, 51.4% (95% CI 44.5% to 58.3%) and 26.4% (95% CI 20.7% to 33.0%) of participants living
in care homes were visually impaired using the VA < 6/12 and VA < 6/18 cut-off points, respectively.
l Visual impairment was correctable with an up-to-date spectacle prescription (uncorrected/
undercorrected VI) for 14.3% (95% CI 11.7% to 17.5%) of participants for VA < 6/12 and 7.7%
(95% CI 5.7% to 10.2%) for VA < 6/18.
l Even with the best spectacle correction, VI remained for 18.1% (95% CI 15.2% to 21.5%) and 8.6%
(95% CI 6.6% to 11.3%) of participants for VA < 6/12 and < 6/18, respectively.
l Cataract was the primary clinically determined cause in 48.0% of cases of post-refraction VI (for VA
< 6/12 criterion). This VI is potentially remediable. AMD was the primary cause in 36.3% of cases.
For VA < 6/18, AMD was the cause in 48.9% of cases and cataract was the cause in 36.1%.
l Distance VA improved by two or more lines on a logMAR chart post refraction in 17.8% of participants.
l 16.2% of participants could not read standard newspaper-size print with their current spectacles;
however, almost two-thirds of these participants could read this print with up-to-date spectacles.
l While research studies rarely include substantial numbers of people with dementia living in care homes,
the PrOVIDe study had 319 care home residents (44%). The unadjusted rates of all types of VI were
between 2 and 2.5 times greater for care home residents than for participants living in their own
homes. After age and sex adjustments, the higher rates of VI persisted in those living in care homes.
l After adjustment for age, sex and group, cognitive impairment assessed by sMMSE score had a
significant independent association with uncorrected/undercorrected VI (VA < 6/18) (p= 0.03) but there
was no evidence for an independent association of sMMSE with VI defined as VA < 6/12.
l Exploratory analysis found evidence for deficits in some vision-related aspects of function and
behaviour in visually impaired participants compared with non-visually impaired participants.
l There was no evidence that management of VI in people with dementia differed from that in the
general population of older people. The percentage of participants advised of a change in spectacle
prescription post refraction was consistent with the national figure. The PrOVIDe referral rate was
6.7%, higher than the national figure of 5% for the population as whole, but this could be due to the
older age-profile of PrOVIDe participants.
l When extrapolated to the UK wider population with dementia, following post-stratification calibration
and imputation, prevalences of VI are higher, with wider CIs, than the PrOVIDe sample rates.
¢ For VA < 6/12, the extrapolated prevalences for presenting, post-refraction and uncorrected/
undercorrected VI were 34.6% (95% CI 29.3% to 40.3%), 22.4% (95% CI 16.4% to 29.9%),
and 13.6% (95% CI 10.5% to 17.4%), respectively.
¢ For VA < 6/18, the extrapolated prevalences for presenting, post-refraction and uncorrected/
undercorrected VI were 20.3% (95% CI 16.7% to 24.6%), 12.2% (95% CI 8.8% to 16.6%) and
8.3% (95% CI 5.9% to 11.6%).
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l For the primary results relating to distance VI and near vision loss, when accounting for missing data
using multiple imputation, the prevalences are greater than estimated from the complete-case analysis.
Prevalences of ocular conditions are similar to those reported in the complete-case analysis.
l For the regression results relating to distance VI, near vision loss and the four eye conditions, there
was no change in the substantive conclusions under the imputation model compared with the
complete-case analysis.
l Point estimates of presenting VI rates are higher for PrOVIDe than for the NDNS subsample for both
definitions of VI, suggesting a meaningful difference between these populations, although there is only
weak evidence to rule out no difference between prevalence rates. For presenting distance VI defined
by VA < 6/12, the point estimates of prevalence are meaningfully lower in the MRC subsample than in
the age-similar participants of PrOVIDe who are living in their own homes. It should be noted that
there may be systematic differences between the samples even after reweighting.
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Chapter 4 Stage 2 results
Introduction
Stage 2 involved the collection of qualitative data from four participant sets:
1. people with dementia
2. family carers of people with dementia
3. professional care workers working in care homes
4. optometrists.
The basic topic guide used with all four participant sets covered the same key areas: experiences of eye
examinations, attitudes towards eye care, and opinions on if or how eye care for people with dementia
could be improved. This approach, using triangulation of participants to explore similar areas from different
perspectives, resulted in the identification of overlapping themes when framework analysis was applied to
the data. The data generated a total of 111 categories across the four sets of participants, although this
number includes duplications; for example, cataract was a data category in every set of participants.
These categories were synthesised into six common themes:
1. eye examinations
2. domiciliary eye care
3. spectacles
4. cataract
5. improving the eye care of people with dementia
6. quality of life.
The structure of this chapter is a description of the characteristics of study participants followed by an
exposition of the six themes.
Characteristics of the sample
Interviews with people with dementia
Interviews were conducted with 36 people with dementia, all of whom had participated in stage 1.
Their key characteristics are listed in Table 39.
The majority of participants (n= 31) lived in their own homes. Participants were informed that they were
welcome to have someone present at the interview and all but two of those living at home and two living
in a care home had a relative or friend in attendance.
Stage 2 interviews were initiated in May 2013, within 6 months of the commencement of stage 1, and
all of the interviewees were recruited from the four regions originally involved in the study. Purposive
sampling was employed to ensure that the sample comprised participants living in all types of location:
city, urban and rural.
The sample was evenly divided between males and females and encompassed the full age range for study
participants, 60–89 years, with a mean age of 77.5 years for women and 75.6 years for men.
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TABLE 39 Interviews with people with dementia
Interview Region Group Sex Age (years) Carer present sMMSE score
1 North Thames 1 Female 88 Son 23
2 North East 1 Female 79 Daughter 24
3 North East 1 Female 79 Husband 23
4 North East 1 Female 76 None 22
5 North East 1 Male 75 Wife 27
6 Thames Valley 1 Male 68 Wife 27
7 Thames Valley 1 Female 76 Daughter 24
8 Thames Valley 1 Male 80 Wife 24
9 Thames Valley 1 Male 60 Wife 30
10 North Thames 1 Female 86 Husband 20
11 Thames Valley 1 Male 63 Wife 20
12 Thames Valley 1 Male 72 Wife 25
13 Thames Valley 1 Male 82 Wife 22
14 North East 1 Male 81 Wife 24
15 North East 1 Male 69 Wife 30
16 North East 1 Female 81 None 21
17 North East 1 Female 62 None 16
18 North East 1 Male 69 Wife 24
19 North Thames 1 Female 79 Partner 12
20 North Thames 1 Female 67 Husband 23
21 Thames Valley 2 Female 74 None 26
22 North Thames 2 Male 88 Son 11
23 Thames Valley 2 Female 89 Daughter 24
24 North East 1 Male 84 Wife 22
25 North East 1 Male 78 Wife 22
26 North East 1 Male 67 Wife 26
27 North East 1 Male 74 Wife 26
28 North Thames 2 Female 80 None 20
29 North Thames 2 Female 79 None 19
30 Thames Valley 1 Female 80 Friend 8
31 Thames Valley 1 Female 67 Husband 30
32 East Anglia 1 Female 81 Husband 22
33 East Anglia 1 Male 83 Wife 24
34 East Anglia 1 Male 87 Wife 26
35 East Anglia 1 Male 82 Wife 27
36 East Anglia 1 Female 73 Husband 15
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Family carer focus groups
A total of 33 family carers attended across the five focus groups. The demographics of the sample are
listed in Table 40. As the table shows, 20 of these focus group participants were caring for a relative at
home and 13 had relatives in care homes, so the focus groups provided insights into experiences in both
care settings.
TABLE 40 Carer focus group participants
Region ID Carer for Relationship Resides at
North East focus group CFG 1.1 Wife Husband Home
CFG 1.2 Mother Daughter Home
CFG 1.3 Mother Son Care home
CFG 1.4 Mother-in-law Daughter-in-law Care home
CFG 1.5 Husband Wife Home
North Thames focus group CFG 2.1 Wife Husband Home
CFG 2.2 Mother-in-law Daughter-in-law Home
CFG 2.3 Brother Brother Home
CFG 2.4 Sister Sister Home
CFG 2.5 Mother and father Daughter Home
CFG 2.6 Father Daughter Home
CFG 2.7 Mother Son Home
North Thames focus group CFG 3.1 Father Daughter Care home
CFG 3.2 Husband Wife Home
CFG 3.3 Mother Daughter Home
CFG 3.4 Wife Husband Home
CFG 3.5 Wife Husband Home
CFG 3.6 Mother Daughter Care home
CFG 3.7 Mother Daughter Care home
CFG 3.8 Sister Sister Care home
CFG 3.9 Mother-in-law Daughter-in-law Care home
Thames Valley focus group CFG 4.1 Husband Wife Home
CFG 4.2 Husband Wife Care home
CFG 4.3 Grandmother Granddaughter Home
CFG 4.4 Wife Husband Care home
CFG 4.5 Mother Daughter Care home
CFG 4.6 Wife Husband Home
CFG 4.7 Wife Husband Home
North East focus group CFG 5.1 Mother Daughter Care home
CFG 5.2 Mother Daughter Care home
CFG 5.3 Mother Daughter Care home
CFG 5.4 Husband Wife Home
CFG 5.5 Mother Son Home
ID, identification number.
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Optometrist focus groups
A total of 34 optometrists participated across five focus groups (Table 41). Four regionally organised
groups each had five or six participants working in a range of optometric settings. A fifth focus group
(focus group 2) was arranged with the optometrists who examined patients for the PrOVIDe study to
capitalise on their experiences of working in domiciliary care.
TABLE 41 Optometrist focus group participants
Focus group ID Primary work setting
1 OFG 1.1 Low vision/locum
OFG 1.2 Independent practice/diabetic retinopathy
OFG 1.3 Independent practice
OFG 1.4 Independent practice
OFG 1.5 Independent practice
OFG 1.6 Independent practice
2 OFG 2.1 TOC domiciliary
OFG 2.2 TOC domiciliary
OFG 2.3 TOC domiciliary
OFG 2.4 TOC domiciliary
OFG 2.5 TOC domiciliary
OFG 2.6 TOC domiciliary
OFG 2.7 TOC domiciliary
OFG 2.8 TOC domiciliary
OFG 2.9 TOC domiciliary
OFG 2.10 TOC domiciliary
OFG 2.11 TOC domiciliary
3 OFG 3.1 Independent practice
OFG 3.2 Hospital
OFG 3.3 Hospital
OFG 3.4 Community practice/hospital practice
OFG 3.5 Part-time
OFG 3.6 Independent practice/locum work
4 OFG 4.1 Glaucoma clinic/independent practice/domiciliary work
OFG 4.2 Community optometrist
OFG 4.3 Independent practice
OFG 4.4 Independent practice/hospital
OFG 4.5 Independent practice
OFG 4.6 Hospital/independent practice
5 OFG 5.1 Hospital
OFG 5.2 Hospital/private practice
OFG 5.3 Community practice/hospital/domiciliary
OFG 5.4 Hospital
OFG 5.5 Community practice/domiciliary
ID, identification number.
STAGE 2 RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
86
Professional care workers
Professional care worker perspectives were explored through one focus group comprising representatives
from a care home company in North Thames, and individual interviews with care workers and managers
employed by a range of companies (Table 42).
Theme 1: eye examinations
This theme describes how eye examinations were arranged, the frequency of examinations and
experiences from patient, carer and professional perspectives. People with dementia were asked about
their experiences of eye examinations, how often they had an examination, where they went and what
their experiences had been.
Provision of the eye examination
In terms of who performed the eye examination, there were variations in responses among interviewees;
some had tended to see the same optometrist or at least had visited the same practice over the years,
while others moved around. None of the 31 interviewees living in their own homes had experienced a
domiciliary eye examination prior to the study.
TABLE 42 Professional care worker participants
ID Role
CHFG 1 Company dementia manager
CHFG 2 Reception and administrator
CHFG 3 Care home manager
CHFG 4 Care team manager
CHFG 5 Relief care team manager
CH interviewee 1 Deputy care home manager
CH interviewee 2 Senior carer
CH interviewee 3 Carer
CH interviewee 4 Dementia unit care manager
CH interviewee 5 Dementia care unit manager
CH interviewee 6 Care assistant
CH interviewee 7 Care assistant
CH interviewee 8 Carer
CH interviewee 9 Nurse
CH interviewee 10 Nurse
CH interviewee 11 Head of care
ID, identification number.
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Conversely, in care homes, most eye examinations were conducted by a company specialising in the
provision of domiciliary services. Care workers described how an optometrist from the company usually
made several visits to the care home during the course of a year and carried out several examinations.
The number of examinations conducted during one visit could be as many as 20 in 1 day, although it was
unclear if these were all conducted by one optometrist. The company often sent two people but, from the
care workers’ accounts, one of these appears to have been either a clinical assistant or a dispensing
optician. Care workers reported that it was rare for a resident to continue to be seen by their previous
optometrist following admission to the care home; two thought that ‘private’ optometrists were reluctant
to carry out a domiciliary visit.
There was a view, expressed mainly by optometrists but also by some participants in all other categories,
that it was desirable to see the same optometrist in order to provide continuity of care. For example:
It’s better and easier to go the same place because they know him, he knows them and that makes
it easier.
Wife of interviewee 9
In my opinion it would be like going to a doctor’s, you’d like to see the same one, because he knows
when he makes his notes, what he’s put down, and then you get to know that person. The continuity
is better, and you feel better. But then even if you go to the opticians, you’ll see different people at
different times, it’s not quite the same.
CFG 2.2
If you go to Mr X in Chiswick High Road, he’s been there a long time, and you go back again, he’s
got your file on you and everything else. But you go to [name of optometrist chain], the young girl’s
gone back to Poland, the other chap’s gone back to wherever and it’s all different again, at the end of
the day.
CFG 2.3
I think something that’s quite important, there isn’t continuity in care these days, so many people
dot around which practice they’ll go to. And as people get older, if they can be encouraged, that
continuity of care I think is so important. And I don’t know perhaps how we could put that over to try
and encourage that.
OFG 3.3
I think it’s kind of nicer for patients to be able to go back to where they’ve gone; you’ve got the
history and the stuff that makes your life a lot easier, and makes the decision-making
more straightforward.
OFG 4.1
Once they’ve found an optometrist they are happy with, stick with them, don’t be tempted by the
latest special offer when they go shopping because continuity really helps everybody, patient and
practitioner alike.
OFG 4.2
Frequency of eye examinations
Most interviewees stated that they had an eye examination annually or approximately every 2 years.
The main reason stated by those who did not do this was that they thought that there was nothing
wrong with their eyes or that they could see through their current spectacles and did not need to see
an optometrist.
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Reports from family carers were consistent with this; most of them said that their relative had regular
(annual or 2-yearly) eye examinations both before and after the onset of dementia. Again, exceptions to
this were linked with a perceived lack of need.
Nan had cataracts removed about 12 years ago and after that her eyesight improved dramatically,
as you would expect. And so since then she hasn’t felt she needed to have her eyes tested again,
because she was so happy with them.
CFG 4.3
There was just one case of someone not having an eye examination following difficulties with a
previous examination:
Researcher: Some of you have already said something about problems coping with certain aspects of
the eye exam, is that right?
CFG 2.7: Yes, that’s right. That was a number of years ago, and that was the reason, she hadn’t had
an eye test for 4 or 5 years, I suppose.
When participants were asked for a view on how often people with dementia should have an
examination, the most commonly expressed view was that annual examinations were necessary. Generally,
family carers and optometrists thought that an annual eye exam was desirable and that 2 years between
examinations would be too long for most people.
Specifically with dementia, it would be a great source of confusion annoyance, irritation, puzzlement
to my wife if she were having problems with her eyes and she didn’t have them checked annually; to
go 2 years would really be just too far in terms of the time involved.
CFG 4.6
However, some participants – particularly some care workers – thought that there was a need for more
frequent testing, as often as 6-monthly, in the belief that as a person’s dementia progressed there was a
need to check if their sight had also deteriorated. For example:
I would say for some of them, yearly, but if their dementia’s starting to go down that little bit, or
they’re not finding their way around it could be their eyes, you know, so I would say that, I would say
a little bit more often.
CH interviewee 2
Experiences of eye examinations
Participants were asked to share their experiences of eye examinations conducted on people with
dementia. Interviewees generally were satisfied with their eye examinations and did not perceive any
problems, but some family carers and care workers expressed doubts about how optometrists could
conduct a full examination because of the cognitive impairment associated with dementia, particularly
those elements of the examination which required a judgement or some type of recall response from the
person being examined.
I have real concerns about what he can see and how you assess what he can see. With hallucinations,
with lack of concentration, lack of ability to focus, all the things that go along with the dementia.
When he was first tested he read the eye chart as a book, trying to make words out of the letters, but
at least that showed that he could see the letters and the last time, which was a year later, he couldn’t
identify the letters. And I honestly don’t know whether it’s vision, or whether there’s a fault between
the eye and the brain.
CFG 3.2
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I have doubts when they put things and say ‘is this better and is that better?’ because you don’t
remember from one to the next. So I’m not confident that she gives the right response, and therefore
she can’t get a proper diagnosis and a proper prescription.
CFG 3.3
I was identifying with what other people were saying, you know, how difficult it is to know to what
extent they’re giving the right answers. She just doesn’t see things a lot of the time and there’ve been
so many occasions where I’ve tried to point something out and she just will not see it. And if she can’t
see it, I’m doubtful about the value of the eye test. There is the other side to it, the health part, which
is obviously, as you were saying, objective, and worthwhile.
CFG 3.4
I think some parts of the eye examination though, are quite threatening for someone who
doesn’t understand.
CFG 4.3
Well just from my own personal experience of having my eyes tested, they ask lots of questions ‘is this
clearer with this lens or that lens’ and it’s quite a lengthy process when you’re having your eyes
checked and to get the right spectacles for you. And if they can’t answer, those questions, I don’t
understand sometimes how they’re getting the right glasses for them.
CH interviewee 10
Problems with the eye examination
Not all family carers had observed a relative having an eye examination. Very few reported going into
the examination room in a practice. Carers of stage 1 participants living in their own homes had mostly
been at home when the PrOVIDe examination was conducted, but few had been present if their relative
had been examined in a care home. Of those who had been present at an examination in a practice
(not a PrOVIDe examination), a small number identified problems they had encountered. The problems
included difficulties with communication and understanding test instructions. Carers explained the effect of
dementia on a person’s ability to understand and respond. For example:
You know the one where you have to count the dots or whatever, they move around, and he
couldn’t, it was inconclusive. They wanted to do it again. And they weren’t really explaining why,
he had to do it again, and he was getting a bit frustrated with that.
CFG 2.6
There were definitely a few instructions that my mum struggled to understand. There was one
machine and she really struggled to sit in the seat and get the right placing for. My sister said there
was something they said would take 10 minutes and took about 30 or something, so that seemed to
be a bit of lack of confidence, a bit of not understanding the instructions, but as far as we know they
muddled through.
CFG 1.2
Our first language is Aramaic, then obviously we came here, she worked on her English. Now, she’s
forgotten all that, gone back to the Aramaic. So when we go, this is our problem, the letters, this is
the thing. So obviously something to do with dementia, rather than the eyesight.
CFG 2.4
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Care home staff also described examinations in which significant cognitive impairment led to
communication problems and lack of co-operation.
The pressures test or ‘can you see out of this eye, can you see best out of this, can you read the
numbers well’. If you’ve got the majority, say 20 residents, and 18 of those residents aren’t able to
verbally communicate, or understand what you’re even asking them, how are you possibly going
to conduct a reasonable eye test on that person?
CH interviewee 3
We did have one [person] that would not get her eyes tested whatsoever. She wouldn’t have nothing
on her face, it used to distress her too much, so we just couldn’t do it.
CH interviewee 4
I had a lady, looked after her a long time, and she wouldn’t let anybody look at her eyes. I mean she
didn’t like anyone very close up at anything, although we did try and try and try . . . so they could
never get her eyes tested to see how bad she had got.
CH interviewee 2
Although family carers gave relatively few examples of difficulties with the ‘mechanics’ of the eye
examination, some expressed concern about the way eye-care professionals – optometrists and hospital
staff – interacted and their understanding of the impact of dementia. The first in the next group of
quotations is from an optometrist who talked about taking her grandmother for an eye examination.
My nana had dementia. I accompanied her for an eye examination. The consulting room had all the
state of art equipment but the optometrist had no experience in examining a patient with dementia.
It was visible through the course of the eye examination.
OFG 2.6
It would be really good if opticians had dementia training. We got some bifocals for my husband,
he’d never worn bifocals before, and I thought ‘well it’ll be easier for him than switching’. It was a
complete disaster, he never wore them. And I feel that the optician ought to have warned me that
that was a bad choice.
CFG 3.2
The optician just couldn’t grasp the concept she had dementia. When she wouldn’t do the peripheral
test, he just couldn’t take that in and he got cross with her and then she got upset.
CFG 4.5
One of the worst ones, was the hospital department, and the girl there – I won’t even go into it ‘cause
I could’ve hit her – when she did put something in wrong, she said ‘what did you do!’ and I said ‘she
can’t remember’; ‘well how can I deal with her if she doesn’t know!’, I said ‘she doesn’t know what
she did’, ‘well look, tell me, just tell me what you did’, I said ‘she doesn’t know’. I could’ve murdered
her, this woman had no concept of dementia whatsoever and she was really aggressive this . . .
optometrist, or whatever you want to call her. And another time they had to go in a little room, on
their own to be tested, and I said ‘I’ll come in with her’, ‘no you can’t’, I said ‘she needs me with her’,
‘no, you stay out here’, I thought ‘you haven’t got a clue’ and that angered me.
CFG 5.3
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There were several pleas from family carers for optometrists to understand the need to involve carers in
the consultation. The main explanation for this was that a carer knew that communicating with
the individual in certain ways would be more likely to elicit an appropriate response or to reduce the
individual’s anxiety. For example:
You mention the word ‘dementia’ but the person I dealt with, did not seem to have the slightest clue
of the implications that this would mean for mobility, for understanding, for me having to be there.
Medically they might not want it but I said ‘you must accept this, I’m afraid, because you just won’t
get anything to happen if I’m not there’.
CFG 4.6
Another thing, if the relative is there, they are going to be more at ease than if it’s just a stranger
doing something to them. I think it will make it more successful.
CFG 5.1
For some family carers, the main area of concern was not the actual eye examination but the issue of
accessibility to the practice (or to a hospital appointment); they explained the difficulties associated with
getting ready for an appointment, travel, parking at the venue, etc.
I think it is a massive logistical exercise, taking somebody to get their eyes examined. It’s not
straightforward to do.
CFG 3.1
What I have had a problem with, is mobility, because of her eyesight. Because I’ve got to take her in,
that’s really where I’ve had the problems, because everyone’s supposed to be disablement friendly,
but not everywhere is.
CFG 2.5
I had difficulties simply because I got to the point where to get my wife anywhere was such a
problem, to get her into the car, that was a major achievement, and she might get in and then get
out again, and that was the end of it.
CFG 4.6
Optometrists talked about the problems of the eye examination from their perspective. As the next set of
quotations demonstrates, the problems included the range of tests, the patient’s reactions, and the
patient’s emotional state and memory problems.
The other thing that I find is that quite a few of the dementia patients don’t seem to be able to cope
with the mirror, so you’ve got to do a direct measurement of vision. So Kay’s pictures would solve that
problem. I mean I often use a logMAR chart, if I’m just not getting any sensible visions.
OFG 1.3
I think the biggest problem for a young optometrist who is coming in to see a patient with dementia
is they probably think ‘I should try and do everything’ and frankly, you just can’t. I mean, if you’ve got
somebody on a slit lamp and you’re trying to see the peripheral fundus and they’re just always looking
to one way, you’ve got to come to a point where that person, the young practitioner has to realise
‘I can do this, this and this’ and that’s the hard bit, working out what you can do and what you can’t,
and what would be reasonable not to do.
OFG 1.2
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It doesn’t matter what equipment you have, it comes back to the fear value. You start shining a light
in somebody’s eye, whether it’s a direct or indirect ophthalmoscope; a direct ophthalmoscope I think is
worse ‘cause you’re right in their face; indirect, you’re shining a light in their eyes, and they’re not
happy, they don’t know why you’re doing it. So it’s not always what kit we’ve got, it’s what kit they
will accept, and sometimes the simpler the better, but it can be so difficult.
OFG 3.3
The patients’ difficulty in doing certain tests, the fields test is probably the most obvious, maybe
tonometry as well, where you can’t get all the pieces of the diagnostic jigsaw you need to enable you
to make as robust a management decision as you might like to do. Which might have several
consequences, it might lead to over-referrals, if for instance you can’t get an adequate view of the disc
and you don’t have normal fields and pressures, you might feel your only option is to refer that
patient. But it also might mean, conversely, that you might not refer that patient, when you should
refer that patient.
OFG 4.2
Well they vary don’t they? And sometimes you can’t even get near them, and they’re aggressive, there
are times when it’s exceedingly difficult and there’s sometimes you wouldn’t think there’s anything
wrong. They co-operate, they answer the questions, may not be sensible answers, not the right
answers, but they come up with answers, and you can often in the early stages get good acuities and
you can do well. But then there comes a point when you can’t.
OFG 5.5
In the early stages of dementia, I manage to get to a position where they go through the whole
routine, and they then make what appears quite a logical decision to make a purchase, and then once
you’ve made the spectacles up, and I’ve had this before, ‘what glasses? I didn’t order any glasses’.
And I think that there are barriers or challenges all the way through that we need to address.
OFG 1.1
However, as far as optometrists were concerned, two of the biggest problems when examining someone
with dementia were related to communication. The first problem was not knowing that someone had
dementia. This excerpt from one focus group demonstrates the consistency of experience.
OFG1.6: Right. The biggest problem, I don’t know if you would class this as a barrier, the biggest
problem is not knowing that the patient has dementia.
OFG1.2: My biggest problem is the family saying nothing and I’ve had three patients in the last month
where the family say nothing. And I’ve taken the patient in the room and you think there’s something
funny going on here, you’re asking their medical history and they’re very vague, they insist that
they’ve never been to an eye hospital and you can see the implant glinting in the light, and then
eventually you work it out. But I think the biggest problem is not being told that the patient has
dementia, and that’s three people in the last month, different practices.
OFG1.3: I would agree with that, yes.
OFG1.4: I would strongly agree with that as well.
OFG1.5: There’s also the patients that haven’t been diagnosed as well.
OFG1.3: Where you’re kind of talking to them and you’re thinking . . .
OFG1.5: Well some of the members of the family just say they’re a bit eccentric.
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OFG1.3: But I mean that’s slightly harder because we’re not necessarily the person to diagnose that,
but, definitely not being told about it makes it more difficult.
Optometrists from the second focus group, all of whom worked for TOC, had more experience of
examining people with dementia and were able to describe being alert to ‘clues’ that might suggest that
someone had dementia. For example, it was a clue ‘if the patients repeat things they have already told me
earlier in the examination’ (OFG2.4). However, another explained that they could go through the full test
but have no clue that the patient had been given a diagnosis (OFG2.2).
Informing the optometrist was something that was discussed in the interviews with people with dementia
and their carers. About half of the interviewees had not told the optometrist but in many instances this
was because the dementia had been diagnosed recently, since the person’s last eye examination. It was
evident from responses that many of these interviewees had not considered telling their optometrist, but
some thought that it was something they would discuss next time, as this sample conversation illustrates:
Researcher: Do they know [at the optician’s] that you have problems with your memory?
Interviewee 12: Probably not because I haven’t been to them for a long time. It was your team that
last sorted my glasses out.
Wife: I think the last time you saw them you were probably just waiting for diagnosis so they probably
don’t. But I’m not 100% sure if we didn’t mention it. But we will next time because then they will
know to be patient.
The second communication difficulty reported by optometrists occurred when they saw a patient
accompanied by a carer or care worker who had insufficient knowledge about the patient or their eye-care
history. They gave examples in which their impression was that the accompanying care worker was the
newest or least experienced member of staff with no knowledge of the patient. The first of the following
two quotations explains the problem, while the second is from an optometrist who explained the
difference it can make when the accompanying care worker is someone who knows the resident.
Often, from care homes, there’s quite a lot of carers, a lot of patients, and some carers have no idea,
they don’t have the information on the patient, so they don’t know if the patient is struggling with
their distance vision or near vision, and then the patient doesn’t know, so often you have no history
whatsoever to go from.
OFG 3.2
I think for me, one of the barriers, again particularly in secondary care, is how well you can liaise with
other people around the person as well. So if you’ve got a care assistant who, who doesn’t know
anything about the person and who’s just come with them in the taxi that day, then that makes life
difficult whereas if you’ve got somebody who’s a key worker and can understand the person’s needs,
and can perhaps give you some insight as to what the function is, so that you’re trying to gauge, like
their coping for cataract and so on. I think that makes a big difference.
OFG 5.1
It was interesting to note that family carers had said that they wanted optometrists to take more notice of
them and that, in their focus groups, the optometrists also stated how useful it was to have the
involvement of the families. This quotation succinctly described the scenario.
Communication with carers is vital. It makes such a difference to have the communication two ways
between all of them.
OFG 3.1
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Some optometrists also talked about multidisciplinary communication, which they thought was inadequate
in many cases. A very small number of optometrists gave examples of contacting an individual’s GP or
other health-care professional to acquire more information or insight, but several other optometrists
described how they would be unable to do the same because of time constraints related to the allotted
time for an appointment.
Theme 2: domiciliary eye care
The discussions that informed theme 1 were mostly related to experiences in community practice; the
exceptions were when participants were referring to experiences in care homes, where most residents
had a domiciliary eye examination conducted. Theme 2 is concerned specifically with the provision of
domiciliary eye care. It covers patient and professional experiences of domiciliary eye care and then moves
on to describe issues that were raised about its provision.
The experience of domiciliary eye care
In stage 1 of the study all participants had a domiciliary eye examination. It was interesting to note during
the stage 2 interviews that, before participating in the study, nearly all of the interviewees and family
carers had been unaware that domiciliary eye care was available. Those who had known of domiciliary eye
care did not realise that people with dementia would be eligible; they thought that it was for people who
were ‘immobile’ or ‘very disabled’.
Some people with dementia and carers expressed surprise at how extensive the examination was and the
amount of equipment used. Now that they knew about it, they thought it useful to know for future
reference, and some said that they would like to have future examinations at home.
Patients and next of kin are surprised about the quality of eye examination given by the optometrists
in a domiciliary setting. It could be because TOC optometrists have more time and this allows them to
perform a thorough eye examination not a Cowboy eye test.
OFG 2.10
Researcher: Did you know it’s possible to have a sight test done at home?
Husband of interviewee 3: No, beforehand, I don’t think we did.
Interviewee 3: No.
Husband of interviewee 3: Well I thought maybe, obviously if people are housebound and can’t get
out there must be some provision for them to have it but I thought maybe your own optician would
be able to come out although I didn’t know to what extent they’d be able to do it because you’ve got
to carry the equipment and stuff around.
Researcher: Did you know it was possible to have your eyes tested at home before we arranged it
this time?
Husband of interviewee 10: We thought you had to be really disabled. My mother died when she was
97 and it wasn’t until she was 96 that she had her eyes done at home. We thought you had to be
really old and disabled you know.
I think when you see all the complicated equipment at the opticians you don’t think that you can
replicate that at home.
CFG 1.3
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Although researchers did not expressly ask for views on the eye examination performed for the study,
many of the stage 1 participants and their carers volunteered complimentary comments on the experience.
When considered collectively, the following string of comments describes what can be perceived as the
benefits and positive aspects of a domiciliary eye examination:
I thought he was great. A nice person. Very tranquil. Just great.
Interviewee 19
I can only compare with what I have at [my practice]. Personally I would say that the one he had with
the people here was more thorough than what I have.
Wife of interviewee 34
She really liked someone coming to the house, there’s nothing like being treated a bit special. We like
the fact that he came here and he took a bit more time, I suppose you’re not being rushed through.
He was here like an hour and it wouldn’t have been like that at the opticians it would have been 10,
maybe 15 minutes. I think that was the difference.
Daughter of interviewee 2
The biggest difference was, I think, dignity, if that’s the right word. He was fantastic, he just treated
her not like a VIP [very important person] but, you know, he was just great, if there was anything that
she didn’t understand, he almost didn’t let her know she didn’t understand ‘cause he explained it, he
wasn’t talking to me he was talking to her.
CFG 1.2
I have to say, when Mum had her eyes done by whoever . . . you sent, no problem at all. He was
charming, you know, he was . . . he obviously understood who he was dealing with and . . .
was appropriate.
CFG 4.5
The care from the home visit was much better than the local one in the high street. Because they
understand, well that’s how it seemed to me, the person who came was excellent, and cared about
mum’s eyesight and things like that.
CFG 2.7
Wife of interviewee 12: It was superb. Very very thorough. They were thorough, polite, they were
kind, patient in their attitude. Excellent.
Researcher: Were you aware of any difference between having your eye test at [local branch of
optometrist chain] and the eye test this time?
Interviewee 12: This one was far more thorough.
Wife: I don’t tend to go in the booth with you, I take you to the optician but I don’t go in the booth
with you. It probably was better. They were particularly caring and understood.
Interviewee 12: And the extent of the equipment they had for making their diagnosis.
Researcher: Did the eye examination take longer, having it done at home?
Interviewee 12: Well I think the extent to which my eyes were tested was far greater.
Interviewee 12 and wife
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Husband: Oh [the domiciliary eye examination] was a lot more relaxed. We have to get all ready, get
on the bus then you’ve got all the trouble of waiting for the buses to come home.
Interviewee 10: This is so much nicer.
Husband: That’s why we kept putting it off really. That’s why we missed one year and put it off to a
second year because every time we went to go, one of us wasn’t well. When there’s two of you
there’s always one of you got something. You think ‘I can’t do it this week I’ll make an appointment
next week’ and then something else crops up. And it goes on and on. But when you’re having it done
at home, if you’re not feeling quite up to it you can still have it done.
Interviewee 10 and husband
The optometrists from the four regionally based focus groups varied in the amount of experience each
one had of conducting domiciliary visits. Those with little experience were sceptical about how much could
be done, or whether or not an examination carried out at home was as good as those conducted in a
practice. However, those who provided domiciliary eye examinations as part of their role extolled the
virtues of testing at home, explaining how the patient was often more relaxed in their own environment
and how the optometrist could also assess the impact of the environment on the patient’s sight. This
exchange is an example of the comparative experiences:
OFG 4.3: I used to do home visits. And I wouldn’t consider doing fields actually, in a home visit really,
I’m not having a go at you, believe me. I just wouldn’t.
OFG 4.6: I often find it sometimes easier to do a home visit on a dementia patient, I find that I get
more useful results. I find stuff like ophthalmoscopy easier to do, because they’re in their home
environment; stuff like pressures is always easier when they’re in their home environment as well.
They’re more relaxed, their reading is better, they have access to things that they normally read, so
you can always try to test out things in their home environment. So it’s often more of a useful, it’s a
more functional eye test.
OFG 4.2: It’s interesting you say you find ophthalmoscopy, I haven’t done domiciliary for years, but I’m
surprised you say that ophthalmoscopy is easier. I would have thought quite the reverse, unless you’re
dilating them, ‘cause you can’t make the room as dark.
OFG 4.6: But they’re less distressed, so they’ll keep still.
As Table 41 showed, some of the optometrists had roles involving domiciliary care but many worked in
community or hospital settings only. The availability of equipment was explored as a factor in community
optometrists’ provision of domiciliary eye care and most of those who did not currently do domiciliary work
thought that they did not have the right equipment to do so. This contrasted with TOC optometrists, all of
whom thought that they were well equipped, as exemplified by this quotation from their focus group.
I feel very set up for a domiciliary eye examination with TOC. I am able to give a good test to provide
the best possible eye care for a patient with dementia.
OFG 2.10
Provision of domiciliary care services
Not all optometrists are obliged to provide domiciliary care but under GOS regulations they should be able
to advise a patient on how to access domiciliary care. The community optometrists who did not provide a
domiciliary service were asked if they could identify a domiciliary services provider for a patient if required.
Two optometrists said that they knew of individual practitioners; otherwise, responses indicated that their
only knowledge related to specialist domiciliary care companies, and even then most had only a theoretical
knowledge of their existence and limited experience of how they operated.
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This area of questioning gave rise to discussions about the whole area of how domiciliary care is provided
and funded. Although the comments about the domiciliary eye examinations conducted for the PrOVIDe
study were complimentary, the comments from focus group participants and care home interviewees
suggested some dissatisfaction with the system of domiciliary care provision.
Care workers described eye-care arrangements in the care home. Usually the care home had an
arrangement with a domiciliary services provider who would send an optometrist to the care home several
times a year. The optometrist usually had a list of who was scheduled for an examination, comprising new
admissions and those for whom the annual examination was due. The optometrist was not usually the
same person on each visit, suggesting consequent impact on continuity of care:
It was OK, but I noticed it’s somebody different that comes every time, so you know, I would think,
you know, the continuity’s not there that, you would get probably possibly yourself if you were going
to the optician.
CH interviewee 5
Not all care workers had first-hand experience of the eye examination. Of those who had observed or
assisted a resident during an examination, some described perceived limitations in the thoroughness of
the examination, albeit with the caveat that this was only their impression. Care workers explained that
the optometrist would see several people in one session; in one home it was reported that as many as
20 people might be seen in one day. There were concerns that examinations sometimes felt ‘rushed’.
CH interviewee 5: They whizz through.
Researcher: They whizz through? OK, tell me about that . . .
CH interviewee 5: Make of that what you will!
CH interviewee 5
I thought they did really well in the morning but when they came back in the afternoon, I did feel that
they just had had enough and they were, they were a bit rushed and they just wanted to get finished
and go because they’d got other people to see. I did feel that, I definitely noticed the difference in
the afternoon.
CH interviewee 8
As much as possible we’re trying to encourage the optometrists, to come later in the afternoon when
the residents are more settled and relaxed because sometimes they come in the morning or too late.
We’ll tell them ‘come on this day then, because it’s less hectic’ because if everything is rush rush rush
the residents feel that as well and that’s the time that they don’t co-operate.
CH interviewee 11
As described in Theme 1: eye examinations, care workers queried how much of the examination could be
accomplished with someone with dementia, particularly with regard to people with advanced or end-stage
dementia, but some suggested that limitations to the examination were at least in part linked to the
optometrist. This care worker described this in some detail.
CH interviewee 3: Some [optometrists] have a better understanding. And as I said before, some will
say, ‘don’t worry, there’s other things I can check’ and have the patience, the understanding, the
knowledge to work alongside a resident with those conditions at that stage. And I’ve also witnessed
opticians who are like ‘well if they can’t do this, there’s no point, I can’t do it’ kind of thing. Which I
understand because if that person doesn’t have an understanding of the dementia and the effect that
dementia can have on that resident they’re thinking ‘well they’re not responding, I’m getting no
response and there’s only so much I can do’ so, you know, I’ve witnessed both them things.
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Researcher: I don’t want to put words in your mouth, I just want to check, make sure what you’re
saying. Do you ever think that they give up too quickly or . . .?
CH interviewee 3: Yeah, like I said, I have worked where I’ve seen very patient people that have come
to test these residents’ eyes, who sympathise, empathise and have the time and patience, and maybe
it is have knowledge and understanding, I don’t know, but I’ve also witnessed where it’s just a case
of, you know, ‘there’s no response and I’m getting nothing so can I have the next patient’ kinda
thing, and that doesn’t help that resident who can’t speak or show any facial expression to respond to
what you’re asking, but might have really bad eyes and might need them glasses, who would be able
to wear them ‘cause wouldn’t take them off or whatever, but for them reasons don’t get that proper
eye test.
CH interviewee 3
The potential for domiciliary examinations to be rushed or incomplete was also a concern for optometrists,
as evidenced by comments about the purpose of the eye examination, limitations of the fee structure and
the potential for exploitation of the system. There was no question that optometrists believed that people
with advanced dementia should have some sort of eye examination but, cognisant of the perceived
limitations already expressed, some thought that a comprehensive eye examination was not always
possible and, if this was the case, wondered if a full examination fee should be paid. A ‘health check’ to
identify conditions which it was in the interest of the patient to treat – for example, finding glaucoma that
needed eye drops to prevent pain and/or further VI – should not incur a full fee. It was noted that an
optometrist might not know in advance that an examination would be limited or even not possible, and if
the optometrist was an independent practitioner attending a single patient, there would be an issue
regarding how to compensate him or her for the time booked out of practice. However, focus group
participants were wary of the ethical and financial considerations of domiciliary service provision in care
homes when multiple examinations might be conducted and the majority of residents might not benefit
from a full examination. These dilemmas are clear in the following extract from one focus group
comprising mainly independent practitioners.
OFG1.4: It’s a difficult one. On the very advanced dementia patients, I don’t like examining them
because I don’t like claiming a fee. What are you going to do, 5 minutes and then claim a full fee,
especially a domiciliary fee.
OFG1.6: I don’t think the amount of time you spend, or what you can get done, should dictate how
you claim something, it’s a matter of what is the good you can do for that patient surely.
OFG1.3: You get the odd one where you think it’s really worthwhile of course, people who’ve been
ignored or had a stroke and maybe got early dementia, but there’s so many people with advanced
dementia and you think really this is a money exercise.
There was some overlap between this theme and theme 5 – improving services for people with dementia –
so further detail is provided in Theme 5: improving the eye care of people with dementia. Similarly,
the debate around the dilemma of providing eye examinations for people with advanced dementia is
compounded by the additional factor of prescribing and dispensing new spectacles. There were suspicions
that some dispensing is unnecessary as many people with dementia do not wear their spectacles. This is
the focus of theme 3.
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Theme 3: spectacles
Spectacles as a theme describes problems related to the failure to wear spectacles as prescribed and to
optometrist dispensing decisions.
Not wearing spectacles
A phenomenon that first emerged during the interviews was of people with dementia not wearing their
spectacles. It was also reported by some family carers during the focus groups but was particularly
reinforced during the interviews with care workers.
Three interviewees, all with prescriptions for reading and distance lenses, stated that they did not wear
spectacles because they felt that they did not need them; one person did not know where her spectacles
were. The interviewer asked the other two people to put on their spectacles and then asked about
changes in vision; both people reported improved vision with the spectacles on. One of them repeatedly
stated that she did not wear spectacles because she ‘didn’t need them’ but she kept a magnifying glass to
hand and stated that she used it ‘if I want to read something, you know. That’s when I use it, to look up
something for the television’ (interviewee 1).
All three interviewees had two pairs of spectacles but did not appear to understand this or why they had
two pairs. For example:
Researcher: Right. Do you have two pairs of glasses?
Interviewee 16: Yes.
Researcher: So, what are they for?
Interviewee 16: I don’t know. I’ve never used them. Those are the ones they left here with me. And
then there are these. I didn’t want to throw them away, they are the ones that your optician gave me.
[takes them out of a case] There they are. But I haven’t used them yet.
A fourth interviewee stated that he only wore his glasses ‘occasionally’ but, when making the appointment
for the interview, his wife stated that she thought the money spent recently on new spectacles was ‘a
waste of money because he refuses to wear them’ (interviewee 11).
Several family carers said that their relative would not wear spectacles and that they did not understand
why, especially when the individual had worn spectacles for many years before the onset of dementia.
Mam’s thing is ‘I can see quite well without my glasses, I don’t need them, I can see what I need to
see without me glasses’.
CFG 1.4
As far as I can remember from being a child, she’s always had glasses, always, and this last couple of
years, she seems to get angry with them on her face, and she’ll take them off, and she’ll look at them
as if ‘what am I doing with these’, and she’ll fling them on the floor.
CFG 5.2
She doesn’t wear them, I’ve never seen her wear them, she’s been prescribed glasses for reading, for
watching television and she doesn’t wear them.
CFG 5.5
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Those whose relatives lived in care homes often attributed the absence of spectacles to the failures of
staff: staff not knowing the resident, high staff turnover, pressure of work and staff saw it as a low priority
to ensure that spectacles were worn. However, care workers also reported residents’ refusal to wear
spectacles as a major issue. The suggestion that failure to wear spectacles was attributable to staff
turnover or to staff being unfamiliar with residents was refuted by care workers’ descriptions of how
spectacle wearing was well documented in care plans. They were aware that relatives often blamed them,
even though the care workers had tried, unsuccessfully, to persuade the resident to wear their spectacles.
These care workers explained the problems they faced.
It does sound like I’m making an excuse of why they haven’t got their glasses, but that’s not the case.
I can only speak for the residents that are in my care and the shifts that I’ve worked on, and I can
honestly say we’ve got more than a good handful of residents in this home, who I know should wear
glasses, have been given glasses, but will not wear them. Or we’ll put them on and not 2 minutes
later they’ll take them off and you’ll put them on, then that resident will become agitated because
you’re trying to put glasses on and they clearly don’t want them glasses on or they don’t understand
that they need them glasses, and in which case you’re going to cause an incident or upset somebody.
CH interviewee 3
We’ve got a gentleman at our place and he’s mobile, you give him his glasses first thing in the
morning, first thing he does is take them off, he doesn’t want to know, doesn’t, but, he can’t see
enough to even feed himself, so now we have to assist him with feeding because he doesn’t want
to wear his glasses. There’s nothing you can do to get him to want to wear his glasses, you try
throughout the day and he just takes them off, throws them away, doesn’t want to know.
CHFG 2
The reasons why people refused to wear their spectacles were something that some carers speculated
on but none really knew. One suggestion was that the persistence of long-term memory and loss of
short-term memory meant that people with dementia remembered the time when they did not wear
glasses and did not remember that they needed them now. Another hypothesis was that a dementia
sufferer’s world ‘shrank’ and an adaptive response (unconsciously) was to go without anything that was
no longer perceived to be necessary. A third theory concerning people who had different spectacles for
distance and near vision was that confusion and fear of wearing the wrong ones resulted in neither pair
being worn. But, in essence, the reasons why some people with dementia refuse to wear their spectacles
were not answered by this study.
Missing and broken spectacles
A second problem was that of ‘missing spectacles’. Focus group participants caring for relatives at home
reported incidences of spectacles going missing, but this was more commonly associated with people living
in care homes.
My mother hides her glasses, hides everything. So that’s the problem with actually getting her to wear
her glasses. She’ll put them in socks, anything, in drawer. One pair we don’t even know where in the
world it might be, we’ve looked everywhere.
CFG 2.7
I think it’s about 2008 when she started having dementia. We actually noticed it because she wasn’t
eating. Also she’d seem to lose her glasses very quickly. And the ones which she’s had most recently,
they’ve gone, they’ve disappeared as well, even with her name on. And none of the staff, in the home
she’s in now, have got a clue where they are.
CFG 3.8
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Care workers identified missing spectacles as a major problem and again they felt that they were often
unfairly blamed. Just as CFG2.7 explained how her mother hid her spectacles, care workers described how
residents would hide spectacles or leave them lying around, or how a resident would pick up another
resident’s spectacles (one care worker reported finding 30 pairs in one resident’s room). Several care
workers explained that the company dispensing the spectacles marked them with the resident’s name and
sometimes whether they were for distance or near vision; still, they went missing.
Another problem, particularly in care homes, was the frequency with which spectacles were broken.
These two care workers summed up the difficulties they faced:
Oh, bane of our lives. If I could make a way for glasses not to go missing I’d be a rich person. It’s
either they get broken because they have them in their hands, sitting on them, they’ve put them
somewhere, or [they are removed by other residents]. You know they’ve got their names on and
everything but they just go, it’s just like they vanish for good forever and it’s like ‘but you only had
them on last night’. We’re not bad at it, but some glasses do go missing, I agree, and that’ll be in
every home, any home that says that they don’t, they’re liars.
CH interviewee 2
You see that lady? You’d open her bag and she’d have maybe five six, seven pairs of glasses, and then
you have other family members saying ‘where’s my mum’s glasses, she hasn’t had them on’ but you
can’t get in, it’s an intrusion to open that lady’s bag, you’ve got to do it discreetly, which can cause a
lot problems but yeah, it is a problem.
CH interviewee 10
Despite the difficulties of individuals refusing to wear spectacles and missing or broken spectacles, there
was general agreement that it was important for people to wear their spectacles, if they could be
persuaded to do so without causing distress.
The cost of spectacles
A considerable number of participants introduced the issue of the cost of spectacles. Although most of
these avoided express statements that spectacles were too expensive or overpriced, they said things such
as ‘the frames were £150 but you want nice frames’ (interviewee 2); ‘so by now, I’ve spent twelve
hundred pounds on glasses in 15 months’ (CFG 4.2); ‘I wouldn’t go to [optician’s name] because I ended
up with a pair of glasses which cost me £400 because they are experts at putting prices on’ (CFG 2.1); ‘to
keep spending out money for glasses that are never gonna come out the bag’ (CFG 3.6). A small number
of people overtly remarked on the deterrent effect of cost:
Researcher: Can I ask, why did you leave it for five years before having your eyes tested?
Interviewee 22: I never had the money. Fluctuating income.
Researcher: Does the cost of spectacles make you reluctant to have your eyes tested, in case you need
new spectacles?
Interviewee 22: Depends on your pocket. If your pocket is a bit low it makes you reluctant to go and
get your eyes tested.
Interviewee 22
It’s a big outlay, you know, if they’re paying three or four hundred pounds for a pair of glasses, it can
actually put you off going.
CFG 5.4
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Overall, the comments suggest that cost was not an explicit barrier to acquiring spectacles for most
participants, but the references to cost raise a question about the extent to which the cost of spectacles is
a concern for some people.
Spectacle dispensing
Two issues emerged in relation to spectacle dispensing: the factors that should be taken into consideration
when prescribing or dispensing, and a concern about unnecessary dispensing, particularly in care homes.
Several optometrists made the point that, to avoid confusion, it was better to keep things as they were as
far as possible and avoid unnecessary changes if new spectacles were required after an eye examination.
This meant not changing the type of lenses, for example moving from single vision lenses to varifocals, or
the style of frame. This view was echoed by family carers who illustrated the point with examples of
unsuccessful changes:
My wife, a couple of years ago she went, and they gave the prescription for her glasses, she normally
wears varifocals, and they gave her some reading glasses, they thought that would be better than
trying to use the reading part of the lens. She’s never used them, never used them at all.
CFG 3.4
We got some bifocals for my husband, he’d never worn bifocals before, and I thought well it’ll be
easier for him than switching. It was a complete disaster, he never wore them. And I feel that the
optician ought to have warned me that that was a bad choice.
CFG 3.2
Beforehand, my mum did wear glasses for short sight, for close work, not all the time, occasionally
when she really needed them, and then as she aged she obviously needed them more, and they got
to a point where she needed two pairs of glasses. At this point she was a few years into the dementia,
and that was hopeless, it was much worse than having one pair of glasses, because she could not
cope with the ‘which glasses’, she just couldn’t cope with the concept of two pairs of glasses. I think it
was because throughout her life it was ‘my glasses’, not ‘which glasses’.
CFG 5.1
Husband: My wife needs both reading and distance glasses and they said would you like to try these
varifocal things and we paid over £300 for a pair of those and you only used them for about a week
and you couldn’t get used to them at all.
Interviewee 3: Because the eyes aren’t the same and I couldn’t you know. It didn’t work, I couldn’t.
Husband: So we had to go back and get separate glasses for distance and reading which cost again.
Returning to the subject of whether or not all new dispensing is necessary, and the association with theme 2
(domiciliary eye care), care workers were asked about the procedure for ordering spectacles for care home
residents. If residents had capacity to make decisions and control their financial affairs, the decision was
theirs. If they lacked capacity, the need for new spectacles was referred to the family. Care workers did say
that there were instances, although rare, when families refused to make the purchase on the basis that the
spectacles were a waste of money as they would not be worn, would go missing or did not improve the
individual’s quality of life.
Despite this defined procedure for ordering spectacles, there were reports from some family carers of
spectacles ‘appearing’ even though the carer had not been consulted. It would appear that this could
happen only if the care home resident was eligible for free spectacles as this would remove the need for a
relative to agree but, as the next quotation demonstrates, this was not always the case.
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He went into a care home and his glasses disappeared for 5 weeks and that was because the optician
had been and taken away everyone’s glasses in order to get them new ones. Goodness knows who
consented to that exam. Then we took part in the study and he had his eyes tested. And then he
moved to another home where – surprise, surprise – I walked in one day and there was an optician
testing everyone’s eyes and getting people to sign the consent form for the exam. So I think some
interesting things go on. Ah, this is a money spinner! They tested his eyes, when he wasn’t due a test,
and provided two pairs of NHS glasses, reading and distance. And he wasn’t entitled to NHS glasses.
CFG 4.2
This was an isolated case but may be the sort of incident that a couple of optometrists had in mind when
they expressed fears that dispensing in care homes was open to exploitation.
The thing is, something’s gone wrong when the actual prescribing rate is higher than the national
average. And something has also gone wrong, because, if anything, I actually prescribe less. When
people just go in and they change the glasses time after time after time, I am suspicious that there
is something.
OFG 5.3
The companies I’m talking about, give glasses every year because they [can’t see the old ones] so they
find something or they use the last time records, and they give new glasses, and they’re all sat in a pot
in the office, because they’re not worn.
OFG 5.5
Theme 4: cataracts
Although cataract is only one of the conditions that can cause VI, it is extremely common . As the results
of stage 1 suggest, a large percentage of people with dementia will develop a cataract. Therefore, the
effect and treatment of cataracts was discussed with every participant set.
The topic of cataract was discussed during the interviews with people with dementia. They were asked if
they would agree to surgery if they developed a cataract that progressed to the stage of causing VI. Nearly
all interviewees said that they would. Several of the interviewees had already had cataract surgery and
reported successful outcomes.
Family carers were, similarly, asked for their views on their relative having cataract surgery if this was
advised. In principle, carers supported surgery if they thought that it would have a positive effect on their
relative’s life. However, they expressed concerns about how their relative would react, physically
and emotionally.
I think we would probably say ‘yes’ but I think we would ask the question ‘is it worth the upheaval’
because we know it would be quite an upheaval and distressing for her when any big event is
coming, whether it’s good or bad, she focuses on it a lot.
CFG 1.2
But would they understand what was happening? That’d be my worry.
CFG 2.7
I’ve only got reservations because of her health. Her physical health.
CFG 3.9
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Is it worth doing it? You’d have it done if you felt it was worth the risks and her going through it,
otherwise I don’t think that I would put her through it. And she’s 85 and has other medical issues
going on anyway. Doesn’t become top of the list, then.
CFG 2.2
Family carers also queried whether or not there would be any complications arising from surgery and their
relative’s ability to cope with pain, eye drops and dressings. The comparative drawbacks of local and
general anaesthetic were also raised, with concerns expressed about both. The following exchange
between two carers illustrates how they weighed the benefits against the risks as applied to the individual.
CFG 4.5: My dilemma is, I don’t think Mum is distressed about it. When she went for the eye test, the
guy was quite amazed by what she could read with the cataracts that she did have, but reading is just,
it’s just nothing to her so I don’t think she’s distressed by them so is it worth the distress of going to
the hospital having the bandages and all that trauma?
CFG 4.6: In a slightly alternative interpretation of that, it would be the distress [my wife] would
experience if she couldn’t do it, rather that the distress she’s currently experiencing, because if she’s
constantly questioning me ‘why can’t I see out of this eye, why can I see better here and not here,
why can’t I, I can’t see that’ you know?
Care workers were more hesitant about supporting cataract surgery, reflecting the fact that most of the
residents they cared for had reached an advanced stage of dementia. They identified the same potential
barriers but thought that the ability to cope would be compromised by the levels of cognitive impairment.
They described the challenging behaviours displayed by some residents and how they thought this would
impact on the ability of those residents to tolerate surgery.
If they’ve advanced dementia, to send them out to the hospital to have an operation would be too
traumatising for that person; they’ll be totally traumatised and it’ll last for days and it’s not worth it
sometimes, it’s too traumatic for them.
CH interviewee 4
There’s no cure for dementia, it’s just going to get progressively worse and so you would think that if
there was some way that you could improve their life, not through the dementia but like improving
their eyesight, you would think well, you know, you’d want to sort of go for it. But that person would
be under a lot of stress, depending on what their understanding of what was going on. Going into
hospital they’d be under a lot of stress, it would be a lot of pressure for the family as well, and then
afterwards there’s the recovery, and everything so it’s a very difficult decision to make, and I really
don’t know. Your automatic thing is ‘if it improves them have the operation’ but it’s not as black and
white as that. When they get to a certain stage of the dementia, they’d lose the understanding of
what you’re saying to them and then they’re suddenly taken away and in this hospital, they would be
so frightened upset, it would just be awful.
CH interviewee 8
Prior to the start of the study, the research team piloted the focus group questions with carers at a
dementia conference. They raised an interesting question with regard to performing cataract surgery at an
earlier stage for people with dementia. That is to say: if a person has a cataract that has not progressed to
the stage of needing surgery, and then that person is diagnosed with dementia, should they be offered
surgery before the cognitive impairment progresses to the state at which capacity to consent is lost or the
ability to cope with the demands of surgery is compromised? When this was raised with carers and care
workers, they agreed that early intervention would be a better option than having to address capacity
issues that may arise from deferring the surgery to a later point in time.
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I think it’d probably be better to do it early on, if possible.
CFG 1.1
I think if someone is naturally anxious, I think it would be much better for them to have something
done at an earlier stage.
CFG 1.5
At the moment, that’s where we are, the cataracts aren’t ripe and my dad can’t read, and he loves
reading, so we’re kind of a bit stuck until they’re ready to be taken out. It’s really crucial to try and get
resolved while he is still quite able to do things.
CFG 2.6
Take it off there and then. It’s not rocket science!
CH Interviewee 2
Yeah, definitely. It’s the better of the two options isn’t it.
CH Interviewee 8
When the same question was put to optometrists, their reaction was mostly one of surprise, suggesting
that this was not something they had previously thought of. But as they talked through the advantages
and disadvantages of early intervention, the majority came down in favour of early intervention. Discussing
scenarios in which people developed a cataract at a later stage of dementia, optometrists debated the
benefits and risks of surgery, citing the same factors as carers and care workers.
The impact of cataracts versus surgery on quality of life was another topic of discussion, and this is
addressed in Theme 6: quality of life.
Theme 5: improving the eye care of people with dementia
This theme emerged from discussions about the following:
l optometrists’ skills and training needs
l the development of the specialist practitioner
l revision of the examination fees structure.
Optometrists’ skills and training needs
Theme 1 included problems associated with conducting an eye examination. This gave rise to discussions
about the extent to which members of the optometry profession were confident and competent to provide
eye care for people with dementia and how they could be helped to improve their skills and knowledge.
Asked about how they felt about their personal clinical skills, optometrists said that they needed more
information about dementia to improve their understanding of the patient’s experience and how to adapt
their procedures, and provide them with insight into the ethical-legal aspects of consent and capacity, as
the following examples demonstrate.
It’s not just the testing, I think maybe we do need to know more about how dementia affects patients
so it’s not specifically to do with their vision. I was reading last night about peripheral awareness and
to do with visual hallucinations similar to Charles Bonnet Syndrome but connected to the dementia.
Now, to be honest, that’s not something I really would ever have considered until I was reading it
last night.
OFG 1.1
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I think a lot more information about dementia and what patients with dementia are going through
would be useful. A way of adapting your routine, or ways of thinking, processes involved, would be
very useful. It would not only open the optometrist’s mind to what the patient is experiencing, but
also give us avenues to experience to empathise better with the patient. I think that’s very important.
OFG 3.1
I think the issue of consent is a big thing really, understanding. I think from a training point of view
from optometrists we don’t really have training on what consent is, and valid consent, and informed
consent and power of attorney.
OFG1.4
They discussed the different ways in which training could be provided, and their preferences were for
interactive methods such as peer review, workshops and talks from people involved in dementia care
rather than distance learning materials. However, the general feeling was that skills and confidence were
best developed through experience: exposure to people with dementia but with access to peers and
mentors who could guide and advise.
Maybe that’s where our peer review training comes into it, dementia cases as part of the case
scenarios. And maybe for young practitioners, encouraged to ask more experienced practitioners
‘I had this really difficult patient the other day, what do I do when they won’t press the button on the
visual field machine’, feeling the courage to say, to admit, that ‘we didn’t know what to do in that
circumstance, what does everyone else do?’. And I think that’s where the peer review, or maybe
mentoring, over and above the pre-registration year, would be really useful, to have someone pick up
the phone and say ‘oh gosh, what did I do’. And our young practitioners don’t have that. They don’t
have anyone to go to.
OFG 4.5
It all comes down to exposure to these patients and experience. And, the more you do, you know, the
more you learn. So you can’t, you can’t get away from the fact that you need to constantly be honing
your skills, with this group of patients, if you want to get better.
OFG 3.4
The Outside Clinic’s optometrists explained how their confidence and competence quickly built up through
experience, but they had more exposure to people with dementia than did the average high-street
optometrist. The clinical governance procedures and supervision for new optometrists operated by the
company also meant that, when they first started work, they had opportunities to ‘shadow’ more
experienced optometrists. The importance of such opportunities was discussed by optometrists in other
groups who talked about the need for supervision and some form of mentorship.
Development of the specialist practitioner
A second suggestion to improve services was to explore the potential for developing a specialist
practitioner role, someone not necessarily limited to working with people with dementia but who would
specialise in older people. This could accommodate eye care for many people with dementia because
the prevalence of both dementia and the major eye conditions causing VI increases with age. They
acknowledged that work was needed to explore the feasibility of this role, including assessing how many
practitioners would be needed, what training would be required and if sufficient professionals would be
interested in this type of role.
An alternative suggestion was to develop a community eye health service in the NHS, rather like
community dental services, with salaried optometrists. This linked into the next area that optometrists
thought needed attention: the service structure around examination fees.
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Revision of the fees structure
The need to allow more time when examining people with dementia was identified by all participant
groups. In the interviews with people with dementia, perceptions about what constituted good practice
were often associated with the optometrist taking time. Family carers raised the need for the optometrist
to allow time to involve them and care workers commented on the number of appointments that were
completed in a session, and wondered if sufficient time was allowed for each examination:
You feel as if, it’s rushed because there’s so many, or even when there’s that few, if you know what I
mean, they probably don’t get the time that’s needed, in all fairness.
CH interviewee 3
Researcher: So they get through 20 [residents in a session]?
CH interviewee 5: Yes, they whizz through, yeah.
Researcher: They whizz through? OK, tell me about that . . .
CH interviewee 5: Make of that what you will.
CH interviewee 5
There was broad agreement from optometrists that examining a patient with dementia can take more time
than examining most other patients, and that appointment scheduling, particularly in large or busy
practices or multiples, does not allow for this.
I think they have special needs. And quite often, they need more time than any other patients that we
see. And somehow with the present system of one size fits all, it doesn’t really work . . . there’s more
to think about before we have a final solution there but it’s quite obvious that to give the proper level
of care, we need to give them the proper level of our time.
OFG 3.4
Despite the time constraints of ‘the system’, optometrists discussed ways to overcome the lack of time.
‘Over-running’ – taking longer than the scheduled time – can have a knock-on effect for the rest of the
schedule, affecting patients and staff, and the only alternative is to prepare for this. One suggested
approach was to book a longer or double appointment. Some optometrists said that they did this, but
others identified two difficulties. The first was anticipating the need if the patient was not previously
known to the practice as someone with dementia. The second difficulty concerned funding. Although
some optometrists said that they or their practices were prepared to absorb the cost of a longer
appointment, this was not the case everywhere, hence the necessity to review the fees structure to meet
patient needs:
Something needs to be done about that at a higher level, at an NHS level, where we can get proper
remuneration for looking after these people properly, because it’s completely unfair on the patient
that they have to be whacked through when they’re going, the majority of them will probably be
going, to the big opticians because the majority of patients are being seen by them and 20 minutes,
if they’re lucky 30 minutes, that’s no way enough. No way.
OFG 4.3
STAGE 2 RESULTS
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Another suggestion was that, on some occasions, it may be desirable to bring the patient back for a second
appointment to complete the examination and prescribing. The next quotation summarised this well:
Taking your time with [the examination] is a double-edged sword, because sometimes if you take too
long, you lose their concentration. There is a delicate balance of making the patient comfortable, but
also getting through what you need to do. I’ve often found that sometimes it’s easier to do it in
chunks and get them to come back, for little visits, rather than doing it all in one sitting. Having a
couple of visits, tends to make them a little bit more familiar with the environment that you’re in, and
more approachable. So the fear factor tends to reduce, the second or third visit, and then you find you
can do more, with them, at that point.
OFG 3.1
Again, the issue of funding was raised as a consideration when scheduling multiple appointments,
but optometrists described this as something that should be overcome rather than remaining an
insurmountable barrier.
There must be somewhere in the system, that allows, in special cases, to get those patients back again
if you haven’t got the right . . . level of information to make a decision.
OFG 3.4
Theme 6: quality of life
The inter-relationship of vision/VI and dementia and the impact on quality of life was a thread that ran
through all themes but emerged as being of such significance that it merits separate explanation.
As this chapter has shown, dementia can impact many aspects of eye care: the ability to complete an eye
examination, wearing spectacles and decisions about cataract surgery. Asked about the importance of
regular eye examinations, all parties agreed that it was desirable to complete at least some form of health
check and ideally a complete eye examination with the aim of identifying and correcting any loss of vision.
As one optometrist succinctly said, ‘confusion and visual impairment, is a much worse combination than
visual impairment on its own’ (OFG 4.5). A second optometrist pointed out that ‘the combination of visual
impairment and dementia is a difficult thing and leads to further deterioration in dementia’ (OFG 5.2).
Similarly, there was agreement that people should be provided with spectacles of the correct prescription,
fit for purpose, and encouraged to wear them wherever possible, but this was said against a backdrop of
an acknowledgement that ensuring that someone wore their spectacles was not always achievable.
Carers eloquently described the importance of vision for relatives with dementia:
Eyesight is so precious and if somebody’s life is being impacted upon so dramatically with Alzheimer’s
or dementia, I think to have the additional thing of going blind would be awful. For my mind, I think I
would want them to have as much done as possible to keep them as healthy as possible so they can
enjoy doing what they can enjoy.
CFG 1.5
My wife’s been an avid reader all her life and given that she has no short-term memory, this is really
part of some of the remnants of who she really is and reading is instinctive with her. I explained
before, how painful it would be to her not to be able to see. It doesn’t matter to me that she’s still
reading the book that she’s been on for the last 18 months, and she can be anywhere in it on any
day, but the fact is, that satisfies her, that pleases her, that fulfils something in her, to be able to
do that.
CFG 4.6
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Many of the optometrists in the study recognised the importance of carer perspectives on what was best
for the individual. For example:
And I think that’s really interesting for optometrists to hear the carers’ perspective, as well, because,
again it’s about that hearing the patient’s life isn’t it? It’s easy for me to say that because I’ve got a
good understanding of what’s impinging on his world. But I do think you’ve got to listen to the carers
and see what is impinging on the world, what really will make life better for them, for the person that
they’re living with.
OFG 5.1
The collective comments of focus group participants described how, as the level of cognitive impairment
increases, care becomes more complex. Carers, care workers and optometrists all talked about the pros
and cons, the risks and benefits, the advantages and disadvantages of intervention in the context of the
underlying question: ‘what would be best for the individual?’. The answer was not as simple as saying that
there is a certain level of cognitive impairment at which stage there would be no point in performing an
eye examination or providing spectacles.
Quality of life was also a major factor in respect of decisions about cataract surgery. As previously
described in theme 4, family carers thought that surgery would be worthwhile if it had a positive effect on
their relative’s life, but they had concerns about how their relative would react, both physically and
emotionally. The quotation below is lengthy but provides a case study of what happened with one lady
who was found to have cataracts, described by her daughter, CFG5.1:
There was no suggestion of doing anything about it when I had previously spoken, about a year,
18 months beforehand to the optician. He said ‘well, it’s not, she might not be able to lie still enough
to have the operation’, he was sort of saying it’s not a good idea to have this dealt with and at that
point it wasn’t so bad. Up to the present date, she’s virtually blind, her glasses make no difference
whatsoever, she’s not particularly interested in the television. She has a notepad and it’s a bit like her
comfort blanket to be honest, her notepad and her pen, and she does a little word puzzle, very
simple, but this is what she does, and everybody knows that mum goes around with her notepad and
she asks for it all the time, and now she can’t see to write, at all. And it’s just making life so terrible,
it’s completely changed everything. She’s anxious because she can’t see and because she hasn’t got
the comfort of this little activity that gave her some purpose, she’s upset, you know . . . Well, up to
date, things have now moved on. Because at the memory clinic test, after that I spoke to the nurse
who came and told her about mum’s eye problems, she then got in touch with me shortly after that
and said ‘would you like to be part of the study’ and I said ‘well if it’ll help mum in any way, yes’.
So now down the line, we’ve had The Outside Clinic come and test her eyes again and through that
she’s been referred to the hospital, we’ve seen the consultant ophthalmologist, who was absolutely
brilliant, you know, exceeded my expectations, and mum’s on a waiting list now to have the cataracts
removed. She’s going to have them removed under general anaesthetic, for two reasons, because she
has a head tremor and also she’s got very bad osteoporosis so she’s got a big curvature of the spine,
and so the consultant suggested that it would be better to do them both in one go under general
anaesthetic, and I couldn’t have asked for anything, a better solution than that. It hasn’t happened
yet, so I can’t tell you what the final outcome is, and the waiting time’s been longer than I thought
it would be, but I’m hoping in a couple months, another couple of months which will be about
6 months after her original consultation, I’m hoping it’ll be done. Which will be the best outcome we
could have really. And I’m hoping that it’ll restore her sight for her to be able to do what she wants to
do. The other thing which the consultant suggested, which is brilliant and shows some thought about
mum’s situation, is that she suggested putting in the new lenses so that she can see to read without
glasses. What she will need is one pair of glasses for distance, which is fine, that’ll mean you know
when she just goes out with me in the car, we take her anywhere we can take the glasses and she’ll
hopefully be able to see her surroundings. But to actually have eyes that work, to do what she needs
to do most of the time, it’ll be fantastic, and it will make a huge difference to her.
CFG 5.1
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The daughter telephoned the CoO a month later; because she had talked about the events leading to her
mother’s planned surgery in the focus group, she wanted to provide an update. Her mother had
undergone the surgery 2 days earlier. The daughter had visited her mother, who was thrilled with the
result because she could see again. The daughter stated that her mother appeared to have improved
cognitively and emotionally and felt that the decision to proceed with surgery, despite fears, had been
completely justified by the outcome.
Summary
Using the qualitative methods of interviews and focus groups, stage 2 explored issues relating to eye care
for people with dementia from the perspectives of people with dementia, carers and optometrists.
People with dementia and their carers (familial and professional) were aware of the importance of eye
examinations and the benefits of correcting VI, where possible, with spectacles or cataract extraction.
The data suggest that most people with dementia had regular eye examinations, but significant cognitive
impairment as the dementia progresses can present challenges. All parties described situations that could
have been improved by optometrists having greater awareness and understanding of dementia or by
better communication between optometrists and the person with dementia and their carers.
Domiciliary eye care provided by optometrists with experience of caring for people with dementia was well
received and appreciated by study participants and is one option for overcoming some of the difficulties
described by some carers. Yet most people with dementia living in their own homes (and their family carers)
were unaware that they were eligible for this type of eye examination. Conversely, in care homes, domiciliary
eye examinations are the predominant form of eye-care provision, but this elicited some concerns about
uniform application of procedures and the potential for the system to become underefficient.
The wearing of prescribed spectacles and intervention for cataracts are the two most common forms of
correction for VI and their value is equally important for people with dementia as for the general
population. However, significant cognitive impairment can lead to individuals becoming reluctant to wear
their spectacles and ethical issues arise with regard to capacity to consent to treatment. There were
understandable and well-argued concerns put forward regarding the pros and cons and the benefits and
drawbacks of intervention and balancing these with achieving optimum quality of life.
Suggestions for improving eye-care provision for people with dementia included more training and
awareness raising of optometrists, reviewing the current fees structure which can militate against
optometrists providing eye examinations in the best way for individuals, and improving communication
between optometrists and carers.
Appreciating the value of multiple perspectives is a key feature of this stage of the study, and the
difficulties, problems or limitations perceived by one set of participants were often shared by the other sets
of participants. However, each participant approached the topic through their personal situation: as
someone in receipt of eye care (people with dementia), someone supporting the eye care of individuals
(carers and care workers) or someone providing eye care (optometrists). Theme 6 demonstrates the
importance of sharing and understanding these various perspectives to improve the quality of life for
people with dementia.
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Chapter 5 Discussion
This chapter discusses key findings from the combined results of stages 1 and 2 in relation to the studyobjectives and existing related research. The mixed-methods approach to data collection – prevalence
data from eye examinations and qualitative research from focus groups and interviews – allowed the
research team to investigate a comprehensive set of objectives as set out below.
Objectives
The four primary objectives of the study were:
1. to measure the prevalence of a range of vision problems in people with dementia
2. to compare the prevalences found in objective 1 with the published data on the general population in a
comparable age range
3. to identify and describe reasons for any underdetection or inappropriate management of VI in people
with dementia
4. to recommend interventions to improve eye care for people with dementia and further research in
this area.
The secondary objectives of the study were:
1. to identify any differences in the level of undetected or inappropriately managed VI between those
living in their own homes and those living in care homes
2. to determine estimates for the percentages of those with dementia likely to be able to perform
successfully elements of the eye examination
3. to relate vision problems in people with dementia with data from functional and
behavioural assessments.
Before discussing the study findings, it is appropriate to highlight the strengths and limitations of the study.
Strengths of the study
The sample is broadly representative of the overall dementia population aged ≥ 60 years in England, in
that it encompasses a wide age range, both sexes, people living at home and in care homes, and
participants who were recruited from several regions. The study is notable in that VI in people who have
cognitive impairment has rarely been investigated in the UK, an exception being the NDNS study57 in which
just 8.4% of the sample had cognitive impairment. The high proportion of care home residents in PrOVIDe
(44%) permitted comparison for many parameters between those living in their own homes and those
living in care homes. There are very limited modern data on VI in care home residents. Residents of
care homes were included in the NDNS study, constituting 23.8% of the sample.57 Another UK study
included a ‘small’ proportion of care home residents.44 Otherwise, they have been either excluded56 or
not identified.27,58,59
Data were collected by skilled optometrists with particular expertise and experience in domiciliary eye care
and in working with people with disability. This contrasts with other major VI studies in which data were
collected by non-eye-care professionals.56,57 The quality of data was also enhanced by the optometrists’ use
of equipment appropriate to domiciliary settings. This equipment is available to all UK optometrists but
evidence from focus groups suggested that not all optometrists use this standard of equipment in a
domiciliary setting.
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Unusually for UK population studies of VI, a full optometric eye examination, including the determination
of refractive error, was carried out in PrOVIDe. This made possible the measurement of VA post refraction
with participants wearing their up-to-date spectacle prescription, which allowed the assessment of the
prevalence of presenting VI, post-refraction VI, and uncorrected or undercorrected VI.
PrOVIDe also measured NVA and distance VA, whereas most UK studies of VI have been limited to the
measurement of distance VA.27,44,56,57 Near vision is an important aspect for many older people, and in
PrOVIDe NVA was measured with the participant wearing their current near spectacles (if any) and
measured again post refraction with the participant wearing their optimum near vision prescription
determined by the optometrist. Recording near VAs is a recommendation in Standards for Reporting and
Measurement in studies of VI prevalence.45 The only previous study reporting NVAs dates from the 1980s.59
Optometric data were supported wherever possible by data on the degree of cognitive impairment,
using sMMSE, and data on participants’ functional and behavioural state using the BADLS and CBI-R.
This allowed the study to consider the person with dementia as a whole.
The qualitative stage of the study involved people with dementia, their family carers, professional care
workers working in care homes, and optometrists; this generated insights from different perspectives on a
range of aspects of eye care. The overall number of stage 2 participants was 119, a considerable sample
size for a qualitative study.
Limitations of the study
Sampling bias is possible owing to quota-sampling and response bias. In group 1 particularly, it is likely
that some volunteers and/or their carers were more health-orientated than the general population.
In addition, the PrOVIDe regional sample may not be fully representative of the general UK population.
It is a strength that the stage 1 sample of over 700 participants represented a wide spectrum of people
with dementia in terms of age, cognitive impairment and setting, and the sample size was sufficiently
powered to meet the primary objectives. However, there was no specific intention to sufficiently power the
sample sizes of groups 1 and 2 to enable detection of differences between groups, nor of associations of
VI with age, sex or cognitive impairment. It was also acknowledged at the design stage that the sample
size would not allow for comparisons to be made on the basis of ethnicity. However, participants were
recruited from a range of demographic areas to encourage a heterogeneous population.
A considerable proportion of VA assessments (≈17%) and sMMSE assessments were not available
owing to a range of factors, notably poor participant co-operation, and this proportion varied across age
(≈9% to 26%) and between groups 1 (≈3%) and 2 (≈33%). Unavailable VA and sMMSE assessments
are likely to come from patients with lower VA and greater cognitive impairment. Findings from
‘complete-case’ adjusted analyses will not suffer from any bias if sufficient covariates are included and
missing data are ‘missing at random’, whereas those from unadjusted analyses will be somewhat biased in
this likely case. However, given that the proportion of missing data is higher in group 2 and increases with
age, this is likely only to underestimate the negative association of these factors on VI, that is, leading to
conservative findings. On the other hand, as discussed in Chapter 2 (see Stage 1 Data analysis plan,
Missing data plan), different study outcomes would be missing in different participants and for varying
reasons, which may lead to some inconsistency in our separate analysis of each study outcome.
Complete-case analysis also leads to less efficient estimates, because it does not use the partial information
available on participants. Notably, it may lead to bias if the causes of missing data are not fully explained
by the covariates in each model, which is likely as our regression models only adjusted for age, sex, sMMSE
(where appropriate) and location.
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To improve the plausibility of our regression analysis assumptions, a multiple imputation procedure was
carried out, with the results discussed in Chapter 3 (see Missing data sensitivity results). There were no
changes in the substantive conclusions relating to our key tables, Tables 11, 15 and 24, under the
imputation model compared with the complete-case analysis.
There is a small risk that participants with VI were systematically underscored in the sMMSE because of
their inability to complete 10% of the items that require visual input, thereby receiving a lower score.
A rudimentary sensitivity analysis was performed modelling both sMMSE scores and MMSE blind scores,
and this showed no change in the conclusions regarding the relationship between either sMMSE or MMSE
blind and age, sex, VI and group. Further work to calibrate the modified MMSE blind scoring system with
that of the sMMSE could more thoroughly address this issue.
Monocular VAs were recorded at both distance and near, both before and after the refraction. Binocular
VA was recorded post refraction for distance vision for the majority of (62%), but not for all, participants.
There is wide variation in the methods used to record VA in previous studies (e.g. best monocular VA,
binocular VA, best monocular pinhole VA, binocular VA when available and best monocular when not,
etc.). For comparison of VI prevalence with published studies, best monocular VAs have been used, as
these were recorded both before and after refraction for virtually all PrOVIDe participants in whom VA
could be measured. When PrOVIDe prevalence data are compared with studies that measured binocular
VA, this makes comparisons less robust.
The Outside Clinic has robust quality control mechanisms regarding record keeping, etc. (see Chapter 2,
Data collection, Stage 1). Every record card was checked by the project manager and any concerns
regarding the data collection were raised with the relevant optometrist. However, there were no additional
internal quality controls regarding the results of the eye examination. No internal checks have been
reported in other UK population studies investigating VI apart from the MRC trial,56 in which the trained
nurses recording VA received regular quality control visits.
The slit-lamp biomicroscope is normally a bulky table-mounted piece of equipment unsuitable for
domiciliary use. A number of cataract grading scales are used in research studies;98 however, these require
the use of a slit-lamp. Optometrists carrying out a domiciliary eye examination normally detect and grade
cataract using a hand-held direct ophthalmoscope. Hand-held ophthalmoscopes were used in PrOVIDe,
and cataract was graded using the published but unvalidated cataract section of the Optometric
Grading Scale.99
The causes of VI in the PrOVIDe sample have mostly been identified by the examining optometrists, and
not definitively made, or confirmed, by an ophthalmologist. This limitation was inherent to the study
design. The accuracy of optometrists’ diagnoses of eye conditions has been investigated; cataract, alone or
with other conditions, was correctly diagnosed in almost 95% of cases.115 For retinal disease, which
includes AMD and diabetic retinopathy, the conditions were correctly diagnosed in > 70% of cases.49,115
Accuracy of glaucoma diagnosis by optometrists is lower, at around 30% of cases.116 However, glaucoma
had already been diagnosed in almost 85% of cases in PrOVIDe and was confirmed by the participants’
glaucoma medication or evidence of glaucoma surgery. The remaining cases were based on the
assumption that 50% of those referred as suspects would have the disease. A detection rate of 50% was
chosen rather than 30%, as the prevalence of glaucoma increases with age, from 2% of those aged
> 40 years to almost 10% in those > 75 years old.117
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Prevalence of visual impairment
Methods of recording VA in previous studies vary between Snellen and logMAR; research settings vary
with some VA measurements taken in participants’ own homes and some in dedicated clinics; some
studies use best monocular VA to define VI while others use binocular VA; age profiles of the samples
vary; some studies exclude those living in care homes, and so on. These factors must be borne in mind
when comparing PrOVIDe prevalence rates for VI with other studies. Two studies, the NDNS and MRC,56,57
provided sufficient details of participants’ age, sex and, in the case of the NDNS, location in either their
own home or residential care, to facilitate reweighting of the estimated rates of VI in PrOVIDe to allow
statistical comparison between rates of presenting VI for distance vision.
Presenting visual impairment
Using the VI prevalence criterion of best monocular VA < 6/12, the overall prevalence in PrOVIDe was
32.5% (95% CI 28.7% to 36.5%) for VA < 6/12. The lower age limit for comparable UK studies is usually
65 years and, when adjusted to exclude participants aged 60–64 years (see Table 8), the VI prevalence
increases to 33.5% (95% CI 29.6% to 37.5%).
A prevalence of 28.3% is quoted in the best comparator data from the NDNS study,57 a national study
which also used best monocular VA data, with a sample aged ≥ 65 years. The reweighted PrOVIDe
prevalence estimate was 23.7% (95% CI 20.0% to 27.7%) compared with our estimate of 17.9%
(95% CI 15.6% to 20.4%) for NDNS for participants in each study aged between 65 and 85 years,
suggesting a meaningful difference between these populations, although there is only weak evidence to
discount no difference between prevalence rates. There are several possible explanations for this difference
in prevalence rates between PrOVIDe and NDNS. VA measurements in NDNS were recorded by trained
nurses rather than by optometrists, ophthalmic nurses or ophthalmologists and some VA measurements
were obtained using a pinhole. VA was recorded in the participants’ place of residence, and standardisation
of lighting conditions was not possible. Although the fieldwork during which VA was assessed was
conducted in 1994/5, so approximately 20 years before PrOVIDe, the NDNS has the strength of being
a truly nationally representative sample from a random sampling frame of over 20,000 addresses from
799 postcode sectors across the UK. Cognitively impaired participants were excluded from this NDNS
estimate of VI prevalence, although their data were presented separately for the VA < 6/18 cut-off point
and are discussed below. Therefore, this comparison between prevalence rates in PrOVIDe and NDNS is
between a sample with dementia and a sample in which subjects ‘classified as mentally impaired by a
memory test’ were excluded.
Other UK studies in this age group found prevalences of 14.5% (95% CI 10.3% to 20.0%),58 30.2%
(95% CI 24.8% to 35.5%)27 and 50.5%.44 All three studies were local in their setting and insufficient data
were provided to allow reweighting of PrOVIDe prevalence rates to permit direct comparison between
their estimates and those of PrOVIDe. In addition, these studies range from 17 to 33 years old.
The prevalence figure of 50.5% from Jack et al.44 is often quoted and was based on a sample with a
similar age range to that of PrOVIDe (≥ 65 years) and which contained a small but unstated number of
participants living in care homes. Their study sample was small (n= 200) and comprised a selective
population of patients admitted to a department of geriatric medicine with acute illness, and was
unrepresentative of older people in general. Snellen VA was recorded, with the last line read correctly
taken as the participant’s VA. These factors, notably selection bias, seem likely to have contributed to the
high prevalence of VI reported in this study.
The large-scale MRC national trial in the 75–89 years age group reported a lower prevalence of 19.9%
(95% CI 17.8% to 22.0%),56 but the study excluded those living in care homes. The reweighted PrOVIDe
prevalence estimate was 28.7% (95% CI 21.3% to 37.4%) compared with 18.0% (95% CI 14.5% to
21.5%) for the MRC study for participants in each study aged between 75 and 89 years who were living
in their own homes. There is some evidence of a difference between prevalence rates, suggesting a
meaningful difference between these populations. Again, in the MRC study VA was recorded by trained
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nurses who may not be as reliable as optometrists in their measurements. Most of the MRC fieldwork
(99.7%) was conducted between 1995 and 1998, at least 16 years before the typical date of
PrOVIDe assessments.
Using the prevalence criterion for VI of the best monocular VA being < 6/18, the overall prevalence of
presenting VI in the PrOVIDe sample was 16.3% (95% CI 13.5% to 19.6%). For those aged 65–89 years
the prevalence of presenting VI was 16.7% (95% CI 13.8% to 20.1%). A prevalence of 14.3% is quoted
in the NDNS.57 The reweighted PrOVIDe prevalence estimate was 11.9% (95% CI 8.5% to 16.3%),
compared with our estimate of 7.4% (95% CI 5.9% to 9.2%) for NDNS for participants in each study
aged between 65 and 85 years, again suggesting a meaningful difference between these populations,
although there is only weak evidence to discount no difference between prevalence rates.
Wormald et al.58 reported a prevalence of 7.7% (95% CI 4.5% to 12.2%). However, although the paper
notes that participants were a random sample of those aged ≥ 65 years from a large GP practice register,
the age and sex breakdown of the sample or of the register is not presented. In addition, only 8.2% of
Wormald et al.’s sample was examined in their own homes, and the prevalence of VI among this subset
was 41%. As a result of these factors, no substantive comparison with PrOVIDe can be made.
In the small subset of the NDNS sample (n= 125) who had cognitive impairment, 64.8% had VI.57
The authors noted that it is unclear to what extent cognitive impairment affected the VA measurements,
which were recorded by nurses.
When comparing group 1 with group 2, using the 6/12 criterion the unadjusted rate ratio of presenting VI
among those in care homes was almost two-and-a-half times greater than for those living in their own
homes (51.4%/21.8%). For the 6/18 criterion, the unadjusted rate ratio of presenting VI for group 2 versus
group 1 was similar (26.4%/10.6%). There was a statistically significant group difference for both criteria
after adjusting for age and sex (p< 0.001). One possible explanation is that those living in their own
homes have more regular eye examinations; however, those living in residential care had a 22% reduction
in the time since their last eye examination compared with those living in their own homes and there was
an increased probability for a shorter interval between eye examinations for those in residential care
compared with those living in their own homes (see Chapter 3, Eye examination data, Time elapsed
since last eye examination). People living in care homes often have multiple comorbidities, which could
increase their risk of developing eye conditions. Similar unadjusted rate ratios of presenting VI in care
home residents and those living in their own homes were found in the NDNS for the 6/12 criterion
(56.8%/22.4%), with an even greater ratio for the 6/18 criterion (35.6%/9.9%).57
Previous studies of care home residents have reported high prevalence rates of vision problems both in the
UK118 and in Australia.119 It has been suggested that VI may be a contributory factor to older people being
placed in care homes.57
In summary, approximately one in three of the PrOVIDe sample had presenting VA < 6/12 and one in
six had presenting VA < 6/18. Prevalences of VI are generally higher in the PrOVIDe dementia population
than in comparable studies of older people that exclude or have lower proportions of participants with
dementia. Based on unadjusted rate ratios, presenting VI was approximately two-and-a-half times more
common in those living in care homes, and a clear, higher rate of VI existed for those living in care homes,
even after controlling for age and sex differences.
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Uncorrected or undercorrected visual impairment
For some PrOVIDe participants with presenting VI, VA improved sufficiently with the spectacle prescription
found during the eye examination that they were no longer classed as visually impaired. These participants
had uncorrected or undercorrected VI, for which there are few robust UK prevalence data and none in
older people with cognitive impairment. One UK study included the determination of refractive error by an
optometrist,59 but the prevalence of uncorrected/undercorrected VI was not reported. Another obtained
autorefractor measurements on participants27 but VA does not appear to have been recorded with the
participant wearing the spectacle prescription determined by the autorefractor. In a third study,44 a full
refraction was performed on a proportion of those with VI, but the number is not stated.
In studies where the improvement in VA that can be produced by an up-to-date spectacle correction has
been investigated, the post-refraction VA has usually been estimated from the best pinhole VA recorded
monocularly.27,56–58 Based on this estimate of post-refraction VA, and knowing the presenting VA for each
participant, the prevalence of uncorrected or undercorrected refractive error can be estimated. The pinhole
disc has been used in most of the comparator studies on VI in older people. The theory supporting its use
is that if the participant’s loss of vision is the result of an out-of-focus image on the retina (which should
be correctable with the appropriate prescription in the participant’s spectacles), then the pinhole can
improve the participant’s vision by reducing the size of the blur circles on the retina. If the loss of vision is
purely due to some pathological cause, such as AMD, then the pinhole should not improve vision.
However, the pinhole has several limitations. It reduces the illumination of the image on the retina, which
can impair vision. Furthermore, in a patient with cataract or other ocular media anomalies, the pinhole can
be aligned with a ‘tunnel’ of clearer vision in a lens with cataract, which leads to an improvement in vision
through the pinhole. However, when the pinhole is removed any attempt by the optometrist to achieve
the same level of vision with the normal pupil size may fail owing to scattering of light through the more
opaque portions of the lens.11 Older patients in general, and particularly those with cognitive impairment,
may have problems with use of the pinhole. This is evidenced by the statement in the paper reporting the
MRC study56 that ‘use of the pinhole was not straightforward in this elderly population and only 62% of
people with visual acuity less than 6/18 in either eye completed a pinhole test satisfactorily’.
Using the VI prevalence criterion of best monocular VA < 6/12, the overall prevalence of uncorrected or
undercorrected VI in the PrOVIDe sample was 14.3% (95% CI 11.7% to 17.5%) for VA < 6/12. In the
PrOVIDe sample aged 65–89 years the prevalence of uncorrected or undercorrected VI was 14.8%
(95% CI 12.0% to 18.0%). The only comparator study found a prevalence of 9% (95% CI 7.0% to
11.4%) based on ‘refractive error causing VI [one or both eyes]’.27 Methodological information on how
this figure was obtained was not fully reported but, as the pinhole was used in this study, it is likely that
improvement with a pinhole from VA of < 6/12 to VA of ≥ 6/12 was the basis on which this prevalence
figure was calculated.
Using the VI prevalence criterion of best monocular VA < 6/18, the overall prevalence of uncorrected
or undercorrected VI in PrOVIDe was 7.7% (95% CI 5.7% to 10.2%). In the PrOVIDe sample aged
65–89 years the VI prevalence was 7.8% (95% CI 5.7% to 10.3%). The only comparator study found
uncorrected or undercorrected refractive error to be the main cause of VI in 40% of their sample.44
Methodological weaknesses suggest that these data are likely to be unreliable for comparison purposes.
For the subgroup of the PrOVIDe sample aged 75–89 years, uncorrected or undercorrected VI was 7.8%
(95% CI 5.6% to 10.7%). The MRC trial45 estimated the prevalence of uncorrected or undercorrected VI
to be 3.2% of their population aged ≥ 75 years. However, this figure of 3.2% is suspect because of the
deficiencies of the pinhole test. The MRC study reports comments on the difficulties of conducting the
pinhole test in older people, which resulted in 38% of missing data. In addition, in the MRC trial, VA
recording was carried out by trained nurses, rather than by optometrists who may be more reliable in their
VA measurements. Any attempt at a comparison with the PrOVIDe post-refraction prevalence estimate is
further hampered by a non-comparable age–sex distribution.
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Many of the studies quoted above do not have age–sex breakdowns from which to assess these
distributions,27,44 and thus it is not possible to make any meaningful comparisons with PrOVIDe prevalence
estimates. Another salient point when attempting to compare PrOVIDe prevalence estimates with previous
studies is the currency of the published data: the Melton Mowbray study59 dates from 1987, Wormald
et al.58 dates from 1992, Jack et al.44 dates from 1995, and the North London study dates from 1998.27
The current ageing population, combined with a changing health services and health-care policy landscape
in the last 20–30 years, is a confounding factor for any attempted comparisons between a 2014 study and
these studies from the twentieth century.
When comparing group 1 with group 2 using the 6/12 criterion, the unadjusted rate of uncorrected or
undercorrected VI among people living in care homes was almost twice that of those living in their own
homes (21.0%/10.6%). For the 6/18 criterion, the unadjusted rate ratio of uncorrected or undercorrected
VI was even greater (12.4%/5.1%). There was a statistically significant independent group difference for
both criteria after adjusting for age, sex and sMMSE scores (p< 0.01 for 6/12 and p= 0.05 for 6/18).
However, as reported in Chapter 4, there are difficulties in ensuring that people living in care homes wear
their spectacles. Prescribing new spectacles with the up-to-date prescription will not guarantee that these
will be worn by all those who would benefit from them.
These prevalence findings for uncorrected or undercorrected VI have possible consequences for increasing
the likelihood of falls. Risk factors for falls include age,78 living in care homes,57,80 cognitive impairment82
and VI.44,83,84,120 Falls are estimated to cost the NHS more than £2.3B per year, and 50% of people aged
> 80 years fall at least once per year.78 If the figure of approximately 14% of participants having
correctable VI (using the VA < 6/12 criterion) is generalisable to the whole population with dementia, and
if regular spectacle wearing could be promoted, this could reduce the number of falls, particularly in care
homes, and even a modest cut in falls rate should produce significant NHS cost savings.
In summary, 14.3% of the PrOVIDe sample had VI (VA < 6/12) that was correctable with their up-to-date
spectacle prescription. For VA < 6/18 the equivalent figure was 7.7%. There is a particular issue in care
homes, where 21.0% of participants were unnecessarily visually impaired using the 6/12 criterion.
Correcting this element of VI could impact positively on NHS costs, quality of life and reduced admission
to care homes.
Post-refraction visual impairment
Following the determination of refractive error, the measurement of VA allows identification of those who,
despite wearing their up-to-date spectacle prescription, remain visually impaired. The prevalence of
post-refraction VI in the PrOVIDe sample was 18.1% (95% CI 15.2% to 21.5%) for best monocular VA
< 6/12, reducing to 8.6% (95% CI 6.6% to 11.3%) for VA < 6/18.
For the subgroup aged 75–89 years, post-refraction VI for VA < 6/12 was 20.4% (95% CI 16.8% to
24.1%), lower than the prevalence of 26.2% (95% CI 22.4% to 30.3%) calculated from data from
the best comparator study in the early 1980s.59 Factors contributing to the higher prevalence in the
comparator study include the recruitment of participants aged ≥ 90 years (although they were only
approximately 5% of the sample of 529), the use of a Snellen chart requiring every letter of the 6/18 line
to be read in order for the participant to be classified as having achieved that level of acuity, and the
recruitment of participants from one market town in England.59 Using the pinhole method for obtaining
monocular VAs which are then used to estimate post-refraction VI, the MRC trial derived a prevalence of
VI of 10.2%,56 for a sample of participants aged ≥ 75 years for VA < 6/18, similar to the prevalence in
PrOVIDe of 9.9% (95% CI 7.4% to 13.1%) for the subgroup aged 75–89 years.
DOI: 10.3310/hsdr04210 HEALTH SERVICES AND DELIVERY RESEARCH 2016 VOL. 4 NO. 21
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Bowen et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
119
In a comparison of PrOVIDe groups 1 and 2, the unadjusted rate of post-refraction VI was approximately
two-and a-half-times greater among those living in care homes using both criteria: 30.2% versus 11.4%
for < 6/12 and 14.2% versus 5.6% for < 6/18, respectively. There was a statistically significant group
difference for both criteria after adjusting for age and sex (p≤ 0.01).
In summary, with best possible spectacle correction VA < 6/12 is present in 18.1% of this sample of
people with dementia. For VA < 6/18 the equivalent figure is 8.6%. Based on unadjusted rate ratios,
post-refraction VI is approximately two-and-a-half times more likely among those living in care homes.
Causes of visual impairment, excluding refractive error
Excluding VI from uncorrected or undercorrected refractive error, 102 participants were classified post
refraction as being visually impaired based on binocular VA (or best monocular VA if binocular VA not
available) being < 6/12, and 47 participants post refraction were visually impaired based on VA being
< 6/18. Comparisons with other studies are difficult, as a variety of definitions were used for the conditions
causing VI. Most studies27,44,58,59 determined clinical status following an examination by an ophthalmologist,
while in the MRC study45 cause was established from GP notes with supporting evidence for some
participants from a survey of the ophthalmologists who last examined each participant.
Criterion for visual impairment: visual acuity < 6/12
As previously shown in Table 17, where more than one possible cause of VI is included for each
participant, cataract (70.6%, 95% CI 60.6% to 79.0%) and AMD (40.2%, 95% CI 30.8% to 50.4%)
predominate, followed by glaucoma (9.8%, 95% CI 5.1% to 17.7%) and diabetic retinopathy (1.0%,
95% CI 0.1% to 6.1%). There is no equivalent comparator with these data. Reidy et al.27 used the
6/12 cut-off point and included the possibility of more than one cause, but their data for each condition
include participants who have VA < 6/12 in one or both eyes. Therefore, for example, a participant with
AMD reducing right-eye acuity to 6/18 but with left-eye acuity of 6/6 was classified in the Reidy et al.27
study as having VI caused by AMD. In PrOVIDe and other studies, it is the participants’ binocular VA or
best monocular VA that is used when classifying participants as VI. Therefore, for the example given
above, either binocular VA or best monocular VA would be at least 6/6 for this participant who would not
be classified as VI.
Where a single cause of VI was identified in PrOVIDe, cataract was responsible for almost half of the cases
of VI (48.0%, 95% CI 38.1% to 58.1%) and all of these cases were potentially remediable with cataract
surgery. AMD accounted for over one-third of cases (36.3%, 95% CI 27.2% to 46.4%). Glaucoma
accounted for 6.9% (95% CI 3.0% to 14.1%) and the figure for diabetic retinopathy was 1.0% (95% CI
0.1% to 6.1%).
In a small sample of 30 participants aged ≥ 65 years, Wormald et al.58 used the same criteria as PrOVIDe.
Cataract was the principal cause of VI in 63% of participants and AMD was the principal cause in 20% of
participants. However, this study was published in 1992 when fewer cataract surgeries were performed;
this is reflected in the 26.6% of PrOVIDe participants who had an intraocular implant in one or both eyes,
compared with 5.8% of Wormald et al.’s sample who were aphakic.
Criterion for visual impairment: visual acuity < 6/18
Where more than one cause for VI was included (see Table 17), AMD (53.2%, 95% CI 38.2% to 67.6%)
and cataract (61.7%, 95% CI 46.4% to 75.1%) are again the most frequent causes, but AMD is more
common and cataract less so than with the 6/12 cut-off point because AMD is more likely to be the cause
of VI as participants’ VAs worsen. Glaucoma (8.5%, 95% CI 2.8% to 21.3%) is a minor contributor. In the
only comparator, the MRC study,45 AMD caused a similar proportion of VI (52.9%, 95% CI 49.2% to
56.5%). However, cataract was identified as a cause in 35.9% (95% CI 31.7% to 40.1%) of MRC
participants. One explanation could be the procedure in PrOVIDe for optometrists and the research team to
record two potential causes, which occurred in 34% of cases, compared with only 16% in the MRC trial.
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Where a single cause was identified, AMD (48.9%, 95% CI 34.3% to 63.7%) overtook cataract
(36.1%, 95% CI 23.1% to 51.5%) as the leading cause of VI, with glaucoma making a small
contribution (4.3%, 95% CI 0.7% to 15.7%). Comparator studies attribute lower contributions from
AMD to VI (14%,58 23%44) but these studies date from the early 1990s when cataract surgery was less
frequently performed.
In summary, the PrOVIDe data should be interpreted with caution as they rely on causes reported by
optometrists. However, for the VA < 6/12 criterion, almost half of VI was caused by cataract, which is
potentially remediable, and approximately one-third was caused by AMD.
Prevalence of specified eye conditions
Comparisons between PrOVIDe estimates of prevalence for the eye conditions and estimates from
population studies are limited by differences between studies in their definitions of conditions and
variations in sample demographics.121 Furthermore, the PrOVIDe estimates are based on identification of
the condition by an optometrist rather than by an ophthalmologist (see Chapter 5, Limitations of the
study). The domiciliary eye examinations carried out in PrOVIDe precluded the use of the bulky slit-lamp
biomicroscope. This limited the optometrist to direct hand-held ophthalmoscopy for assessment of the
ocular media and fundus, rather than using the clinically superior examination techniques of a slit-lamp
assessment of the ocular media and binocular indirect ophthalmoscopy to examine the fundus.
The overall prevalence of AMD in PrOVIDe was 17.7% (95% CI 15.0% to 20.8%), rising to 18.3% (95%
CI 15.5% to 21.4%) when adjusted to include only those aged between 65 and 89 years (see Table 12).
A Bayesian meta-analysis estimate of UK prevalence for late stage AMD for those aged > 65 years is
approximately 9.9%,19 but the PrOVIDe estimate will include those with less severe AMD (see Chapter 2,
Data collection, Stage 1, The eye examinations). A European study of people aged ≥ 65 years, which
included the UK among its seven centres, graded fundus photographs according to the Rotterdam staging
system, in which Grade 0 represented no AMD and Grade 4 was late-stage neovascular AMD. The
prevalence of AMD Grades 1–4 was 52.4%, reducing to 15.9%, similar to the PrOVIDe prevalence, when
those with Grade 1 (mildest visible signs of AMD) were excluded.122
Prevalence of cataract in PrOVIDe was 59.0% (95% CI 55.2% to 62.7%) for grades 1–5, reducing to
38.0% (95% CI 34.5% to 41.7%) when grade 1 (minimal visible cataract) was excluded. The best
comparator data come from the Eye Diseases Prevalence Research Group (EDPRG),123 which included data
from major population studies in the USA, Europe and Australia.121 Definitions of significant cataract varied
between studies contributing to these estimates but all of these definitions are likely to exclude early
cataract (grade 1 in PrOVIDe). The prevalence of cataract in those aged > 60 years was calculated for this
report from published EDPRG data to be 37.8%,123 similar to the grades 2–5 estimate from PrOVIDe.
Glaucoma prevalence in PrOVIDe was estimated to be 7.1% (95% CI 5.3% to 9.3%), increasing to 7.2%
(95% CI 5.4% to 9.5%) when adjusted to include only those aged between 70 and 89 years. A Bayesian
meta-analysis estimated a pooled prevalence of open-angle glaucoma in white populations aged > 70 years
to be approximately 6%.39 This figure is similar to that from PrOVIDe, although the meta-analysis had no
upper age limit and the PrOVIDe figure was not limited to open-angle glaucoma nor to white populations.
The prevalence of diabetic retinopathy in PrOVIDe was 2.0% (95% CI 1.1% to 3.4%) of the overall
sample, and the prevalence of diabetes was 12.0% (95% CI 9.8% to 14.7%). The prevalence of diabetes
in the adult population in England in 2013 was estimated to be 6.0%,124 with the higher prevalence in
PrOVIDe reflecting the older population in this study. In a UK diabetic population screening study,
25.3% of type 2 diabetics had some form of diabetic retinopathy.32 In a US non-Hispanic white diabetic
population aged > 65 years the estimated prevalence of diabetic retinopathy was 26.4% (95% CI 21.4%
to 32.2%).121 The PrOVIDe sample was predominantly white and the diabetics were predominantly type 2;
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therefore, applying this approximate figure of one-quarter of diabetics having diabetic retinopathy32,121 to
the 12% of diabetics in PrOVIDe gives an estimate of 3% of the total sample having diabetic retinopathy,
a figure which lies within the 95% CI for diabetic retinopathy in the PrOVIDe sample.
In summary, comparisons with published population studies should be interpreted with caution. However,
when assumptions are made in an effort to compare like-with-like, the prevalences of the four conditions
in PrOVIDe are similar to those in the best comparator studies.
Factors affecting visual impairment prevalence data
The prevalences of presenting and post-refraction VI increased significantly with age after adjusting for sex
and group for both VI criteria (p≤ 0.01), confirming previous UK studies.44,56,57 However, after adjusting for
sex, group and sMMSE score, there was no evidence for an independent age effect on uncorrected/
undercorrected VI. This suggests that when post-refraction VI (frequently the result of age-related eye
conditions) is excluded, then uncorrected/undercorrected VI (the result of wearing an incorrect spectacle
prescription) is not dependent on the age of the participant. In addition, for VI defined as VA < 6/18 there
was evidence of an association (independent of age, sex, sMMSE score and group) between the time since
last eye examination and the probability of having uncorrected/undercorrected VI, with an OR of 1.23
(95% CI 1.04 to 1.42). Here, ORs are expressed as the increase in odds of VI for every year increase in the
time since last eye examination, at a fixed age, sex, group and sMMSE score. There was no evidence of a
similar association for VI defined as VA < 6/12.
There was no evidence of any independent sex difference for presenting VI, unlike most other UK
studies,44,56,57 nor for post-refraction VI or for uncorrected/undercorrected VI for VA < 6/12. There was a
statistically significant independent sex effect for uncorrected/undercorrected VI for VA < 6/18, with an
adjusted OR for males versus females of 0.45.
The prevalence of AMD, when adjusted for sex and group, increased significantly with age, with an
OR of 1.18 (95% CI 1.13 to 1.24), as found in other studies.121 Similarly, there was an independent age
effect on the prevalence of the combination of cataract (grades 1–5 or grades 2–5) and an IOL in one or
both eyes, again consistent with other studies.123 As the population of the UK rapidly ages,3 age-related
eye disease and VI will become greater public health issues. There was no evidence for an independent
age effect for glaucoma, which was found in other studies;39,121 however, the definitive studies are
meta-analyses or used data pooled from a number of population studies. No evidence of independent
sex differences was found for any conditions apart from diabetic retinopathy (adjusted OR for males
vs. females 3.69, 95% CI 1.19 to 13.80). This result should be interpreted with caution, as only
14 participants had diabetic retinopathy.
Association between Standardised Mini-Mental State Examination and
Mini-Mental State Examination blind scores
The sMMSE instrument can be modified for participants with loss of vision, to compensate for their
performance on the three sMMSE items which require significant visual input.125 MMSE blind is often used
with visually impaired participants, and the three items requiring significant visual input are omitted and
the test score out of 27 is rescaled to give a score out of the usual maximum of 30. In PrOVIDe, the
sMMSE instrument was used at recruitment on all participants, at a stage when the recruiter would not
normally be aware if the participant was visually impaired or not. This could lead to an overestimation of
cognitive impairment through the use of sMMSE in visually impaired participants.
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To test this possible effect, a linear regression model was fitted to the sMMSE scores, adjusting for age,
sex, residential status and presenting VI [ordered in terms of severity ‘better than 6/12 (none)’, ‘6/12–6/18’,
‘worse than 6/18’]. The coefficient point estimates and statistical significances were then qualitatively
compared with those of a model of sMMSE blind scores (see Table 29). A rudimentary sensitivity analysis
was performed, modelling both sMMSE scores and MMSE blind scores, and this showed no change in
the conclusions regarding the relationship between either sMMSE or MMSE blind and age, sex, VI and
residential status. The difference in the mean sMMSE and MMSE blind scores according to these models
was approximately 0.75, with a higher mean score for MMSE blind. This difference is much lower than the
maximum possible difference of 3. There is an indication of higher MMSE blind scores in both non-visually
impaired participants and in moderately visually impaired participants.
In summary, the prevalences of presenting and post-refraction VI increase significantly with age. There is
no independent age effect for uncorrected/undercorrected VI. The prevalences of both AMD and cataract
increase significantly with increasing age after adjustment for sex and group. No independent sex effect
was found for AMD, cataract or glaucoma.
Improvement in visual acuity post refraction
Distance acuity
The mean improvement in VA following refraction was 0.09 logMAR units, equivalent to almost one line
improvement on the logMAR chart, with no significant differences between groups 1 and 2. Similar
improvements were measured for AMD, cataract, glaucoma and diabetic retinopathy. All mean improvements
were statistically significant. Clinical significance is more relevant and best described by the percentages of
participants who achieved improvements in acuity greater than set criteria (see Table 22).
As noted in Chapter 3 (see Change in distance visual acuity from pre to post refraction, Improvement in
visual acuity post refraction based on lines of improvement on distance test charts), the percentage of the
sample who improved by ≥ 0.16 logMAR units has also been recorded. This criterion was chosen as it
represents an improvement greater than the average change in acuity between two lines on a Snellen
chart, which is 0.154 log units.57 Although all of the distance VA measurements in the PrOVIDe study
were made using charts with logMAR progression of letter sizes, previous studies that have investigated VI
in older people have often used charts with Snellen progression.44,58,59 Snellen charts have several
disadvantages compared with logMAR charts, notably the unequal progression in letter sizes between lines
on the chart. However, to permit comparisons between PrOVIDe results and those obtained in previous
studies that used Snellen charts, the ‘equivalent’ improvement in terms of lines of Snellen acuity has also
been calculated.
There was an improvement equivalent to more than one line on a Snellen chart in 20.4% of participants,
an improvement that clinicians often regard as clinically significant. When improvement in distance VA was
assessed using a pinhole in a sample of comparable age (n= 207), it was estimated that 27% would have
benefited from a refraction by virtue of an increase of VA of greater than one Snellen line.58
In PrOVIDe, 17.8% of participants improved by two or more lines on the logMAR chart (≥ 0.20), a figure
similar to NDNS (21.2%), again using a pinhole to estimate post-refraction VA.57 The test–retest reliability
of logMAR charts similar to those used in the PrOVIDe study, namely Bailey–Lovie and Early Treatment
Diabetic Retinopathy Study (ETDRS) charts, have 95% confidence limits for change of ± 0.12 logMAR units
for Bailey–Lovie and ± 0.14 logMAR units for ETDRS charts;126 therefore, changes greater than this are
unlikely to occur by chance. Similar methods to the PrOVIDe study were used by Lavery et al.,59 in which
optometrists carried out a full refraction and measured the improvement in VA based on best monocular
VA. Using Snellen acuity, 6.8% of the sample who had spectacles improved their VA by at least two lines.
This is equivalent to an improvement of approximately three lines or more on a logMAR chart, and 6.8%
of the PrOVIDe sample improved their VA by three logMAR lines or more.
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Near acuity
Near acuity has rarely been recorded in previous studies, although its measurement under standardised
conditions is recommended in population studies of VI.45 Standard newspaper print is approximately N8
size,127 and 16.2% (95% CI 13.1% to 19.9%) (n= 77) of the 475 PrOVIDe participants for whom NVA
was recorded both pre and post refraction were unable to read N8 print with their current near vision
spectacles (see Table 23). Almost two-thirds of this visual loss (n= 49) was correctable with the optimum
spectacle prescription for near vision. However, this proportion of participants achieving N8 acuity with
their up-to-date spectacle prescription when this was not achievable with their current spectacles should
be interpreted with caution, as other important aspects of near visual function were not evaluated in
PrOVIDe. Although the research optometrists recorded the VA as the smallest print that could be read
fluently, the ability to carry out sustained reading of this size of print comfortably (critical print size) was
not assessed, nor was reading speed. The ability of a participant to read N8 print over a short period of
time does not necessarily mean that he or she will be capable of reading newsprint in comfort for a
reasonable period of time. It is estimated that in order to read print comfortably an acuity ‘reserve’ is
required;128 for example, for someone to read N8 print comfortably for a reasonable period of time, they
would usually need have a NVA of N4.
In the Melton Mowbray study, the only other UK population study to record NVA following an
optometrist’s refraction,59 11.2% of the sample were unable to read N8 after refraction, almost twice the
5.9% in PrOVIDe. The reason for this difference is unknown.
There was no evidence for independent sex effects on near vision loss. There was a statistically significant
independent group effect for presenting near vision loss for both near vision loss criteria, for post-
refraction near vision loss for the NVA <N8 criterion, and for uncorrected/undercorrected near vision loss
for the NVA <N10 criterion. This group effect is similar to that found for distance VI. There were also
some similarities with distance VI with regard to the effects of age; the prevalences of post-refraction near
vision loss increased significantly with age after adjusting for sex and group for both near vision loss
criteria, consistent with the increased incidence of age-related eye conditions. No other independent age
effects were found for presenting or uncorrected/undercorrected near vision loss.
In terms of the number of extra lines on the near vision chart that could be read following refraction,
28.6% read one extra line, 9.3% read two extra lines and 6.6% read three or more lines (see Table 25).
Improvements of more than three lines occurred in 7.2% of those in care homes, and improvements in
NVA of this magnitude have the potential to turn reading books and newspapers from being a chore into
being a pleasure; for example, an improvement of four lines from N10 to N4 should allow the participant,
previously unable to read standard newspaper print of N8 size, to have sufficient acuity reserve to be able
to read N8 comfortably.
In summary, mean improvement in VA post refraction was approximately one line of logMAR acuity.
Distance acuity improved by two or more lines post refraction in 17.8% of participants. Of the participants,
16.2% could not read standard newspaper-size print with their current spectacles, and for almost
two-thirds of these participants this was correctable.
Clinical limitations of the eye examination
Patient dependent
Visual acuity and determination of refractive error
Cognitive impairment and the patient’s level of co-operation can limit an optometrist’s ability to perform a
complete eye examination. The PrOVIDe study is unique in quantifying these limitations for key tests and in
relation to the participant’s level of cognitive impairment.
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In just eight cases (1.1%) the optometrist was unable to carry out any part of the eye examination.
The determination of refractive error by objective methods using a retinoscope was possible in both eyes
of almost 90% of participants (see Chapter 3, Ability of participants to complete individual elements of
the eye examination). Focus group and anecdotal evidence from community optometrists suggests that
optometrists have concerns that elements of the eye examination, notably VA and subjective refraction,
are unlikely to be possible in people who have dementia. However, both tests were possible in > 80% of
participants. The pinhole test was also possible in > 80% of those in whom it was attempted. However,
the optometrists decided, based on their assessment of the participant’s co-operation and cognition, not to
attempt the pinhole test in > 70% of the sample. The MRC trial, in their national sample of older people,
noted that the pinhole test was not straightforward, proving unsuccessful in 38% of those in whom the
test was attempted.56
Optometrists in focus groups reported other difficulties faced during eye examinations of people with
dementia, including the inability of some people to cope with VA charts presented at 6m by means of a
mirror. Charts viewed directly (e.g. Kay pictures) may be preferred. The CoO Guidance document C5
The domiciliary eye examination130 states the equipment used in domiciliary examinations should include a
‘portable test chart (preferably illuminated)’, and although Kay pictures are available only in booklet form,
similar charts can be selected in portable computerised systems.
Evaluating the health of the eyes
Visual fields examination is a challenge in the domiciliary setting.129 This test is requested by TOC
optometrists when clinically necessary and if, in the professional judgement of the optometrist, the
individual could cope with the demands of the test. Although visual fields tests were requested for only
21% of participants, the test was possible in > 90% of those in whom it was attempted.
Tonometry, using the Icare tonometer, was possible in almost 95% of all participants and in > 99% of
those in group 1 (see Table 26). The importance of tonometry in older people suspected of having
dementia is reinforced by the increasing prevalence of glaucoma with age,40 and elevated IOP is a major
risk factor for POAG.
Examination of the retina and remainder of the fundus is facilitated by pupil dilatation. Ophthalmoscopy
becomes more difficult in patients with cataract or if the patient’s pupil diameter reduces, and both factors
are exacerbated by increasing age. Pupil dilatation with tropicamide eye drops was attempted on all
participants, and was possible in two-thirds. Reasons for not dilating included the absence of informed
consent and the participant declining dilatation (see Table 19); poor participant co-operation accounted for
only 14% of non-dilatations.
Ophthalmoscopic examination of the fundus was possible in > 90% of participants and almost 98% in
group 1. This examination is crucial in the detection of AMD, glaucoma and other rarer conditions that
can cause significant loss of vision or blindness. In this test the optometrist places the ophthalmoscope
around 1–2 cm from the patient’s eye and directs bright illumination into the eye. The optometrist is
also in the patient’s personal space. All these factors could cause distress, which makes the level of
co-operation achieved impressive.
For all but one of these tests, the sMMSE scores for those in whom the test was possible were statistically
significantly higher than for those in whom the test was not possible (see Table 28). The exception was the
objective assessment of refractive error using a retinoscope. These differences were confirmed from logistic
regression, after adjustment for age, sex and group. It should be noted that sMMSE scores were missing
for 54 participants, who are more likely to be older and more likely to live in care homes than participants
for whom sMMSE scores are available.
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Group 1 participants were significantly more likely than group 2 participants to be able to undertake each
key test (apart from objective assessment of refractive error by retinoscopy) (see Table 26). The differences
between groups were greatest for subjective assessment (95.1% vs. 63.6%), the measurement of VA
(97.4% vs. 65.8%), dilatation (81% vs. 50.5%) and visual fields (52.5% vs. 3.6%). When adjusted for age
and sex, this statistically significant independent group effect persisted for the subjective examination, VA
measurement, tonometry and dilatation (p≤ 0.03). There was some evidence of a group effect for ability
to complete the fundus examination (p= 0.06), but little evidence for a group effect for the ability of the
participant to complete the objective determination of refractive error (p= 0.20).
In summary, most key elements of the routine optometric eye examination could be successfully completed
on > 80% of participants. Objective tests were more likely to be successfully completed than subjective
tests, notably retinoscopy and fundus examination. Visual fields and the pinhole test were possible in a
minority of participants. For all key tests, with the exception of retinoscopy, sMMSE scores were
significantly lower in those unable to complete the tests. Participants living in care homes were significantly
less likely to be able to undertake most key tests.
Setting dependent
The CoO guideline C5 The Domiciliary Eye Examination130 notes that people able ‘to attend a practice for
examination should be encouraged to do so, since it is recognised that a dedicated consulting room is the
optimum environment in which to conduct their eye examination . . .’. It follows on: ‘. . . for the patient
who is unable to access a community practice the optimum environment will be their place of residence’.
It is desirable for the examination to take place in the environment best suited to the individual, and taking
vulnerable people or those with challenging behaviour to an optometrist’s practice may increase stress
levels and make them feel intimidated.129 Optometrists in focus groups who had experience of domiciliary
examinations reported some advantages to examining people in their own homes, including that people
are more relaxed at home than in a practice environment. In addition, there is access to the reading
material used by the person, and their habitual visual environment, notably lighting, can be assessed.
From the public perspective, very few people with dementia who were interviewed in stage 2 or carers in
focus groups had been aware of the availability of domiciliary services prior to participating in PrOVIDe.
Despite the rapid increase in numbers of domiciliary sight tests over the past decade,51 there remains a
need for greater publicity of the service.
A theme from optometrist focus groups was the importance of the presence of a carer with good
knowledge of the patient throughout the examination. This view is supported by the CoO guideline C5:
‘Wherever possible, the domiciliary visit should take place when a relative or carer is present’.130 Not all
optometrists appreciate the potential benefits of having a carer present as, in the family carers’ focus
groups, pleas were made for optometrists to understand the need to involve carers. For PrOVIDe
participants living at home, a carer was present in almost 90% of examinations. However, for participants
living in care homes, > 40% of examinations were conducted with no carer present. Some optometrists in
focus groups reported that the presence of a carer or care worker was no guarantee that the carer knew
the patient well, but someone with good knowledge of the person being examined may be able to
provide some or all of the history and symptoms91,129 and may help the individual feel more at ease.
The presence of a carer during the eye examinations conducted during stage 1 of PrOVIDe had a positive
impact on the successful completion of all five key elements of the eye examination that were evaluated.
These five were: (1) objective assessment of refractive error; (2) subjective assessment of refractive error;
(3) VA measurement; (4) fundus examination by ophthalmoscopy; and (5) tonometry, and this positive impact
was statistically significant for VA measurement with an unadjusted rate ratio of 1.9 (95% CI 1.2 to 3.0).
In summary, a domiciliary setting may offer some advantages, allowing the visual environment to be
assessed. There remains a need to publicise domiciliary services. Having a carer present with good
knowledge of the person being examined is beneficial and may have a positive impact on the successful
completion of key elements of the eye examination.
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Practitioner dependent
The need for optometrists examining people with dementia to have adequate training and experience was
a message that emerged from focus groups. Family carers had experiences of optometrists (outside
PrOVIDe) who lacked understanding of the impact of cognitive impairment on the examination and who
failed to communicate adequately. Non-TOC optometrist focus group members thought that they would
benefit from further knowledge of dementia in general and training in the management in optometric
practice of people with dementia. Specific topics included how best to adapt usual eye examination
routines to accommodate the cognitively impaired and the need for greater information on issues of
consent and capacity. Preferences were for interactive rather than didactic approaches to training, and the
limitations of the didactic approach to optometric training in glaucoma have been published.131
Continuing Education and Training and Continuing Professional Development training is readily available to
optometrists in a variety of forms. However, where there is a desire for greater experience in examining
people with dementia, the opportunities to gain this by observing practitioners with expertise in this area,
and/or having peers/mentors who could advise their less-experienced colleagues, are not currently available.
The development of optometrists who are specialist practitioners was suggested. There are long-standing
UK precedents for the development of specialist optometrists in contact lenses and orthoptics and,
more recently, in therapeutics132 and glaucoma.133,134 However, the process of establishing a specialist
qualification for optometrists is lengthy, requiring the drafting of a syllabus, core competencies, training
programmes and assessment procedures.135 The viability of a specialist qualification should be a topic for
further research. Through the CoO Higher Qualifications framework, optometrists can already obtain
Professional Certificates in low vision, medical retina and glaucoma, and Professional Higher Certificates in
low vision, glaucoma and contact lenses.136
Excluding the TOC focus group, most optometrists who did not currently undertake domiciliary work felt
that they did not have adequate equipment to carry out a satisfactory examination in a home environment.
In summary, optometrists identified the need for further, preferably interactive, training in dementia and its
management in practice. A specialist higher optometric qualification in the care of older people could
improve eye care. The viability of this specialist qualification should be a topic for further research.
Quality of optometric practice
Degree of satisfaction with eye examination
In general, stage 2 interviewees were satisfied with their eye examinations prior to the PrOVIDe
examination, although some carers expressed doubts about the ability of optometrists to carry out the
subjective elements of the eye examination. The CoO guideline C491 stresses the need for the optometrist
to be flexible during the examination, adapting techniques and using alternative appropriate methods.
The PrOVIDe optometrists examined according to these guidelines and were able to conduct subjective
examinations on > 80% of participants, although subjective refraction was less likely to be possible as the
degree of cognitive impairment progressed. There was frequent praise from participants and carers for
the PrOVIDe optometrists, particularly for their understanding of how to relate to and communicate
with the participants. The thoroughness of the examination and the length of time allocated also received
favourable comment.
Communication between carers and health-care professionals
Focus group optometrists commented that family carers did not always inform them that their relative had
dementia, and that this information frequently emerged during the examination. Knowing this from the
outset would make the subsequent examination more efficient and a better experience for all parties.
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Optometrists expressed the desirability of continuity of optometric care for people with dementia.
Continuity depends, at the practice level, on patients returning to the same practice and, at the individual
level, on requesting the same optometrist. Some interviewees reported continuity in their choice of practice
and optometrist, while others moved around. CoO guideline C5130 states that domiciliary eye examinations
should not be seen as a ‘one-off’ service but as part of the provision of continuing care to the patient.
Continuity of care may be even less likely for people living in care homes, where most eye examinations
are carried out by optometrists working for companies that supply domiciliary services.
Time allocated for the eye examination and the NHS fee structure
The need to allow sufficient time to conduct the eye examination in people with cognitive impairment
was a recurrent theme from participants, carers and optometrists. The CoO guideline C4 notes that
optometrists ‘should be prepared to take longer to complete the eye examination’91 if the patient’s
responses are slow. There is considerable variation in the duration of optometric eye examinations even in
people without cognitive impairment.55 Optometrists in Scotland can carry out a maximum of 20 sight tests
per day but no maximum applies in England.137 As a result, optometrists in England are often scheduled to
carry out sight tests every 20 minutes (or less) throughout the working day. Individuals who require a
longer examination than the norm can play havoc with appointment scheduling, affecting other patients
and other practice staff. Booking longer appointment slots for people with cognitive impairment attracts
no extra NHS funding, nor does the alternative of the patient returning for a second appointment. Family
carers expressed concerns about the logistical challenges of bringing their relative to the optometrist’s
practice for an eye examination, so returning for a second appointment may not be a realistic option for
some people with dementia. In the UK, apart from Scotland, the current NHS sight test fee is £21.10,138
which is reported to be less than half of the actual cost of providing a sight test.52 This fee leads to a
situation in which NHS sight tests outside Scotland are financially viable to a practice only when subsidised
by the purchase of spectacles.52,139 Overall expenditure on GOS has fallen in real terms since the 1950s, a
situation not common to any other service provided across the NHS.139
Although focus group comments regarding the PrOVIDe domiciliary eye examinations were complimentary,
some concerns were expressed regarding eye-care provision in care homes. There was potential for
examinations to be rushed, against the ethos of the CoO guideline C4. When examining people with
advanced dementia, it is not always possible to carry out a full sight test. All agreed that an eye health
check in people with dementia was valuable, but optometrists queried if a partial sight test should attract
the full NHS sight test fee in instances when a full test is not possible. The current NHS fee structure does
not compensate the optometrist who may have taken time out of practice to carry out a domiciliary sight
test but who is unable to claim the fee because the patient was not sufficiently co-operative to complete
most of, or any of, the sight test. This could be a disincentive for independent practitioners to provide
domiciliary services.
Spectacle dispensing
When dispensing new spectacles to people with dementia, optometrists reported that it was good practice
to minimise change from the type of lenses (e.g. separate pairs for distance and near vision, bifocal,
progressive power lenses) and frames (e.g. style and colour) used in previous spectacles, as changes may
be confusing and contribute to a refusal to wear the new spectacles.
In summary, stage 2 interviewees were generally satisfied with the quality of eye examinations. It is
desirable for the practice to be informed, when an appointment is made, that the person to be examined
has dementia, and for the optometrist to be informed of this prior to beginning the examination.
Continuity of care is desirable but not always achieved, especially in care homes. Allowing more time for
the eye examination is desirable but not always possible owing to practice timetabling difficulties. The NHS
sight test fee structure does not take into account the particular issues arising when people with dementia
have sight tests (e.g. extra time required, only partial sight tests possible, no test possible). When
dispensing spectacles, unnecessary changes should be kept to a minimum.
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Inappropriate management of visual impairment in people
with dementia
Inappropriate management of spectacle prescriptions
For spectacle prescriptions, inappropriate management could be revealed if large changes in spectacle
prescription occurred over a short period of time. Determination of refractive error is subject to variability.
If the same person is examined by two different optometrists under identical conditions, the variability,
or reproducibility, of the two measurements of refractive error can be calculated.140 The reproducibility of
refractive error in older people with cognitive impairment is unknown. However, the reproducibility
of subjective refractive findings in people aged < 60 years without cognitive impairment is approximately
± 0.75 dioptres (D).140,141 Furthermore, the multiple eye examinations from which this ± 0.75 D figure was
calculated were completed over a relatively short period of time, during which refractive errors of younger
people would be unlikely to alter. However, refractive errors can change more rapidly in older people with
cataract, especially nuclear sclerosis cataract, and in the weeks following cataract surgery. For these reasons,
the 95% reproducibility limits are likely to be wider, possibly considerably wider, than ± 0.75 D in people
with cognitive impairment. Furthermore, people with dementia may not be wearing their current spectacles
or, as noted in focus groups, their own spectacles, so any change in prescription noted by the optometrist
may be based on an erroneous baseline. All of these factors make the identification of inappropriate
management difficult. Nevertheless, in PrOVIDe the optometrists had access for some participants to the
prescription statement issued at the previous sight test, on which the date of that sight test was recorded.
When this previous sight test took place a short time before the PrOVIDe examination, it was possible to
compare the PrOVIDe spectacle refraction with the prescription issued at the previous eye examination. Of
the 6.2% (n= 44) of PrOVIDe examinations that took place within 2 months of the previous examination,
there was evidence of potential inappropriate refractive management in only one case.
If there was large-scale inappropriate management of spectacle prescriptions at the eye examination
previous to the PrOVIDe examination, this could result in a higher than usual proportion of participants
being advised that a change in spectacle prescription would be beneficial. The proportion advised of a
change following their eye examination was 63.4%. This figure is almost identical to the percentage
(63.5%) of ‘changed or new’ spectacle prescriptions for people of all ages in the UK52 and, although not
age-matched, supports the view that inappropriate management is unlikely to be occurring on a large
scale in the PrOVIDe sample.
Inappropriate management of eye conditions and dispensing of spectacles
If inappropriate management of eye conditions had been detected, this could have resulted in a higher
than expected referral rate following the PrOVIDe eye examination. The PrOVIDe referral rate was 6.7%
(n= 47), higher than the national figure for people of all ages of 5% reported in 2011/12.52 However,
a higher percentage of referrals could be expected in older people as a result of the greater prevalence of
eye conditions in this population.
Only nine PrOVIDe referrals were for potential cataract surgery out of a total of 209 participants with
grades 2–5 cataract. Referral for possible cataract surgery in PrOVIDe was made according to the Action
on Cataracts guidelines, which require three criteria to be satisfied before referral: VA is reduced as a result
of the cataract; visual symptoms, as a result of the cataract, are impacting on the individual’s lifestyle; and
the affected individual is willing to undergo surgery to remove the cataract.30 Although VA was often
reduced as the result of cataract (see Table 21), in the majority of cases quality of life may not have been
affected sufficiently to warrant referral and/or the participant/carer was unwilling to undergo/agree to
surgery. Cataract surgery was often discussed during the eye examination with the participant and/or
carer, allowing the participant’s family to make an informed decision based on quality-of-life issues.
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The low referral rate for cataract surgery, together with the high proportion of participants with an
intraocular implant in at least one eye (26.6%), suggests that there is no evidence of inappropriate
management of cataract in the PrOVIDe sample. However, although cataract surgery had been carried out
in over one-quarter of the sample, an unknown proportion of these participants had surgery before they
developed dementia.
In summary, there is no evidence of a high proportion of inappropriate management of either spectacle
prescriptions or eye conditions in the PrOVIDe sample. This conclusion must be interpreted with caution,
as diagnosis and appropriate management of eye conditions were not confirmed by an ophthalmologist.
One case was identified in which possible mismanagement of the spectacle prescription had occurred.
Intervals between eye examinations and spectacle dispensing
The consensus among optometrists and carers was that annual eye examinations were appropriate for most
people with cognitive impairment, although some care workers thought that more frequent testing was
required. In the ‘Older people and eye tests’ survey of those aged > 60 years, 53% thought that people
should have annual sight tests and 32% thought that the interval should be every 2 years.53 Annual GOS
eye examinations for people aged ≥ 70 years are possible under the Department of Health’s Memorandum
of Understanding50 and this age group will include the majority of those with dementia.2 Those aged
< 70 years may be entitled to an eye examination annually, or more frequently, at the practitioner’s initiative
for a clinical reason. If annual eye examinations are to become the norm for all with cognitive impairment,
an alteration to the Memorandum of Understanding will be required to permit this for those < 70 years.
It is estimated that 77% of PrOVIDe participants had their previous eye examination within the previous
2 years and 59% within the previous year (see Figures 9 and 10). These results are broadly similar
to those from the Older People and Eye Tests survey53 (88% and 53%, respectively). In the NDNS57 a lower
proportion (44.8%) of respondents reported having had an eye test in the previous 12 months. In surveys
in Australia, Canada and the USA, a similar proportion (60–70%) of older adults had visited an eye-care
provider, although not necessarily an optometrist, in the previous year.142 Data from the Optical
Confederation survey for 2011/12 give an average interval between eye examinations of 27 months
overall and 30 months for those of working age,52 which is broadly consistent with findings in PrOVIDe
(see Figures 9 and 10).
The results of two regression analyses revealed that living in residential care is independently (of age, sex,
group and sMMSE score) associated with a shorter interval since the last eye examination than living at
home. In addition, when the time interval since the last eye examination was added as a continuous
covariate to the primary model for uncorrected/undercorrected VI (see Table 11), then for VA < 6/18 it
emerged that a person living in a care home was more likely to have uncorrected/undercorrected VI than a
person living in their own home, even if both had the same time interval since their last eye examination.
Taken together, these two findings raise the possibility that eye examinations may be more difficult to
conduct in care homes than in people’s own homes, given the current level of optometric training.
However, this suggestion should be treated with caution and as a signpost to possible further research.
Any future research in this area should incorporate a larger set of measured potential confounders in the
time since last examination and VI model. These could include factors involved in a person’s admission to a
care home, socioeconomic factors (e.g. education) and general health factors, to account for the fact that
these may influence frequency of eye examinations and also influence VI. Access to records of the previous
eye examination would be crucial to assessing the factors involved in the non-correction/undercorrection
of VI.
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A total of 154 (22.0%) PrOVIDe participants had not had an eye examination for more than 2 years. The
main reasons offered in stage 2 for not attending for optometric examination were the belief that nothing
was wrong with the eyes and having no problems with current spectacles, reasons that have previously
been reported.11,53 Other reasons for older people not attending for regular eye examinations included
difficulties in travelling to the practitioner’s practice,53 the cost of glasses53 and the assumption that a
reduction in vision is a normal process as people age.11 The longer the intervals between examinations,
the greater the changes in prescription that are likely to be found.
Concerns were expressed during interviews regarding the possibility of the unnecessary dispensing of new
spectacles, particularly in care homes. In PrOVIDe, almost 40% of participants were dispensed new glasses,
with approximately 10% of the remaining participants taking their prescription for spectacles which may
have been made up into spectacles elsewhere. The costs of new spectacles can deter older people from
accessing eye care.53,143 There was some evidence from stage 2 that the cost of spectacles could be an
issue. People with limited financial resources can get financial assistance in the form of a ‘voucher’ that
can be used towards the cost of spectacles,144 although not everyone may be aware of their entitlement.
Additionally, despite relatively low incomes, some older people would still not qualify for assistance.
In summary, although one-fifth of participants had not had an eye examination for > 2 years, nearly 80%
of PrOVIDe participants were having regular eye examinations. However, the possibility of the sample
and/or their carers being more health conscious than the norm suggests this conclusion should be treated
with caution. Some concerns were expressed regarding the potential for unnecessary dispensing of
spectacles, particularly in care homes.
Issues connected with wearing spectacles
Carers, particularly in care homes, noticed some people with dementia being reluctant to wear their
spectacles. The reason given by interviewees was that the glasses were not needed, even for those
interviewees who had successfully worn glasses before the onset of dementia. This may be an accurate
assessment of the situation, as some people will have clearer vision without their spectacles, especially if
their refractive error has changed or if they are wearing someone else’s glasses, and so on, but in some
cases a participant’s decision that glasses are not needed is unlikely to have been made on the basis of
better VA without the spectacles. There is no obvious explanation for this phenomenon, although carers
suggested that short-term memory loss reinforced long-term memories of not requiring spectacles for
distance, or that glasses were being shed along with other items considered unnecessary in the ‘shrinking
world’ of the participant.
Missing and broken spectacles were another issue and reported to be common in care homes. Labelling
spectacles with the wearer’s name, date of supply and purpose (e.g. for distance or near tasks) facilitates
the return of spectacles to the rightful owner.91 Carers can also benefit from the optometrist providing
a brief report that includes the person’s visual problems, the purpose of the spectacles and a
recommended date for re-examination.129 Labelling current spectacles with names and functions would
also assist optometrists when they carry out an eye examination.
Stage 2 data revealed that some people with dementia refused to wear their glasses, although the exact
reasons for this were unknown. In the PrOVIDe study it could be argued that some participants classified
as having uncorrected/undercorrected VI are not correctable in practical terms because they will not
wear any glasses prescribed. To investigate this possibility, those cases in which the research optometrists
recorded that spectacles were ‘lost’ or were ‘damaged or in poor condition’ were investigated. Broken
glasses would have been recorded as ‘damaged or in poor condition’, but so too would damage that fell
short of the spectacles being broken, for example very scratched lenses. The proportion of participants
with damaged/poor-condition glasses in the uncorrected/undercorrected VI category was compared with
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the proportion in the remainder of the sample, to test if the proportion of damaged/poor-condition glasses
was significantly different between the two groups.
For VI defined by the VA < 6/12 cut-off point, and for uncorrected/undercorrected VI, 6 out of 84 (7.1%,
95% CI 3.3% to 14.7%) participants had lost or damaged spectacles. Of the six participants with lost or
damaged spectacles, three had lost their spectacles and the remaining three participants had damaged
spectacles. For the remainder of the sample, 41 out of 624 (6.6%, 95% CI 4.9% to 8.8%) had lost or
damaged spectacles.
For VI defined by the VA < 6/18 cut-off point, and for uncorrected/undercorrected VI, 4 out of 45 (8.9%,
95% CI 3.5% to 20.7%) participants had lost or damaged spectacles. Of the four participants with lost or
damaged spectacles, two had lost their spectacles and the remaining two had damaged spectacles. For the
remainder of the sample, 43 out of 663 (6.5%, 95% CI 4.9% to 8.6%) had lost or damaged spectacles.
There is no evidence from this analysis to suggest that the proportion of participants with lost or damaged
spectacles is greater in the uncorrected/undercorrected VI group than in the remainder of the sample.
However, the numbers with lost or damaged glasses are low in the uncorrected/undercorrected VI group
for both the VA < 6/12 and VA < 6/18 cut-off points, so this result should be interpreted with caution.
In summary, there is the potential for people with dementia to be wearing inappropriate spectacles owing
to loss, breakage or cost. Labelling spectacles with the wearer’s name and the purpose for which they
should be worn can be helpful.
Expedited cataract surgery
In stage 1 of PrOVIDe, cataract of all grades, clinically significant cataract (grades 2 and above) and IOLs in
one or both eyes were all common occurrences, found in 59%, 38% and 27%, respectively, of the
sample. Cataract was identified in stage 1 as a major cause of VI at both the VA < 6/12 and VA < 6/18
cut-off points. As a result, the issue of when to intervene and initiate cataract surgery was a topic
discussed in interviews and focus groups in stage 2, which led to consideration of the problem of capacity
as cognitive impairment progresses. Participants interviewed were generally positive about cataract surgery
and those who had undergone surgery reported positive outcomes. Family carers appreciated the possible
benefits but had concerns regarding the physical and emotional demands on their relatives. Care workers
expressed concerns about how those with more severe cognitive impairment might cope with surgery.
Each focus group was asked if it would be beneficial to offer expedited cataract surgery to those with both
cataract and dementia before the person’s cognitive impairment was sufficiently advanced to compromise
surgery or before they lacked capacity to consent. Carers and care workers all agreed that early
intervention would be beneficial; the idea was also supported by optometrists, although not unanimously.
The benefits of cataract surgery in care home residents were demonstrated in a small US study.145
One inclusion criterion was a sMMSE score of ≥ 13 that excluded those with more severe cognitive
impairment. The mean and SDs of the sMMSE scores for the intervention (21.1, SD 5.3) and control
groups (19.7, SD 5.3) suggest that many of the subjects had mild to moderate cognitive impairment.
Cataract surgery significantly improved short-term vision-targeted quality-of-life measures, in addition to
improvements in VA. In a small-scale Japanese study of 20 subjects and 20 controls, the grade of cognitive
impairment after cataract surgery improved in 12 patients (60%), was unchanged in seven patients (35%)
and was worse in one patient (5%). Mean scores on the Revised Hasegawa Dementia Scale in the cataract
surgery group improved from 12.5 (SD 5.3) points preoperatively to 16.6 (SD 6.2) points postoperatively;
the improvement was significant (t=−5.02; p< 0.0001).146 VI as a result of cataract may cause stress to
attentional mechanisms, and cognitive performance may improve following cataract surgery in some
patients with early cognitive impairment.26 In patients with more advanced cognitive impairment the
benefits of cataract extraction are less clear.
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The benefits of expedited cataract extraction, as measured by the effect on falls, are more equivocal.
In one UK study limited to female subjects, expedited first eye cataract extraction significantly reduced the
risk of recurrent falls, the overall rate of falls and the fracture risk, although there was no significant
difference in the rate of first falls. No subjects had sMMSE scores of < 15, and the distribution of sMMSE
scores (median 27 in both the expedited group and controls) and range of scores (15–30 and 18–30,
respectively) suggests a sample containing a minority of cognitively impaired subjects. However, the
cataract extractions in the intervention group were expedited by only 11 months on average, and surgery
expedited by several years could bring greater benefit.79 A similar study investigated the effects of second
eye surgery on falls, finding no significant difference for any of the measures of falls between the groups
with expedited second eye cataract surgery and those remaining on the waiting list for second eye
surgery.147 Based on these studies, a Cochrane review included in its implications for practice that
‘Expedited first eye cataract surgery for people on a waiting list significantly reduces rate of falls compared
with waiting list controls’.148 Recommendations for clinical practice for the management of those at
moderate or high risk of falling, which includes people with dementia, included having regular eye
examinations and early referral for first eye cataract extraction as appropriate.81
Another small-scale study investigated the effects of expediting binocular cataract extraction by 6 months in
the cognitively impaired.149 Preliminary results suggested that expedited cataract surgery in people with
dementia has the potential to improve behavioural measures while decreasing neuropsychiatric symptoms
and carer distress. The intervention also reduced the decline of cognitive function as measured by sMMSE
scores. In summary, further research is needed into expedited first eye cataract surgery in those with
cognitive impairment.
Visual impairment and behavioural and functional ability
This exploratory analysis, using ordinal logistic regression, compared data from the BADLS and CBI-R
instruments for the visually impaired and non-visually impaired subsamples for both VI cut-off criteria
based on presenting VA. Adjustments were made for age, sex and residential status, and the resulting ORs
are estimates of the independent effect of VI on these function activities and behaviours. To compensate
for the number of multiple comparisons the conservative Bonferroni correction was used, altering the
cut-off p-values to 0.0025 for BADLS and to 0.0011 for the CBI-R instrument. All 20 BADLS items had ORs
of > 1.0, which indicates an adverse effect of VI on each of these activities, for the VA < 6/12 criterion,
and 19 out of 20 were > 1.0 for the VA < 6/18 criterion. For the VA < 6/12 criterion, ORs were significant
for the ‘toilet/commode’ and ‘telephone’ activities, both of which are dependent on visual input for
successful completion. For the VA < 6/18 criterion, there were no statistically significant estimated ORs for
any activity.
For the CBI-R, for both the VA < 6/12 and the VA < 6/18 criteria, 75% of the 45 behaviours have ORs of
> 1.0, indicating an adverse affect of VI. The only behaviour with a statistically significant OR for VI defined
by VA < 6/12 was ‘has difficulties writing (letters, Christmas cards, lists, etc.)’, for which good visual
performance is crucial, but there was also some evidence for a VI effect for other behaviours requiring
efficient processing of visual input, namely ‘has difficulties using the telephone’, ‘has problems handling
money or paying bills’ and ‘has difficulties grooming self (e.g. shaving or putting on make-up)’. No
behaviours had significant ORs for the VA < 6/18 criterion, although there was some evidence for an
independent VI effect on ‘has difficulties writing (letters, Christmas cards, lists, etc.)’ and for a behaviour
with less obvious links to vision, ‘makes tactless or suggestive remarks’.
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Visual impairment is frequently associated with an increased risk of visual hallucinations, and the
prevalence of visual hallucinations in dementia is common, particularly, for example, in the Lewy body
dementias.150,151 In this context, the co-occurrence of VI and cognitive impairment/dementia is likely to be
additive. An interesting future question arising out of our findings is whether or not correcting VI can lead
to a clinical reduction in visual hallucinations. There is weak evidence for an adverse effect of VI on visual
hallucinations from PrOVIDe data, with estimated ORs of 1.47 (95% CI 0.95 to 2.25; p= 0.08) and 1.52
(95% CI 0.90 to 2.54; p= 0.11) for the VA < 6/12 and VA < 6/18 criteria, respectively.
This preliminary investigation suggests that VI in the cognitively impaired causes deficits in some activities of
daily living and behaviours that are vision-related. The association between VI and various aspects of daily
living, both social and physical, is well documented.11,45,69–71,76,145 However, people with moderate to severe
cognitive impairment have often been excluded from these studies.56,70,145 PrOVIDe uses only VA to define
VI, and other aspects of visual function are known to influence visual performance, notably contrast
sensitivity70,76 and visual fields.76 Psychosocial factors, such as coping strategies and having a pessimistic
attitude to life, may also affect how people with VI report on their visual function.45 Nevertheless, the
measurement of VA used in PrOVIDe has been found to be the best predictor of self-reported ‘vision-related
activity limitation’.76 Cataract surgery, which can, at a stroke, eliminate VI for some people, significantly
improved vision-related quality of life in elderly patients, and cognitive impairment and depressive mental
status also improved in parallel with improvement in vision-related quality of life.152
The importance of considering each individual and their needs in terms of quality of life was commonly
raised in focus groups. Although the benefits of improving VA are undeniable, there was an expressed
need to weigh this against the potential risks of distress caused by an eye examination, trying to force
people to wear spectacles if they do not want to, or having cataract surgery. Minimising stress during the
eye examination to allow a thorough eye health assessment is important. Optometrists should take into
account the carer’s perspective on what is best for the person with dementia.
In summary, an exploratory analysis found some significant deficits in vision-related aspects of function and
behaviour in the visually impaired participants that can impact on quality of life. Optometrists and carers
should work together to maximise quality of life for each individual.
Generalisability
The possibility of sampling bias limits, to a degree, the generalisability of the PrOVIDe findings. In group 1
particularly, the likelihood of some participants and/or their carers being more health-orientated than the
general population is suggested by the high proportion of participants who had undergone a recent eye
examination (see Figure 9). While it might be expected that group 2 participants would have regular
eye examinations organised by their care home, it was more surprising to find this in group 1, because
participants and/or carers would have to make a specific effort to organise an eye examination.
Participants in PrOVIDe were aged between 60 and 89 years at recruitment, and our results may not be
generalisable to those with dementia outside this age range. However, a strength of PrOVIDe was the
inclusion of the full range of cognitive impairment, including 27% of participants who either were unable
to be assessed using the sMMSE or scored ≤ 9 on the sMMSE.
Although PrOVIDe participants were recruited from a range of demographic areas to encourage a
heterogeneous population comprising a range of ethnicities, data on ethnicity were not collected, as the
sample size would not have allowed for analysis of variations between ethnic groups.
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Recruitment targets were stratified by two wide age groups and sex to reflect the age–sex distribution of
the UK dementia population at the time. To achieve the overall sample recruitment target in the duration
of the project, there was some over- and under-recruitment to several strata. This, and the non-ignorable
proportion of unobserved distance VA and NVA within the sample (missing data), limits the generalisability
of extrapolating our unadjusted prevalence estimates to the wider UK population with dementia. To obtain
more plausible prevalence estimates within the sample, multiple imputation (not just for complete cases)
was used. To then calibrate our prevalence estimates to the latest-available wider UK data from the
Alzheimer’s Society,2 within the sample and post-stratification population calibration weights were derived
and extrapolated population prevalences were calculated. We also accounted for the clustering effect of
our sampling by regions and by sites within regions. Given all of this, extrapolated prevalences for distance
VI and near vision loss (1) are higher in these population estimates than the PrOVIDe sample rates, and
(2) have wider CIs. Feature 1 reflects the undersampling and increased difficulty in obtaining VA measures
from people more likely to have worse VA. Feature 2 reflects the design effect and the large variation in
calibration weights.
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Chapter 6 Conclusions
Summary
This is the first large-scale investigation of VI in the dementia population in England. The overall
prevalences of presenting VI were 32.5% and 16.3% for VA < 6/12 and VA < 6/18, respectively, in people
with dementia aged 60–89 years. Prevalence estimates of presenting VI in those with dementia from
PrOVIDe are generally higher, after adjusting for age and sex differences, than estimates from previous
population studies of older people that used comparable methods and which either excluded or had low
proportions of participants with dementia. There is a lack of robust comparative prevalence data for
uncorrected/undercorrected VI; prevalences in PrOVIDe were 14.3% for VA < 6/12 and 7.7% for VA
< 6/18. Distance acuity improved by two or more lines post refraction in 17.8% of participants.
For post-refraction VI, the element of VI that remains even with best spectacle correction, prevalences were
18.1% and 8.6% for VA < 6/12 and VA < 6/18, respectively. For VA < 6/12, almost half of this VI was the
result of cataract, and is potentially remediable: approximately one-third was caused by AMD.
When extrapolated to the wider UK population with dementia, following post-stratification calibration and
imputation, prevalences of VI are generally higher, with wider CIs, than the PrOVIDe sample rates. For VA
< 6/12, the extrapolated prevalences for presenting, post-refraction and uncorrected/undercorrected VI
were 34.6% (95% CI 29.3% to 40.3%), 22.4% (95% CI 16.4% to 29.9%) and 13.6% (95% CI 10.5%
to 17.4%), respectively. For VA < 6/18, the extrapolated prevalences for presenting, post-refraction and
uncorrected/undercorrected VI were 20.3% (95% CI 16.7% to 24.6%), 12.2% (95% CI 8.8% to 16.6%)
and 8.3% (95% CI 5.9% to 11.6%), respectively.
While research studies rarely include substantial numbers of people with dementia living in care homes,
the PrOVIDe study included 319 care home residents (group 2). The unadjusted rate ratios of presenting,
uncorrected/undercorrected and post-refraction VI were all two to two-and-a-half times greater in those
living in care homes, and the differences in proportions between groups 1 and 2 were statistically
significant. After adjusting for age and sex (and, for uncorrected/undercorrected VI only, for sMMSE), the
group effect remained statistically significant. Presenting VI prevalence in participants living in care homes
was 51.4% for VA < 6/12 and 26.4% for VA < 6/18, and, for both VI criteria, > 40% of this presenting VI
was correctable with spectacles.
The prevalences of presenting and post-refraction VI increased significantly with age after adjusting for sex
and group for both VI criteria. However, after adjusting for sex, group and sMMSE score, there was no
evidence of an independent age effect on uncorrected/undercorrected VI. There was no consistent
evidence for any independent sex effect. For uncorrected/undercorrected VI for VA < 6/18, women were
more likely to be in this category.
Near vision is rarely investigated in VI studies; 16.2% of PrOVIDe participants could not read standard
newspaper-size print with their current spectacles; however, almost two-thirds of these participants could
read standard newspaper-size print with up-to-date spectacles. After adjusting for age and sex
(and, for uncorrected/undercorrected VI only, for sMMSE), there was a significant independent group
effect for presenting near vision loss for both the <N8 and the <N10 criteria, for post-refraction loss for
the <N8 criterion and for uncorrected/undercorrected loss for the <N10 criterion.
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There was no evidence that the management of VI in people with dementia differed from that in the
general population of older people. The percentage of participants advised of a change in their spectacle
prescription post refraction was consistent with the national figure. In terms of the management of eye
disease, if the study had identified considerable inappropriate management it could have resulted in a
higher than expected referral rate following the PrOVIDe eye examination. Although the PrOVIDe referral
rate was 6.7%, higher than the national figure of 5%,52 the higher percentage of referrals could be
expected owing to the age range of the sample.
An exploratory ordinal logistic regression analysis found significant deficits in some vision-related aspects
of function and behaviour in the visually impaired participants, compared with the non-visually
impaired participants.
Key messages
The high prevalence of participants with uncorrected/undercorrected VI, the disproportionately high
prevalence of VI in care home residents and the high proportion of those with VI due to potentially
remediable cataract suggest that eye care for people with dementia could be enhanced by attention to
the following:
l more information about eye care for people with dementia and carers
l better communication between optometrists and carers and between optometrists and other
health-care professionals
l tailoring the eye examination, spectacle dispensing and treatment of eye problems to meet the needs
of the individual
l providing professional development, training and guidance for optometrists.
More information about eye care for people with dementia and carers
The results have demonstrated that it is possible for optometrists to conduct most of the key components
of the eye examination on > 80% of people with dementia in this study, with visual fields being the
exception. The important health checks of tonometry and ophthalmoscopy were possible in > 90% of
participants. Those participants unable to carry out some elements of the examination were usually people
classified, using the sMMSE, as having severe cognitive impairment. However, the qualitative data suggest
that some carers and care workers were unsure if people with dementia could have a full eye examination
if they had difficulty answering questions. This indicates a need to increase their awareness about the
purpose, scope and limitations of eye examinations in order to encourage uptake of eye examinations in
line with health-care recommendations.
Better communication between optometrists and carers and between
optometrists and other health-care professionals
The qualitative data revealed that communication between optometrists and those responsible for caring
for people with dementia could be improved. Ensuring that optometrists know when they are dealing with
someone with cognitive impairment would enable them to tailor the examination to meet the individual’s
needs. This would include involving a family member whenever possible, something that family carers
identified as being highly relevant. Where individuals having an eye examination are accompanied by a
professional care worker, it is important that the care worker knows the individual and has the relevant
information to hand; optometrists should ensure that they make time to contact the care home for further
information if necessary.
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Tailoring the eye examination, spectacle dispensing and treatment of eye
problems to meet the needs of the individual
Improving VA, identifying possible causes of VI and referring the patient for medical intervention when
necessary are the main responsibilities of the optometrist when examining an older person with cognitive
impairment. However, the needs of the individual and quality-of-life issues should be taken into
consideration by the attending optometrist and discussed with carers. This may impact on decisions
regarding the desirability of subjecting an individual to a full eye examination, if this is likely to cause
substantial distress, minimising unnecessary changes when prescribing and dispensing spectacles and
possible referral for cataract surgery or other interventions.
Providing professional development, training and guidance for optometrists
The PrOVIDe study was led by the CoO, the professional, scientific and examining body for optometry in
the UK, working for the public benefit. More than 70% of UK optometrists are members, which places the
College in an excellent position to increase professional awareness of eye care for people with dementia
by providing information and guidance and opportunities for professional development, and exploring the
possibility of a mentorship scheme.
Key implications for practice
Table 43 provides a list of the key implications for practice, together with the audiences for which these
implications are relevant.
TABLE 43 Key implications for practice
Key implication Relevant audiences
More information about eye care for people with dementia
and carers
l Professional organisations (e.g. CoO, Association of
Optometrists, Royal College of General Practitioners)
l Charities (e.g. Alzheimer’s Society, Thomas
Pocklington Trust, RNIB)
l Universities training optometrists
l DOCET
Better communication between optometrists and carers and
between optometrists and other health-care professionals
l Professional organisations (e.g. CoO, Association of
Optometrists, Royal College of General Practitioners)
l Universities training optometrists
l DOCET
Tailoring the eye examination, spectacle dispensing and
treatment of eye problems to meet the needs of the individual
l Professional organisations (e.g. CoO, Association of
Optometrists, Association of British Dispensing
Opticians)
l Universities training optometrists
l DOCET
Providing professional development, training and guidance
for optometrists
l Professional organisations (e.g. CoO, Association
of Optometrists)
l DOCET
DOCET, Directorate of Optometric Continuing Education and Training.
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Limitations of the study (see Chapter 5 for full details)
l Sampling bias is possible owing to quota-sampling and response bias. Some participants and their
carers might have been more health-orientated than the general population. In addition, the PrOVIDe
regional sample may not be fully representative of the general UK population.
l A considerable proportion of VA assessments (≈17%) and sMMSE assessments were not available
owing to a range of factors, notably poor participant co-operation, and this proportion varied across
age (≈9% to 26%) and between group 1 (≈3%) and group 2 (≈33%). To improve the plausibility of
our regression analysis assumptions, a multiple imputation procedure was carried out, with the results
discussed in Chapter 3 (see Missing data sensitivity results). There were no changes in the substantive
conclusions relating to our key tables, Tables 11, 15 and 24, under the imputation model, compared
with the complete-case analysis.
l Monocular VAs were recorded at both distance and near, both before and after the refraction.
When PrOVIDe prevalence data are compared with those from studies that measured binocular VAs,
this makes comparisons less robust.
l The causes of VI in the PrOVIDe sample have mostly been identified by the examining optometrists,
and not definitively made, or confirmed, by an ophthalmologist. This limitation was inherent to the
study design.
Recommendations for research
Further improvements to eye care for people with dementia may be recommended depending on the
results of further research. Four areas have emerged from this study with recommendations for
further research:
1. development of an eye-care pathway for people with dementia
2. early intervention for cataract
3. the role of the specialist practitioner
4. eye care for other vulnerable groups.
Development of an eye-care pathway
The first recommendation is for research into the development of an eye-care pathway for people with
dementia, which could be supported by local commissioners, that considers what should happen in terms
of eye care when an individual is diagnosed with dementia. This could include the following questions:
l What information do individuals and carers need to promote uptake of eye examinations?
l How regularly should people with dementia have an eye examination? Is there a need for more
frequent eye examinations than is currently advised for the general population of similar age?
l In acknowledgement of the problems regarding spectacles for people with dementia (increased
incidence of spectacles being broken or lost) should there be additional financial support for spectacle
provision? For example, should there be financial subsidies to provide spectacles made from materials
less likely to break?
l What are the barriers to and facilitators of providing continuity of eye care for individuals?
l What modifications are required to the current structure for GOS funding of sight tests in both
community practice and domiciliary practice? This could include establishing minimum requirements for
a health check when there are difficulties in completing a full eye examination, and providing adequate
remuneration for the extra time often required for the examination of people with dementia.
l Should the threshold for considering cataract surgery be lower for people with dementia than for the
general population?
The last research question is related to the second area of research recommendations.
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Early intervention for cataract
People with dementia who were interviewed for PrOVIDe said that they would have cataract surgery if
needed. Carers described balancing the risks, burdens and benefits of cataract surgery against the impact
on quality of life. The potential for different outcomes in decision-making depending on who is responsible
suggests that it would be preferable for the decision to be made while an individual had mental capacity
to decide. This gave rise to the second recommendation for research, that there should be research into
the effects of early cataract intervention for people in the early stages of cognitive impairment. Should this
research demonstrate benefits from early intervention, these could lead to local commissioning of
expedited cataract surgery when clinically necessary.
The role of the specialist optometric practitioner
The third recommendation for research is to explore the potential of developing the role of a specialist
optometric practitioner for people with dementia. This would include establishing the competencies for the
role, training requirements and feasibility. Initial research should consider the possibility of insufficient
interest from the optometric profession and consider if this could be accommodated within the alternative
of a specialty for working with older people. Research should also explore how the role would be
positioned in the current mixed economy of health-care provision; that is, would specialists be independent
practitioners or employed by the NHS in hospital, or in community/domiciliary settings? If this research
suggested that there is potential for the specialist optometric practitioner, this role could be developed by
the CoO, who already offer higher qualifications in other specialisms (e.g. contact lenses, low vision).
Eye care for other vulnerable groups
The findings of the PrOVIDe study suggest that optometric care for people with dementia could be
improved. It follows that research should also be conducted into the prevalence of undetected or
uncorrected VI and the provision of optometric care for other vulnerable groups. Based on the study
findings regarding the lack of awareness of domiciliary eye care, one such target group would be older
people with chronic illness and disability who have difficulty accessing community-based optometric
practice. Depending on the outcome of this research, local commissioners and optometric professional
organisations could become involved in improving eye care for these groups.
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Appendix 1 Annotated Strengthening the
Reporting of Observational Studies in
Epidemiology checklist
The comments in the right-hand column of the checklist below give detail of compliance of the PrOVIDestudy with the STROBE criteria.
Item
Item
number Recommendation PrOVIDe compliance
Title and abstract 1 (a) Indicate the study’s design with a
commonly used term in the title or
the abstract
(a) Compliant: the cross-sectional design is
included in both the title and the abstract
(b) Provide in the abstract an
informative and balanced summary of
what was done and what was found
(b) Compliant
Introduction
Background/rationale 2 Explain the scientific background and
rationale for the investigation being
reported
Compliant: pages xxiii, xxv and 1–16
Objectives 3 State specific objectives, including any
prespecified hypotheses
Compliant: page 16, Aims and objectives
Methods
Study design 4 Present key elements of study design
early in the paper
Compliant: page 17, Methods
Setting 5 Describe the setting, locations, and
relevant dates, including periods of
recruitment, exposure, follow-up and
data collection
Compliant: pages 17–27
Participants 6 Cross-sectional study: give the eligibility
criteria, and the sources and methods
of selection of participants
Compliant: pages 19–20, Recruitment
of participants
Variables 7 Clearly define all outcomes, exposures,
predictors, potential confounders, and
effect modifiers. Give diagnostic criteria,
if applicable
Compliant, where applicable: pages 20–8
and, for additional diagnostc criteria,
page 41
Data sources/
measurement
8a For each variable of interest, give
sources of data and details of methods
of assessment (measurement). Describe
comparability of assessment methods if
there is more than one group
Compliant: pages 20–7, for Stage 1
(quantitative study) Data collection and
pages 27–8 for Stage 2 (qualitative study)
Bias 9 Describe any efforts to address potential
sources of bias
Compliant: page 17 (England-wide
recruitment), pages 19–20 (inclusion of
participants who lacked mental capacity to
consent), pages 33–5 (matching sample
profile with UK population with dementia),
pages 29–30 (logistic regression was used
to control for covariates), pages 30–1
(missing data plan), pages 68–70
(use of sMMSE blind)
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Item
Item
number Recommendation PrOVIDe compliance
Study size 10 Explain how the study size was arrived at Compliant: pages 18–19 (Sample size)
Quantitative variables 11 Explain how quantitative variables were
handled in the analyses. If applicable,
describe which groupings were chosen
and why
Compliant: pages 20–7 (Stage 1 Data
collection), pages 37–40 (Levels of cognitive
impairment in the sample), page 41
(Prevalence of visual impairment)
Statistical methods 12 (a) Describe all statistical methods,
including those used to control for
confounding
(a) Compliant: pages 28–32 (Stage 1 Data
analysis plan)
(b) Describe any methods used to
examine subgroups and interactions
(b) None
(c) Explain how missing data were
addressed
(c) Compliant: pages 30–1 (Missing
data plan)
(d) Cross-sectional study: if applicable,
describe analytical methods taking
account of sampling strategy
(d) All prevalence estimates and their
inferences were adjusted for the two-stage
sample design and for the deviation of
age, sex and residence distributions in the
recruited sample from those of the target
population. Page 31 (Extrapolating
prevalence to the UK dementia
population)
(e) describe any sensitivity analyses (e) Compliant: pages 30–1 (Missing
data plan)
Results
Participants 13a (a) Report numbers of individuals at
each stage of study, e.g. numbers
potentially eligible, examined for
eligibility, confirmed eligible, included in
the study, completing follow-up and
analysed
(a) Compliant: pages 33–7 (Recruitment)
(notably Figure 3) and pages 41–3 (notably
Figures 6 and 7)
(b) Give reasons for non-participation at
each stage
(b) Compliant: pages 33–7 (Recruitment),
pages 41–3 (Prevalence of visual
impairment) and pages 57–8 (Reasons for
not dilating)
(c) Consider use of a flow diagram (c) Compliant: see flow diagrams in
Figures 1, 3, 6 and 7
Descriptive data 14a (a) Give characteristics of study
participants (e.g. demographic, clinical,
social) and information on exposures
and potential confounders
(a) Compliant: pages 33–40
(Demographics and characteristics of the
sample). There is no exposure data in our
data set. We had no access to social data
(b) Indicate number of participants with
missing data for each variable of interest
(b) Compliant: Tables 5–10, pages 63–4
(Factors associated with near vision loss)
Outcome data 15 Cross-sectional study: report numbers of
outcome events or summary measures
Compliant. The summary measures
(counts) of all important outcome
measures are given in Tables 7–10
(distance visual impairment), Table 12
(eye conditions) and Tables 21 and 22
(near vision loss)
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
156
Item
Item
number Recommendation PrOVIDe compliance
Main results 16 (a) Give unadjusted estimates and,
if applicable, confounder-adjusted
estimates and their precision (e.g. 95%
CI). Make clear which confounders
were adjusted for and why they were
included
(a) Compliant. All estimates are available in
the report in both unadjusted and
adjusted (for age, sex and where
appropriate sMMSE) ORs
(b) Report category boundaries when
continuous variables were categorised
Compliant. For example, Table 5 (cognitive
impairment categorised by sMMSE score),
Table 8 (variations in VI prevalence with
age), Tables 13 and 14 (prevalence of eye
conditions with age), etc.
(c) If relevant, consider translating
estimates of relative risk into absolute
risk for a meaningful time period
N/A
Other analyses 17 Report other analyses done, e.g.
analyses of subgroups and interactions,
and sensitivity analyses
Compliant: pages 30–31 (Missing data plan)
for details of sensitivity analyses
Discussion
Key results 18 Summarise key results with reference to
study objectives
Compliant: pages 137–9 (Summary)
Limitations 19 Discuss limitations of the study, taking
into account sources of potential bias or
imprecision
Discuss both direction and magnitude
of any potential bias
Compliant: pages 114–115 (Limitations of
the study)
Interpretation 20 Give a cautious overall interpretation
of results considering objectives,
limitations, multiplicity of analyses,
results from similar studies, and other
relevant evidence
Compliant: pages 116–134
Generalisability 21 Discuss the generalisability (external
validity) of the study results
Compliant: pages 134–135
(Generalisability)
Other information
Funding 22 Give the source of funding and the role
of the funders for the present study
and, if applicable, for the original study
on which the present article is based
Compliant: NIHR
N/A, not applicable.
a Give such information separately for cases and controls in case–control studies and, if applicable, for exposed and
unexposed groups in cohort and cross-sectional studies.
Note
An Explanation and Elaboration article discusses each checklist item and gives methodological background and published
examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the
websites of PLoS Medicine at www.plosmedicine.org/, Annals of Internal Medicine at www.annals.org/ and Epidemiology
at www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.
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Appendix 2 Stage 2 focus group question
schedules
Focus group for family carers
1. Introductions
Going around the group, can I ask you to introduce yourself, giving the name that you would like group
members to use when addressing you?
2. Opening question
(‘Round Robin’ style question designed to be answered by all participants. The question should be
something that everyone can answer.)
As you know, this research study is about visual impairment in people with dementia. But before we get onto
that I’d like to start with a general question about eye examinations. I’ll go around the group again to ask:
l How often do you think people should have their eyes tested?
(Reinforce that the question is to find out opinions, not to identify a right answer or to find out who is
right and who is wrong.)
3. Follow-up
If the national recommendation was not identified by any group participant in response to question 2,
explain what this is. Then ask the group for their views on this recommendation.
4–8. Key questions
Explain that I won’t go around the whole group in turn for the remaining questions that they can answer
if and when they would like to.
4. I’d like to move on now to ask you some questions about eye care and the person with dementia that
you care for:
l Did they have regular eye tests before the dementia started?
[Follow up to find out if they still have eye tests, how regularly and when the last test was (before
participation in stage 1 of this study.]
5. I’d like to hear about your experiences of your friend or relative’s eye tests:
l Has anyone had any problems finding an optometrist to do the test?
l Were you present at the test and if so do you remember/were you aware of any difficulties in
conducting the eye test?
6. If the person you care for has an eye problem and you are willing to share this information with
the group:
l Did you know about the eye problem before they developed dementia?
l As far as you are aware, has the dementia affected the management of the eye problem?
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7. From my own experience I know that there are all sorts of things that are important when you are
caring for people with dementia. Like making sure they have enough to eat and drink, continence, safety,
and so on:
l How important is it that people with dementia have their eyes tested?
l If they need glasses, how important is it for them to wear them?
8. If your friend or relative needed hospital treatment for an eye problem, for example they had a cataract
and removing it would help them to see better, how would you feel about them having that treatment?
9–10. Summary questions
9. I’ve covered the main things that I wanted to ask you about:
l Is there anything that you would like to raise that hasn’t been covered?
10. Before we end, I have one final question. I’ll go around the group so that everyone has a chance to
answer if you would like to:
l If you could say one thing about eye care for people with dementia, that you would like health-care
providers to hear, what would that be?
Focus group for care workers
1. Introductions
Going around the group, can I ask you to introduce yourself, giving the name that you would like group
members to use when addressing you?
2. Opening question
(‘Round Robin’ style question designed to be answered by all participants. The question should be
something that everyone can answer.)
As you know, this research study is about visual impairment in people with dementia. But before we get onto
that I’d like to start with a general question about eye examinations. I’ll go around the group again to ask:
l How often do you think people should have their eyes tested?
(Reinforce that the question is to find out options, not to identify a right answer or to find out who is right
and who is wrong.)
3. Follow up
If the national recommendation was not identified by any group participant in response to question 2,
explain what this is. Then ask the group for their views on this recommendation.
4–8. Key questions
Explain that I won’t go around the whole group in turn for the remaining questions, that they can answer
if and when they would like to.
4. I’d like to move on now to ask you some questions about eye care and the people with dementia that
you care for:
l When people are first admitted to the care home, what do you do to find out about any history of
eye problems?
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5. What arrangements are made for people to have an eye test?
l Has anyone had any problems finding an optometrist to do the test?
l Have you been present at eye tests and if so do you remember/were you aware of any difficulties in
conducting the eye test?
6. Are there any particular problems about providing eye care for people with dementia in care homes?
7. From my own experience I know that there are all sorts of things that are important when you are
caring for people with dementia. Like making sure they have enough to eat and drink, continence, safety,
and so on:
l How important is it that people with dementia have their eyes tested?
l If they need glasses, how important is it for them to wear them?
8. If someone with dementia needed hospital treatment for an eye problem, for example, they had
a cataract and removing it would help them to see better, what is your view about them having
that treatment?
9–10. Summary questions
9. I’ve covered the main things that I wanted to ask you about:
l Is there anything that you would like to raise that hasn’t been covered?
10. Before we end, I have one final question. I’ll go around the group so that everyone has a chance to
answer if you would like to:
l If you could say one thing about eye care for people with dementia, that you would like health
providers to hear, what would that be?
Focus group for optometrists
1. Introductions
Going around the group, can I ask you to introduce yourself, stating your profession, and giving the name
that you would like group members to use when addressing you?
2. Opening question
(‘Round Robin’ style question designed to be answered by all participants. The question should be
something that everyone can answer.)
As you know, this research study is about visual impairment in people with dementia. But before we get onto
that I’d like to start with a general question about eye examinations. I’ll go around the group again to ask:
l How often do you think people with dementia should have their eyes tested by an optometrist?
(Reinforce that the question is to find out opinions, not to identify a right answer or to find out who is
right and who is wrong.)
3. Follow-up
If the national recommendation was not identified by any group participant in response to question 2,
explain what this is. Then ask the group for their views on this recommendation.
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4–7. Key questions
Explain that I won’t go around the whole group in turn for the remaining questions, that they can answer
if and when they would like to.
4. I’d like to move on now to ask you some questions about eye care and the people with dementia that
you examine:
l What are the main barriers, if any, that you come across when examining someone with dementia?
l How can these barriers be overcome?
5. Do you feel adequately prepared in terms of your professional training and experience for the
examination of patients with dementia?
l If not, what additional training do you think would be most useful?
l What form of training would you prefer: hands-on training, via DVD, paper based, short courses,
or some combination?
6. If you were asked to carry out a domiciliary examination on a patient with dementia, do you have access
to the equipment required to perform an adequate domiciliary examination?
7. You are asked by a patient to carry out a domiciliary examination, but you are not able to provide this
service yourself or through someone else in your practice:
l Would you be able to recommend optometrists or dispensing opticians or companies who would be
able to make a home visit to examine the patient?
8–9. Summary questions
8. I’ve covered the main things that I wanted to ask you about:
l Is there anything that you would like to raise that hasn’t been covered?
9. Before we end, I have one final question. I’ll go around the group so that everyone has a chance to
answer if you would like to:
l If you could say one thing about eye care for people with dementia, that you would like health-care
providers to hear, what would that be?
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Appendix 3 Stage 2 interviews topic guide
IMPORTANT NOTE: the following question schedule is a guide and will be used flexibly and appropriatelyaccording to the abilities and responses of the interviewee.
1. I know that you had your eyes tested recently as part of this research study. When did you last have
your eyes tested before that?
l Ask about how often they normally have their eyes tested and whether this has changed in recent years.
2. Do you have spectacles?
l Ascertain type of spectacles (reading, long distance, bifocals, progressive power lenses).
l Ask about whether they wear their glasses as prescribed.
l When did they last have new glasses or new lenses in their own frames?
3. Do you have a magnifying glass?
l Did they get the magnifying glass from opticians or from a hospital?
l Ask if they use their magnifying glass.
l If used, establish what tasks magnifying glass is used for.
l When did they last have their magnifying glass checked by the optician or at the hospital?
4. Does your eyesight cause you any problems?
5. Do you usually go the same optician to have your eyes tested?
l Ask if they have any worries about seeing an optician (optometrist).
l Ask if they find any problems coping with the eye test.
l Ask about satisfaction with how the optician (optometrist) dealt with them.
l Ask if the optician (optometrist) knows about their dementia.
6. Before you took part in the research study, did you know about the possibility of having an eye
examination done at home?
7. Do you have/have you had any eye problems that meant you had to go to the hospital, for example,
a cataract?
l Ask about their experience, before or since they found out they had dementia.
l If applicable, in their opinion, does/did having dementia make any difference to their treatment
(look for positive as well as negative comments).
8. What is your opinion about eye care for people with dementia?
l Anything that could be improved?
l Any suggestions about how things could be improved?
9. Thank you. That’s all I wanted to ask you about. Is there anything that you would like to say that I
haven’t asked you about? Anything you want to add?
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Appendix 4 Odds ratios and inferences under the
multiple imputation model
Imputed multivariable (adjusted) odds ratios for each type of
visual impairment by age, sex, and group
OR 95% CI p-value
Presenting VI (VA < 6/12) (n observed= 588)
Age (per year) 1.03 1.00 to 1.06 0.050
Sex: male 0.75 0.51 to 1.11 0.152
Group: residential care 3.66 2.40 to 5.57 < 0.001
Post-refraction VI (VA < 6/12) (n observed= 590)
Age (per year) 1.03 0.99 to 1.07 0.121
Sex: male 0.82 0.51 to 1.32 0.417
Group: residential care 3.86 2.10 to 7.11 < 0.001
Under-/uncorrected VI (VA < 6/12) (n observed= 575)
Age (per year) 1.01 0.97 to 1.04 0.793
Sex: male 0.75 0.45 to 1.23 0.247
sMMSE (per unit score) 1.00 0.97 to 1.04 0.903
Group: residential care 1.96 1.13 to 3.42 0.018
Presenting VI (VA < 6/18) (n observed= 588)
Age (per year) 1.02 0.98 to 1.05 0.326
Sex: male 0.95 0.57 to 1.58 0.843
Group: residential care 3.50 2.21 to 5.55 < 0.001
Post-refraction VI (VA < 6/18) (n observed= 590)
Age (per year) 1.03 0.98 to 1.08 0.282
Sex: male 1.56 0.86 to 2.81 0.138
Group: residential care 3.98 2.12 to 7.50 < 0.001
Under-/uncorrected VI (VA < 6/18) (n observed= 575)
Age (per year) 0.99 0.94 to 1.04 0.761
Sex: male 0.46 0.21 to 1.04 0.063
sMMSE (per unit score) 0.96 0.93 to 1.00 0.072
Group: residential care 1.87 0.92 to 3.81 0.085
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Imputed multivariable (adjusted) odds ratios for age-related
macular degeneration, cataract, diabetic retinopathy and
glaucoma/ocular hypertension by age, sex and group
OR 95% CI p-value
Post-examination cataract (grades 2–5) (n observed= 695)
Age (per year) 1.11 1.08 to 1.14 < 0.001
Sex: male 0.80 0.57 to 1.13 0.208
Group: residential care 0.99 0.70 to 1.39 0.480
Post-examination diabetic retinopathy (n observed= 694)
Age (per year) 0.94 0.87 to 1.00 0.062
Sex: male 2.45 0.80 to 7.57 0.118
Group: residential care 2.23 0.75 to 6.62 0.147
Post-examination glaucoma or OHT (n observed= 694)
Age (per year) 1.01 0.97 to 1.05 0.528
Sex: male 1.38 0.82 to 2.31 0.227
Group: residential care 0.75 0.44 to 1.30 0.311
Post-examination AMD (n observed= 694)
Age (per year) 1.17 1.12 to 1.23 < 0.001
Sex: male 0.79 0.50 to 1.23 0.292
Group: residential care 0.63 0.41 to 0.97 0.037
Post-examination diabetes (n observed= 699)
Age (per year) 0.98 0.95 to 1.02 0.318
Sex: male 1.14 0.71 to 1.83 0.582
Group: residential care 1.18 0.74 to 1.89 0.493
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Imputed multivariable (adjusted) odds ratios for each type of
near vision loss by age, sex, group, and (for undercorrected/
uncorrected visual impairment) by Standardised Mini-Mental
State Examination score
OR 95% CI p-value
Presenting NVA <N8 (n observed= 476)
Age (per year) 0.98 0.95 to 1.01 0.250
Sex: male 1.06 0.71 to 1.58 0.772
Group: residential care 3.38 2.18 to 5.24 < 0.001
Post-refraction NVA <N8 (n observed= 568)
Age (per year) 1.00 0.96 to 1.04 0.915
Sex: male 0.94 0.57 to 1.54 0.795
Group: residential care 5.52 2.92 to 10.45 < 0.001
Under-/uncorrected NVA <N8 (n observed= 468)
Age (per year) 1.03 0.89 to 1.18 0.717
Sex: male 0.53 0.15 to 1.91 0.327
sMMSE (per unit score) 0.92 0.85 to 0.99 0.035
Group: residential care 3.70 0.69 to 19.92 0.127
Presenting NVA <N10 (n observed= 476)
Age (per year) 0.98 0.94 to 1.02 0.291
Sex: male 1.00 0.61 to 1.63 0.987
Group: residential care 4.59 2.27 to 9.28 < 0.001
Post-refraction NVA <N10 (n observed= 568)
Age (per year) 1.03 0.95 to 1.11 0.521
Sex: male 0.70 0.33 to 1.47 0.343
Group: residential care 5.41 2.22 to 13.23 < 0.001
Under-/uncorrected NVA <N10 (n observed= 468)
Age (per year) 1.02 0.86 to 1.21 0.811
Sex: male 0.59 0.14 to 2.47 0.466
sMMSE (per unit score) 0.93 0.87 to 1.01 0.075
Group: residential care 4.45 0.72 to 27.54 0.107
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Appendix 5 Further prevalence estimates of
distance visual impairment for the UK populations
aged 60–74, 65–89 and 75–89 years with dementia
Projected prevalence (with 95% confidence intervals) of
distance visual impairment in the population of people with
dementia in the UK between 65 and 89 years old
Population prevalence (%), estimate (95% CI)
Distance VI
Presenting (VA < 6/12) 35.7 (30.4 to 41.3)
Presenting (VA < 6/18) 20.7 (17.1 to 24.8)
Post refraction (VA < 6/12) 22.9 (16.9 to 30.3)
Post examination (VA < 6/18) 12.5 (9.1 to 17.0)
Under-/uncorrected (VA < 6/12) 14.2 (11.1 to 18.0)
Under-/uncorrected (VA < 6/18) 8.4 (6.1 to 11.4)
Projected prevalence (with 95% confidence intervals) of
distance visual impairment in the population of people with
dementia in the UK between 75 and 89 years old
Population prevalence (%), estimate (95% CI)
Distance VI
Presenting (VA < 6/12) 38.2 (32.3 to 44.6)
Presenting (VA < 6/18) 22.0 (18.2 to 26.3)
Post refraction (VA < 6/12) 24.9 (18.2 to 33.1)
Post refraction (VA < 6/18) 13.7 (9.9 to 18.5)
Under-/uncorrected (VA < 6/12) 14.6 (11.3 to 18.7)
Under-/uncorrected (VA < 6/18) 8.5 (6.3 to 11.3)
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Projected prevalence (with 95% confidence intervals) of
distance visual impairment in the population of people with
dementia in the UK between 65 and 74 years old
Population prevalence (%), estimate (95% CI)
Distance VI
Presenting (VA < 6/12) 26.6 (19.8 to 34.9)
Presenting (VA < 6/18) 16.1 (9.6 to 25.8)
Post refraction (VA < 6/12) 15.8 (9.0 to 26.5)
Post refraction (VA < 6/18) 8.4 (3.9 to 17.3)
Under-/uncorrected (VA < 6/12) 12.6 (7.1 to 21.2)
Under-/uncorrected (VA < 6/18) 7.9 (3.3 to 18.0)
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
170
Appendix 6 Public and participant involvement in
the study
Public and participant involvement was a key element in the development and completion of thePrOVIDe study. We engaged the views of people with dementia and carers at the design stage to
ensure that the perspectives of people living with dementia were at the centre of the project’s design and
development. People with experience of caring for people with dementia were involved as coapplicants
and in research roles. This ensured that the study was conceived, planned and executed from the carers’
perspective, always keeping in mind the best interests of people with dementia.
This appendix describes how PPI was integrated into all stages of the study.
Public and participant involvement in developing the research
idea: step 1
George Hancock died at the age of 89 years after having dementia for approximately 10 years. For the first
few years he lived with his wife, supported by his family. Five years before his death he and his wife went to
live with his eldest daughter and her son. At first, family care centred on reassuring him about his failing
memory and keeping him safe. As the dementia progressed, the main issues were diet, hydration, hygiene
and continence. His wife and daughter were supported by the extended family and they felt that they were
doing their best for him, right up to the time that he moved into a care home for the last few months of his
life. But, looking back, they cannot remember him having an eye examination even though he wore glasses.
Why? Was it because the family were more concerned with the more pressing physical and psychological
needs? Or was eyesight overlooked as his cognitive state deteriorated and he no longer read or watched
television or took interest in his surroundings? No one knows. But when the NIHR Dementia Themed
Call for research proposals was announced in 2011, George’s experience struck a chord with his
daughter-in-law (Beverley Hancock) who, by that time, was working as a research adviser to the CoO.
Public and participant involvement in developing the research
idea: step 2
Michael Bowen at the CoO had already started discussions with Sarah Buchanan at the Thomas
Pocklington Trust and the chief executive of the Alzheimer’s Society about conducting some pilot research
into dementia and sight loss. This followed a multiagency conference, at which four people affected by
dementia and sight loss contributed to conference presentations.
The CoO is a professional body for optometrists but it also has a role in promoting public interests, while
the Thomas Pocklington Trust is a charitable organisation concerned with older people and sight loss.
The Alzheimer’s Society is the UK’s leading research and service provision charity for Alzheimer’s and
dementias. All three organisations have a tradition of PPI in developing their research programmes. With
support from a leading academic in optometry (David Edgar), they drafted an outline research proposal
and took it to a workshop organised by the Alzheimer’s Society in response to the NIHR Dementia
Themed Call.
At the workshop researchers were invited to present their research idea to a series of small groups of
Alzheimer’s Society Research Network volunteers and Alzheimer’s Society staff. After the workshop,
Alzheimer’s Society informed the CoO team that the proposal was one of the most highly rated by
participant feedback. The Alzheimer’s Society was willing to join the project as a coapplicant, and several
Research Network volunteers (who were all currently or previously caring for people with dementia)
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had expressed interest in being part of a Steering Group. This was a great confidence booster as we saw it
as confirming something we already thought, namely that the proposed research was addressing an
important topic for people with dementia and their carers, and that people would be interested and want
to participate.
Public and participant involvement in developing the research
idea: step 3
The outline funding application was shortlisted and a Steering Group was formed. James Pickett, at that
time Research Officer with the Alzheimer’s Society, and Susan Maskell, a Research Network volunteer who
had cared for her mother when she had dementia, joined the Steering Group and contributed to the full
application as coapplicants. Their experience of people with dementia, at both the organisational and the
personal level, was invaluable in informing the application. The cost of PPI was factored into the funding
application in accordance with INVOLVE guidelines.153
Lay members of the respective Research Committees of the CoO and Thomas Pocklington Trust reviewed
and contributed to the application prior to submission.
Public and participant involvement in managing the
research study
The PPI representatives from the Thomas Pocklington Trust (Sarah Buchanan) and the Alzheimer’s Society
(Susan Maskell and James Pickett) oversaw the management of the study in their role as members of the
Steering Group, providing advice and information as required and asking the research team lots of questions.
Susan Maskell, in particular, was keen to assist as much as possible and was actively involved in several stages:
l assisting with the design of participant information literature and letters of invitation to participate
l supporting the development of the ethics submission to the Research Ethics Committee and helping to
prepare the response to the Research Ethics Committee’s questions
l offering to go into care homes to explain the study to people with dementia, their relatives and
care workers
l reading interview and focus group transcriptions and assisting with data analysis
l adding her perspective to the presentation of research findings
l reviewing the report to the NIHR.
Less easy to itemise are the numerous instances in which our PPI members made us review our practices
and procedures by asking us why we were planning to do things in a certain way or by contributing an
idea, opinion or the value of their experience.
Public and participant involvement in dissemination
The PPI representatives will be involved in disseminating the research findings. For example:
l A range of journal submissions are planned and they will contribute as authors.
l They will be actively involved in agreeing the content and design of leaflets and information
on websites.
l Susan Maskell contributed to a workshop on eye examinations for people with dementia at the CoO’s
annual conference.
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The PrOVIDe study team are grateful to the PPI members of the Steering Group for all the help and advice
that they provided. Their continuing input will ensure that work will continue to make the study findings
available as widely and as clearly as possible.
Impact of public and participant involvement
The Steering Group and Management Group were clear that there were several points in the development
and delivery of the project where input from Susan Maskell as the PPI representative on the team was
central to avoiding a design flaw or to identifying an effective solution to a problem. Overall, the
consensus was that not only had the PPI involvement across the study enabled the project to be more
relevant and engaging to potential participants, but it had also ensured that the study was technically
more effective and efficient as a piece of research.
In addition to the direct benefits to the PrOVIDe project, the experience of PPI’s impact on developing and
delivering good research led to the CoO and the Thomas Pocklington Trust further developing their
internal PPI engagements to make more effective use of PPI in the design and delivery of future research.
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Appendix 7 Revised protocol and
explanatory note
Background
When PrOVIDe was initially approved for funding, the approach to recruitment set out in the final detailed
proposal did not incorporate a recruitment approach that sought to stratify the final sample to reflect the
best estimates of the demographics of the UK’s dementia population for characteristics of age and sex.
The original approach proposed and approved by NIHR was to recruit to two groups: group 1 was to be
people with dementia living in their own homes and group 2 was to be people with dementia living in
residential care. As the detailed approach to recruitment developed, it was agreed by the steering group
that stratified recruitment targets should be set based on the best available estimates for the age/sex
profile for the UK dementia population as a whole.
Using the Alzheimer’s Society’s best estimates of these demographic characteristics for the UK dementia
population, the study’s statistician developed a proposed approach with age/sex targets for recruiting,
while maintaining the overarching sample targets. The intention of this stratification was to increase the
likelihood that the final sample for the study would be representative of the wider UK’s dementia
population, so far as age and sex were concerned. It is worth noting that the study was powered to
achieve the primary objective of the study – to gather prevalence data on VI from all causes in the
dementia population in sites across England – and the study was designed to allow the study to achieve
the desired sample size (n= 385) even if there were high rates of missing data. We had no prior
information regarding what the test completion rates would be, and therefore we allowed for up to a
50% missing data rate in this sample of people with dementia. This gave our overall sample size of
770 and we split this number into 385 participants living in care homes and 385 living in their own homes.
This division was not based on a sample size calculation, and it should be noted that at this stage there
was considerable uncertainty as to the size of any difference in prevalences of VI between these two
groups of participants. However, this number of 385 participants in each group would allow us, provided
the rates of missing data were not too high, to address the secondary objective of identifying any
differences in the level of undetected or inappropriately managed VI between those living in their own
homes and those living in care homes.
Rationale for changes
As noted, the initial changes to the recruitment strategy were to support the potential to achieve a final
sample that was as representative as possible of the wider UK dementia population. The stratification of
recruitment targets to reflect the wider population’s demographic characteristics was acknowledged to
introduce additional challenges to the recruitment process, but it was felt to be worthwhile. This change
was approved by NIHR prior to the commencement of recruitment to the study.
During the course of the study, it became clear that beyond the inherent challenges associated with
recruiting people living with dementia to participate in research, there were additional barriers specific
to recruiting people living with dementia who were living in residential care settings. As the project
progressed, recruitment was very closely monitored, and towards the end of the planned recruitment
phase it became clear that it would not be possible to achieve recruitment targets by the study completion
date if the precise sample stratification was adhered to, for sex, age and, ultimately, for residential care
settings. Following correspondence with NIHR regarding these issues, the research team carried out some
preliminary analyses of the data collected up to that point to inform the decision-making process in
relation to whether or not to seek to extend the duration of the recruitment phase (and, thus, the overall
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duration of the project), or to adjust the final sample size to reflect what was achievable. Two options
were presented to NIHR: accept a slightly smaller final sample or extend the project. On 11 March 2014
NIHR approved the approach to accept a smaller sample size with less rigid adherence to sample
stratification for age and sex.
Impact of changes
The preliminary analyses showed that the original sample size of 770 had been a conservative estimate.
The project team had used such a cautious estimate because the best available prevalence data from
previously published studies on VI in people living with dementia were so variable, and there were
limitations associated with the best available data on the prevalence of key eye conditions/diseases for
the general UK population as a whole. In addition, the proportion of missing data was unknown and likely
to be high. The study was powered to take the ‘worst-case scenario’ for possible prevalence rates.
Statistically, if the actual prevalence rates found in the study were > 50% or < 50%, then the sample
required would be smaller than the planned 385. There was additional resilience built in through the
inclusion of the second 385 participants in group 2. The preliminary analyses showed that the study would
be adequately powered to address the primary research question with this adjusted approach.
Recruitment targets were stratified by two wide age groups and sex to reflect the age/sex distribution
of the UK dementia population at the time. To achieve the overall sample recruitment target within
the duration of the project there was some over- and under-recruitment to several strata. This and the
non-ignorable proportion of unobserved distance VA and NVA in the sample (missing data) limits the
generalisability of extrapolating our unadjusted prevalence estimates to the wider UK population with
dementia. To obtain more plausible prevalence estimates within the sample, multiple imputation (not just
for complete cases) was used. To then calibrate our prevalence estimates to the latest-available wider UK
data from the Alzheimer’s Society,2 within-sample and post-stratification population calibration weights
were derived and extrapolated population prevalences were calculated. We also accounted for the
clustering effect of our sampling by regions and by sites within regions. Given all this, the impact overall of
our changes was that the extrapolated prevalences for distance VI and near vision loss (1) are higher in
these population estimates than the PrOVIDe sample rates, and (2) have wider CIs. Feature (1) reflects the
undersampling and increased difficulty in obtaining VA measures from people more likely to have worse
VA. Feature (2) reflects the design effect and the large variation in calibration weights.
The study team and NIHR considered these changes very carefully prior to making them and the final
analysis of the data set shows that the decision to adjust the recruitment approach and the final sample
size did not impact negatively on the overall value of the final data set. For the sake of transparency and
clarity, it was agreed to include the final revised protocol and this explanatory note.
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